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Platelets are anucleated, small, short-lived discoid cells derived from progenitor 
megakaryocytes in the bone marrow and in the lungs [1, 2]. The normal range of platelet 
numbers in healthy individuals ranges from 150 to 450 x 109 cells per litre of blood. Platelets 
have a diameter of 2-5µM and can survive 7-10 days in the circulation. The key role of 
platelets is maintenance of vascular integrity through the process of primary hemostasis. 
In recent years, additional roles of platelets beyond hemostasis have been recognized, 
including inflammation and host defence [3, 4].
Platelet structures
Platelets harbour various types of granules including alpha (α)-granules, dense granules 
and lysosomes. α-granules are the largest and most numerous of all platelet granules. 
Depending on the size of the platelet, the number of α-granules ranges from 40-80 
granules per platelet. They contain many molecules that are essential for platelet function, 
including P-selectin, von Willebrand Factor (VWF), absorbed fibrinogen, coagulation factor 
V, cytokines, chemokines and growth factors [5, 6]. Dense granules contain adenosine 
triphosphate (ATP), adenosine diphosphate (ADP), serotonin, calcium, magnesium and 
pyrophosphate that are all necessary for hemostasis [4, 6]. Lysosomes store glycohydrolases 
including human neuraminidase (NEU1) that are able to degrade glycoproteins, glycolipids 
and glycosaminoglycans. Lysosomal membranes contain lysosomal membrane-
associated proteins (LAMP)- 1 and 2 and CD63 [4, 7]. Platelets also harbour functional 
mitochondria which are involved in energy metabolism and regulation of platelet 
activation and apoptosis [8]. During platelet activation, the discoid shape of resting 
platelets changes into an amorphous shape with pseudopodia due to remodelling of the 
resting cytoskeleton. The process of platelet activation, depending on the stimulatory 
pathway, is accompanied by selective degranulation in which some granular molecules 
are delivered to the membrane or to the extracellular matrix [6]. 
Platelets contain different structures regulating their hemostatic function and facilitating 
interactions with the environment. These include the glycoprotein (GP)Ib/IX/V complex 
(receptor for VWF), GPVI (receptor for collagen), CLEC-2, integrin αIIbβ3 (GPIIbIIIa complex; 
receptor for fibrinogen), thrombin receptors (PAR1-4), P2-receptors including P2Y1 and 
P2Y12 receptors (receptor for ADP) and P2X1, (receptor for ATP), platelet-endothelial cell 
adhesion molecule 1 (PECAM-1) and P-selectin [7, 9]. Despite being anucleated, platelets 
contain megakaryocyte-derived mRNA and have been suggested to synthesize proteins 
such as interleukin (IL)-1β and IL-18 [10, 11], although some suggests that this is probably 
a contamination by leukocytes [12]. Platelets also contain microRNA with regulatory 
functions. Platelets can transfer their mRNA or microRNA to other cells via release of 
platelet microparticles [13, 14]. 
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Activated platelets rapidly bind to leukocytes via ligation of platelet P-selectin to leukocyte 
P-selectin glycoprotein ligand 1 (PGSL-1). The affinity to bind platelets varies between 
leukocyte subpopulations. Monocytes have the highest affinity, followed by granulocytes 
and lymphocytes [15]. Other important receptors that mediate platelet-leukocyte interaction 
include CD40 ligand (CD40L) to leukocyte CD40, GPIbα, junctional adhesion molecule-3 
(JAM-3) or integrin αIIbβ3 to leukocyte CD11b/CD18 (Mac-1) integrin complex; and intercellular 
adhesion molecule (ICAM) to lymphocyte function-associated antigen 1 (LFA-1) [15, 16].
Platelet sialic acid: Platelets glycoproteins are decorated by sialic acid, a 9-carbon 
monosaccharide with a carboxyl group which contributes to the overall electronegative 
charge of a platelet [17]. Platelets contain the N-acetylneuraminic acid (Neu5Ac) type of 
sialic acid of which about 60% is liable to cleavage  by neuraminidase [18]. Platelet sialic 
acid plays a major role in platelet function and survival in the circulation. Platelets lose 
their surface sialic acid in the process of aging, but also by the action of endogenous 
or exogeneous neuraminidase. Desialylation of platelets leads to platelet apoptosis, 
phagocytosis and clearance from the circulation by the Ashwell-Morel receptor (AMR) 
in the liver [19, 20]. Desialylation of platelets also mediates platelet hyperreactivity to 
secondary stimulation and allows for more intercellular interaction as a result of reduced 
surface electronegativity [21, 22].  
GP1bα, the primary receptor for VWF, is the most heavily sialylated glycoprotein and 
the primary target of desialylation [23]. GP1bα has therefore gained much attention in 
thrombocytopenic conditions associated with platelet desialylation. Binding of VWF 
to GP1bα has been reported to induce platelet desialylation and subsequent clearance 
of chilled platelets following platelet transfusion [24]. Engagement of GP1bα triggers 
translocation of lysosomes containing endogenous human neuraminidase (NEU1) to the 
membrane where it cleaves off sialic acid [25]. VWF binding mediates platelet clearance 
in different conditions, the most well-known being von Willebrand disease type 2B 
[26]. However, previous studies have also suggested VWF to be an important mediator 
of thrombocytopenia in infectious diseases such as dengue infection, malaria or 
leptospirosis [27–29]. However, it is still unknown whether thrombocytopenia observed in 
these conditions is results, among other factors, from platelet desialylation mediated by 
VWF-platelet interaction.
Except for desialylation by endogenous neuraminidase, platelets can also lose sialic acid 
by exogenous neuraminidase. Some pathogens such as influenza virus and Streptococcus 
pneumoniae express neuraminidase, which facilitates their colonisation of host cells [30]. 
In a mouse model, systemic infection with Streptococcus pneumoniae induced platelet 
desialylation and clearance via the Ashwell-Morel receptor [31]. Platelet activation is also 
a feature of many infections, including S. pneumoniae [32–34]. It is likely that remodeling 
of platelet glycoproteins by pneumococcal neuraminidase also alters platelet function 
although these effects are not well known.
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Lectins are proteins that bind sialic acid and are widely used to detect sialic acids in in 
vitro assays. Several types of lectins are available and they bind to specific sugar moieties. 
For example, Sambucus nigra lectin (SNA) binds to α-2,6-sialoglycans, while Maackia 
amurensis lectin II (MALII) binds to α-2,3-sialoglycans [35]. When sialic acid is cleaved off, 
the underlying β-galactose residue is exposed and this can be detected by lectins like 
Ricinus communis agglutinin (RCA). 
Figure 1 – Pictorial illustration of platelet sialic acid. Platelet glycoproteins like GP1bα contain 
N-linked sialic acids that can be cleaved off by pathogenic or endogenous neuraminidase (NEU1). 
Engagement of endothelial derived VWF to GP1bα receptor triggers the translocation of NEU1 to 
the membrane. Desialylated platelets are removed from the circulation by liver macrophages that 
recognized exposed galactose residues. In vitro, both sialic acid and galactose residues can be 
identified by specific lectins. 
Platelet activation
The process of platelet activation can be classified into three stages [36]. (1) Interaction 
between platelet agonists with their respective receptors on platelets. (2) Downstream 
signalling leading to increased cytosolic Ca2+ and changes in the shape of the platelet and 
(3) Integrin activation. Platelet activation begins with signalling from activated surface 
receptors following ligation of platelet agonists such as collagen, thrombin, ADP or 
thromboxane. This process is followed by a downstream intracellular signal that leads to 
elevation of cytosolic Ca2+ concentrations. Ca2+ ions are mobilised from internal storages 
and from the extracellular space. The increase in cytosolic Ca2+ triggers further downstream 
events leading to integrin activation and thromboxane formation [37]. Changes in the 
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platelet shape occur as a result of reorganisation of the platelet microtubular ring and 
actin cytoskeleton resulting in formation of filopodia and lamellapodia [38]. During platelet 
activation, platelet granules translocate to the membrane where they fuse with the 
membrane and release their contents into the extracellular space. Some of the granular 
proteins remain attached to the surface. Platelet granules contains hundreds of biologically 
active proteins with different functions in hemostasis, thrombosis, inflammation and 
host defense [6, 9, 39]. Some of these proteins, such as ADP and thromboxane, amplify 
platelet activation through a positive feedback loop, while proteins such as Regulated 
upon Activation Normal T Cell Expressed and Secreted (RANTES), transforming growth 
factor beta (TGFβ) and IL-1β are involved in inflammatory responses [40]. Activated platelets 
also release proteins with microbicidal actions such as thrombocidins, platelet factor-4 
(PF4) and thymosin β-4 [41]. The activation of platelet surface receptors and integrins alters 
their affinity for their ligands. For example, activated integrin αIIbβ3 binds fibrinogen 
and VWF leading to outside-in signalling, which greatly amplifies platelet activation, 
aggregation and adhesion [42].  
The process of platelet activation is regulated by intrinsic inhibitory pathways involving 
endothelium derived nitric oxide (NO) and prostacyclin (PGI2). These compounds facilitate 
the synthesis of cyclic adenosine monophosphate (cAMP) by adenylyl cyclase, which in 
turn inhibits platelet activation and, by doing so, prevents excessive platelet activation [36]. 
Platelet activation and reactivity test by flow cytometry: Different platelet assays are 
available for diagnosis of platelet disorders and evaluation of platelet inhibitory therapies 
[43]. What all platelet test unite is their vulnerability to ex vivo platelet activation. While 
the traditional light transmission aggregometry test remains a commonly used method, 
flow cytometry-based tests have become increasingly popular [44]. This method involves 
labelling of platelets in suspension with fluorescent monoclonal antibodies or dyes that 
can bind to specific platelet structures. Advantages of flow cytometry over aggregometry 
are that only a small volume of blood is required and that whole blood can be used rather 
than platelet rich plasma (PRP), avoiding platelet activation due to manipulation of 
blood. Moreover, flow cytometry can also be used in conditions with thrombocytopenia 
and assesses both the platelet activation status of circulating platelets as well as their 
response to agonist-induced ex vivo activation. The latter is referred to as platelet 
reactivity. Finally, flow cytometry-based assays can evaluate the effect of antiplatelet 
therapy, detect intracellular molecules and platelet interaction with other cells or 
pathogens [45, 46]. Disadvantages of this method are the high costs of reagents, the need for 
a specialized operator and expensive equipment. 
In the current thesis, the flow cytometry method has been used to study platelet 
activation and reactivity using ADP, thrombin receptor activating peptide (TRAP-6), cross-
linked collagen related protein (CRP-XL) and protease activated receptor (PAR)-4 agonists 
as platelet stimulants. Main readouts include expression of the α-granule membrane 
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protein P-selectin, binding of fibrinogen to activated integrin αIIbβ3, binding of VWF 
to GPIbα, and platelet-leukocyte aggregation. Flow cytometry was also used to assess 
platelet sialic acid in different settings. 
Changes in platelet numbers during infections
Platelets are released from long pro-platelet elongations of mature megakaryocytes 
into sinusoidal blood vessels where they undergo further processes to develop a number 
of distinguishable structural and functional elements. About 100 billion platelets 
are produced daily whereby only a small fraction of these platelets are consumed for 
hemostasis [40]. Within 8 to 10 days, the rest of the platelets are cleared from the circulation 
by the reticuloendothelial system in the liver and spleen. The process of platelet 
production from megakaryocytes is regulated by a hormone called thrombopoietin 
(TPO) and a variety of other immunomodulatory peptides, whereas the intrinsic platelet 
apoptotic program and glycosylation of surface proteins regulates platelet survival [2, 23]. 
The process of platelet production and survival is well regulated in normal physiology. 
In pathological conditions, this equilibrium is disturbed resulting in a decrease 
(thrombocytopenia) or increase (thrombocytosis) in platelet numbers. Thrombocytopenia 
is common in infections like dengue and malaria, but also in severe bacterial infections. 
General causes of thrombocytopenia during infections include pathogen-mediated 
platelet destruction or decreased platelet production due to increased levels of cytokines 
such as interferon (IFN)-α/β and tumour necrosis factor alpha (TNFα) [47, 48] or increased 
platelet consumption. The latter occurs through disseminated intravascular coagulation 
(DIC), increased binding of platelets to VWF and the endothelium, formation of platelet-
leukocytes aggregates or loss of platelet sialic acid with subsequent platelet removal from 
the circulation as a result [47, 49]. Thrombocytosis is more commonly observed in chronic 
inflammatory diseases like tuberculosis. Possible mechanisms include increasing levels of 
TPO and inflammatory mediators such as IL-6, IL-1β and IFNγ, which are known to promote 
thrombopoiesis [48, 50]. Interestingly, althγγough viral infections are mostly associated with 
low platelet counts, thrombocytosis also occurs frequently in patients with a respiratory 
syncytial virus (RSV) infection [51]. The underlying mechanism is still unknown.  
Platelet functions
Platelets have different functions in key physiologic processes. The most well-known are 
their roles in hemostasis, immune response and host defence and inflammation. 
a  Platelets and hemostasis: An important function of platelets is to stop bleeding at the 
site of interrupted endothelium, a process known as hemostasis. In short, as this thesis 
does not focus on the hemostatic role of platelets, platelets plug the interruption at 
the site of the endothelium unless the distance is too large. A sequence of events takes 
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place to stop the bleeding: (i) Adhesion: platelets rapidly adhere to collagen and VWF 
exposed outside the normal endothelium. (ii). Activation: platelets change shape and 
degranulate whereby receptors are turned on and chemical messengers are secreted, 
(iii). Aggregation: Platelets connect to each other by forming bridges. When a platelet 
plug (primary hemostasis) is formed, the coagulation cascade is activated and fibrin is 
deposited around the platelet plug (secondary hemostasis). These processes overlap 
and the final result is a blood clot. The process is completed by clot retraction and 
platelet inhibition [6, 52]. 
b  Platelets in immunity and inflammation: Several structural and functional properties 
of platelets favor the argument that platelets belong to the family of innate immune 
cells [3, 53]. Platelets express several functional toll-like receptors (TLRs) such as TLR2, 
TLR3, TLR4, TLR7, and TLR9; and damage associated molecular patterns (DAMPs) [54]. 
Through these receptors, platelets can recognize pathogens or signals of the acute 
phase response and initiate their antimicrobial effector function, which includes 
release of antimicrobial peptides, reactive oxygen species, and cytokines such as 
TNFα. Platelets are also capable of interacting directly with bacteria, viruses, fungi and 
parasites via several other surface receptors [55–57].
Platelets granules harbor hundreds of microbicidal proteins that can inactivate or kill 
bacteria and fungi [41, 56, 58]. Platelets can also bind and internalize viruses such as dengue 
and human immunodeficiency virus (HIV) [55, 59], although the fate of ingested viral 
particles is not clear. Meanwhile, Plasmodium falciparum, the parasite causing severe 
malaria, primarily infects red blood cells and platelets can bind to parasite red blood cells, 
after which Platelet Factor-4 plays a role in killing the parasites [60].
Primarily, platelets survey the body for foreign particles and trigger leukocyte extravasation 
and recruitment to the site of infection via release of chemokines such as CCL5 (RANTES), 
CXCL4 (PF4), CCL2 (MCP1) and CXCL7 (NAP-2) [61]. Platelets crosstalk with leukocytes triggers 
intracellular signalling in the immune cells which results in amplification or inhibition of 
immune-inflammatory responses [40]. Platelets can tether with a wide range of immune 
cells, including monocytes/macrophages, neutrophils, dendritic cells and lymphocytes, 
enabling them to modulate both the innate and adaptive immune responses. In addition, 
platelets also offer co-stimulatory molecules (CD40L and TREM1 ligand) and growth 
factors (TGFβ1 and PDGF) to immune cells [15].
Platelets have a high affinity for adhering to monocytes and granulocytes [15]. Platelet 
tethering to monocytes results in monocyte activation and differentiation, including 
foam cell formation, surface expression of CD16 and tissue factor [62], and upregulation 
of production of pro-inflammatory cytokines, for example TNFα, IL-6 and IL-1β [15, 16]. In 
contrast, platelets may also stimulate monocytes to produce more anti-inflammatory 
cytokines, such as IL-10. This has been described in the setting of tuberculosis [63]. Platelets 
can also trigger the formation of neutrophil extracellular traps (NETs) and increase the 
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oxidative burst and phagocytic ability of neutrophils [61]. In adaptive immunity, platelets 
mediate T-cell proliferation, B-cell isotype class switch and regulate IL-10 production from 
dendritic cells [4, 16]. On the other hand, immune cells phagocytose platelets and remove 
preformed aggregates [64]. 
The role of platelets in immunity and host defense is not limited to systemic infections 
during which platelets are in close contact to other immune cells. Recently, the lung has 
been identified as a second site of platelet production [1]. Platelets are hypothesized to have 
a pathophysiologic role in the modulation of lung infections [65]. In this thesis, I focus on 
two pulmonary infections: RSV and pulmonary tuberculosis. Platelet counts and platelet 
related genes are increased during RSV infection [51, 66] and low platelet counts are a risk 
factor for adverse disease outcome and incidence of viremia in RSV [67]. Platelet counts 
are also frequently increased in pulmonary Mycobacterium tuberculosis infection [68, 69]. 
Platelets were recently implicated in the formation of granulomas and transformation of 
macrophages into phagocytic anti-inflammatory cells capable of harbouring mycobacteria 
[63]. Together, these observations suggest that platelets may play a so far unsuspected role 
in the pathogenesis and immune responses in these respiratory infections. 
Human functional genomics Project (HFGP): an integrated approach linking platelet 
function and inflammation: The HFGP (http://www.humanfunctionalgenomics.org/) was 
established in 2013 with the main aim of characterizing and understanding interindividual 
variation of human immune responses by combining omics-based data (e.g. genomics, 
microbiome, metabolome) with immune responses in large cohorts of healthy and 
diseased individuals [70]. The project provides a methodological framework through 
which functional studies linking different biological processes can be performed. As 
part of the HFGP, our group performed a comprehensive analysis of the relation between 
platelet numbers and function with inflammatory responses in healthy adults of Western 
European ancestry [71]. Under the umbrella of the HFGP, we also enrolled a cohort of 300 
healthy individuals from Kilimanjaro region in Northern Tanzania, a semi-urbanized 
region in the Sub-Saharan Africa (SSA). The primary aims of enrolling this cohort were 
to explore the determinants of interindividual variations in platelet numbers and 
function. This was achieved by systematically correlating platelet measurements with 
host and environmental factors, in vivo inflammatory mediators and ex vivo cytokine 
production capacity. SSA is facing a rapid demographic transition, in which rural lifestyle 
is being replaced by urban lifestyle. Fuelled by mass urbanization, sedentary lifestyles 
and increased availability of nutrient-poor processed foods,  non-communicable diseases 
(NCD) are rapidly increasing in this region along to existing burden of infectious diseases 
[72–74]. The underlying pathophysiologic pathways of the increase in NCD are only partly 
understood so far. As platelets play role in the pathogenesis of NCD particularly of 
cardiovascular diseases (CVD), we therefore explored determinants of platelet activation 
and reactivity in the Tanzanian functional genomics cohorts, putting special emphasis on 
the difference between individuals living in urban or rural areas.
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Aim and scope of the thesis
The overall aim of this thesis is to investigate the interaction of platelets with infectious 
diseases and inflammation. Special focus is given to the roles of platelet desialylation in 
dengue and pneumococcal infections, platelet-mediated effects on host response in RSV 
and tuberculosis and the effects of demographic transition in SSA on platelet phenotype.
Sialic acids have been identified as important regulators of platelet function and survival 
in the circulation [23]. Haemorrhagic viruses like dengue cause both thrombocytopenia 
and platelet dysfunction [27, 75]. We and other groups of researchers have previously shown 
that plasma VWF is increased during dengue [76]. Because interaction of platelets with VWF 
is reported to induce platelet desialylation [24], we aimed to study whether VWF binding 
to circulating platelets is indeed increased during dengue infection and whether this is 
associated with platelet desialylation. In chapter 2, we explore these platelet clearance 
mechanisms in two cohorts of Indonesian dengue patients. Clinical data were validated 
with a set of in vitro experiments. 
Streptococcus pneumoniae is the most common bacterial cause of community acquired 
pneumonia. It can also lead to invasive infections including bacteraemia. Invasive 
pneumococcal infections are associated with pronounced platelet activation [33, 77] and this 
might contribute to the increased risk for cardiovascular complications during or after 
a pneumonia [78]. Streptococcus pneumoniae produces a neuraminidase, called NanA [79]. 
We hypothesized that this neuraminidase is able to remove platelet sialic acids and that 
this contributes to platelet activation. In chapter 3, we describe studies in which we used 
pneumococcal culture supernatants to study the effects of NanA on platelet desialylation, 
platelet activation status and platelet reactivity, and characterized involved pathways. 
Furthermore, the propensity of neuraminidase inhibitors and platelet function inhibitors 
to prevent NanA effects on platelet was explored.
While the role of platelets in immunity and inflammation is increasingly acknowledged 
and the lung has recently been identified as a site of platelet production [1], the role of 
platelets in respiratory infections are poorly understood. Platelet numbers are increased 
during some viral respiratory infections like human rhinovirus and RSV [51, 80]. Whether 
the increase in platelet numbers during these infections might be part of the host innate 
defence mechanism is unclear. This observation triggered us to explore whether platelets 
modulated immune responses to RSV infection. We used an in vitro model of isolated 
peripheral blood mononuclear cells (PBMC) and washed platelets to study the role of 
platelets and platelet-leukocyte interaction in innate immune responses against RSV, and 
the ability of platelets to prevent RSV infection of monocytes (chapter 4).
Pulmonary tuberculosis is also frequently associated with thrombocytosis [68, 69]. 
Granuloma formation is a hallmark of tuberculosis infection. Monocytes/macrophages 
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are key cells in tubercular granuloma formation as well as in the systemic inflammatory 
response. Platelets were recently shown to be involved in granuloma formation and are 
also known to modulate monocyte function [63, 81]. We therefore aimed to study platelet-
monocyte aggregation in peripheral blood in tuberculosis and determined whether this 
aggregation modulates inflammatory responses. In a cohort of Tanzanian patients with 
pulmonary tuberculosis, we studied the formation of platelet-monocytes aggregates 
(PMA), and the contribution of platelet activation to monocyte phenotypic changes in 
vivo and in vitro. Finally, we studied how platelets and PMA modulate innate cytokine 
responses to Mycobacterium tuberculosis (Chapter 5).
Different studies have explored causes of variation in platelet numbers between 
individuals in different pathological conditions. However, there is also a marked variation 
in platelet numbers and platelet reactivity in healthy individuals, owing to both genetic 
and non-genetic factors. This variation has primarily been studied in populations of 
Caucasian ancestry or other ethnic groups living in the west [71, 82, 83]. Findings from these 
studies are highly variable, whereby genetic polymorphisms and non-genetic factors such 
as the female gender, old age and increased obesity have been associated with enhanced 
platelet reactivity [84–86]. Similar data are not yet available for populations in SSA which are 
in the middle of the demographic transition. In chapter 6, we describe for the first time 
the architecture of platelet number and reactivity in a healthy SSA population in Northern 
Tanzania (Kilimanjaro region) in East Africa. Using the approach of the HFGP, we performed 
a comprehensive assessment of the influence of a set of environmental and non-genetic 
host factors on platelet parameters. Associations between platelets and inflammation 
and host defence was also assessed. 
Finally, in chapter 7 we provide a summary and general discussion of the findings in this 
thesis.
Outline of the thesis
–  Desialylation of platelets induced by Von Willebrand Factor is a novel mechanism of 
platelet clearance in dengue. (Chapter 2)
–  Desialylation of platelets by pneumococcal neuraminidase A induces ADP-dependent 
platelet hyper-reactivity. (Chapter 3)
–  Platelets modulate innate immune response against Human Respiratory Syncytial 
Virus In Vitro. (Chapter 4)
–  Platelet-monocyte interaction in Mycobacterium tuberculosis infection. (Chapter 5)
–  Platelet activation and reactivity in healthy individuals in Sub-Saharan Africa: effects 
of demographic transition. (Chapter 6)
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Abstract
Thrombocytopenia and platelet dysfunction are commonly observed in patients with 
dengue virus (DENV) infection and may contribute to complications such as bleeding and 
plasma leakage. The etiology of dengue-associated thrombocytopenia is multifactorial 
and includes increased platelet clearance. The binding of the coagulation protein von 
Willebrand factor (VWF) to the platelet membrane and removal of sialic acid (desialylation) 
are two well-known mechanisms of platelet clearance, but whether these conditions also 
contribute to thrombocytopenia in dengue infection is unknown. In two observational 
cohort studies in Bandung and Jepara, Indonesia, we show that adult patients with dengue 
not only had higher plasma concentrations of plasma VWF antigen and active VWF, but 
that circulating platelets had also bound more VWF to their membrane. The amount of 
platelet-VWF binding correlated well with platelet count. Furthermore, sialic acid levels in 
dengue patients were significantly reduced as assessed by the binding of Sambucus nigra 
lectin (SNA) and Maackia amurensis lectin II (MAL-II) to platelets. Sialic acid on the platelet 
membrane is neuraminidase-labile, but dengue virus has no known neuraminidase 
activity. Indeed, no detectable activity of neuraminidase was present in plasma of 
dengue patients and no desialylation was found of plasma transferrin. Platelet sialylation 
was also not altered by in vitro exposure of platelets to DENV nonstructural protein 1 or 
cultured DENV. In contrast, induction of binding of VWF to glycoprotein 1b on platelets 
using the VWF-activating protein ristocetin resulted in the removal of platelet sialic acid 
by translocation of platelet neuraminidase to the platelet surface. The neuraminidase 
inhibitor oseltamivir reduced VWF-induced platelet desialylation. Our data demonstrate 
that excessive binding of VWF to platelets in dengue results in neuraminidase-mediated 
platelet desialylation and platelet clearance. Oseltamivir might be a novel treatment 
option for severe thrombocytopenia in dengue infection.  
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Author Summary
Dengue is the most common arbovirus infection in the world. A decrease in 
the number of blood platelets is an almost universal finding in severe dengue. 
Binding of the coagulation protein von Willebrand factor (VWF) and loss of 
sialic acid residues from the platelet membrane are two main mechanisms of 
clearance of senescent platelets under non-pathological conditions. Here, we 
show that platelets from patients with acute dengue have bound more VWF 
and have lost sialic acid from their membrane. Sialic acid can be cleaved by the 
enzyme neuraminidase. We show that neuraminidase activity in the plasma is 
not increased and that neither dengue virus itself nor nonstructural protein 1, a 
protein secreted by dengue virus, cleave sialic acid from the platelet membrane. In 
contrast, binding of VWF to platelets results in translocation of neuraminidase to 
the platelet membrane and subsequent cleavage of sialic acid. This process could 
be inhibited by the neuraminidase inhibitor oseltamivir, a commonly used anti-
influenza drug. Altogether, our results indicate that VWF binding to platelets is 
increased in dengue infection, leading to the removal of sialic acid and platelet 
clearance. Oseltamivir may prevent this process and thus represent a novel 
treatment option for low platelet numbers in dengue infection. 
Introduction
Dengue is the most common arboviral infection in the world with an estimated number 
of 390 million annual cases, of which 96 million manifests with symptomatic disease [1]. 
A subset of patients with symptomatic infections develops potentially life-threatening 
complications in which bleeding and vascular plasma leakage are the most common [2]. 
To date, there is no curative therapy for dengue and clinical observation and treatment of 
complications remain the core principles of dengue management. 
Thrombocytopenia is an early and consistent feature of dengue virus infection [3-6] 
and dengue complications are usually preceded by a rapid drop in platelet count [2]. 
Traditionally known for their key role in hemostasis, platelets are nowadays well known 
to have important additional functions, including regulation of inflammation and host 
defense [7-9] and preservation of endothelial integrity [10], especially under inflammatory 
conditions [11].
Circulating platelets of dengue patients are activated and excessive platelet activation 
may lead to platelet exhaustion [12-15], which likely contributes to thrombocytopenia and 
dengue complications. Other well-known mechanisms of increased platelet clearance 
under non-pathological conditions are the binding of von Willebrand factor (VWF) to 
platelets and loss of sialic acids from the platelet membrane [16]. VWF is a multimeric protein 
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that is present in plasma, platelets, and endothelial cells. Endothelial activation results 
in the release of VWF from Weibel-Palade bodies into the blood circulation. Its primary 
function is platelet adhesion and aggregation at sites of vessel injury [17]. The antibiotic 
ristocetin induces binding of VWF to platelets and may cause thrombocytopenia, and as a 
consequence, it was removed from clinical practice [18]. We have previously shown that the 
plasma of children with severe dengue contains increased levels of circulating VWF in an 
active – platelet binding – conformation and increased VWF proteolysis [19]. Importantly, 
enhanced VWF binding to platelets – as seen in von Willebrand disease (VWD) type 2B - 
was shown to induce phagocytosis of VWF/platelet complexes by macrophages in the 
liver and spleen and promote thrombocytopathy by inhibition of platelet integrin αIIbβ3, 
the platelet fibrinogen receptor [20, 21]. Increased platelet phagocytosis, as well as impaired 
platelet αIIbβ33 function, have also been described in patients with dengue [15, 22]. 
Most platelet glycoproteins, including the extracellular domains of Glycoprotein 1bα (GPIbα; 
‘the major VWF receptor’), are decorated with N-glycans and O-linked glycans, which are 
covered by sialic acids [23, 24], a family of monosaccharides with a 6-carbon backbone. Loss 
of terminal sialic acids, which can be mediated by human sialidase neuraminidase 1 (NEU1) 
or exogenous sialidase, exposes β-galactose and β-N-acetyl-D glucosamine (β-GlcNAc), 
which can be recognized by macrophages or the hepatic asialoglycoprotein receptor 
(ASGPR; also called the Ashwell–Morell receptor) [25-28]. Recently, binding of VWF to GPIbα 
under physiological shear was shown to induce platelet desialylation [29]. 
The aim of our study was to investigate these platelet clearance processes during the course 
of the disease in patients with dengue and their relationship with thrombocytopenia and 
platelet reactivity. We first show that dengue is associated with increased binding of VWF 
to platelets. In a follow up clinical study, we also show that circulating platelets have 
markedly reduced surface sialic acid. Both VWF binding and desialylation were associated 
with thrombocytopenia. In a set of ex vivo studies, we then show that VWF binding to 
platelets leads to NEU-1 mediated desialylation, which can be inhibited by the sialidase 
inhibitor oseltamivir. 
Materials and Methods
Patients and study design
Two observational clinical studies were performed in Indonesian patients with acute 
dengue and conducted according to the principles expressed in the Declaration of 
Helsinki. In study 1, the binding of VWF to circulating platelets was investigated and 
related to thrombocytopenia and platelet reactivity. In study 2, sialic acid on the platelet 
surface was determined. Both studies were exploratory in nature and therefore no sample 
size calculation was performed. 
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Clinical study 1. This study was conducted in Hasan Sadikin general hospital and Salamun 
Hospital in Bandung between January to June 2015. Febrile patients (≥37.5 αC) aged α 1 
year old, with clinically suspected acute dengue infection, thrombocytopenia (platelet 
count <150 x 109/l), and a positive result of either a dengue non-structural protein 1 (NS1) 
rapid test (PanBio Dengue Early Rapid, Alere), DENV in-house RT-PCR and/or dengue 
IgM (PanBio Dengue Duo cassette, Alere) were enrolled. Patients with chronic diseases, 
use of antiplatelet drugs or pregnancy were excluded. Medical history and physical 
examination were performed daily with special emphasis on bleeding manifestations and 
plasma leakage. Blood was drawn at admission and during the course of the infection, 
in which day 1-3 after onset of fever corresponds roughly with the febrile phase,  day 4-6 
with the critical phase, and day 7-13 with the recovery phase of a dengue infection [2, 30]. 
Convalescent samples were also taken >13 days after fever onset. Plasma leakage was 
defined as an increase in hematocrit of ≥ 20%, a single high hematocrit value (> 50% 
for men and > 44 % for women), or by plasma leakage in the form of ascites or pleural 
effusion as determined by daily handheld ultrasonography, as described previously [31]. A 
group of healthy volunteers was recruited among hospital staff to serve as controls. None 
of the controls experienced a fever or other complaints in the past month and all had a 
normal complete blood count. 
Clinical study 2. This study was performed from January to March 2016 in Kartini Hospital, 
a district hospital in Jepara, Central Java. Febrile patients clinically suspected of acute 
dengue infection with one of the following diagnostic criteria were enrolled: aged α 5 years, 
positive NS1 test, positive results of dengue-specific IgM or seroconversion for dengue-
specific IgM or IgG (PanBio Dengue Duo cassette, Alere). Patients with chronic diseases, 
use of antiplatelet drugs or pregnancy were excluded. Two blood samples were drawn for 
this study: one sample at the critical phase or early recovery phase and one sample at the 
convalescence phase. Two control groups were enrolled: one group of patients with non-
dengue febrile illness and a group of adult healthy volunteers recruited among hospital 
staff. 
Ethics Statement
The first clinical study was approved by the local Medical Ethical Committee of the Medical 
Faculty of Padjadjaran University, Hasan Sadikin General Hospital. The second clinical 
study was approved by the local Medical Ethical Committee of the Faculty of Medicine, 
Diponegoro University, and Kartini Hospital. In both clinical studies, written informed 
consent was obtained before enrolment from all patients and healthy controls, and in 
the case of pediatric subjects, a parent or guardian provided written informed consent on 
behalf of the child.
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Laboratory assays clinical studies
Platelet reactivity and VWF binding to platelets. Venous blood was collected in 3.2% 
citrate anti-coagulated vacutainers (BD Biosciences). Platelet activation and reactivity 
were determined by flow cytometry using a method previously described [32]. Briefly, 
the platelet membrane expression of P-selectin (CD62P) and platelet-fibrinogen binding, 
which correspond with platelet degranulation and aggregation, respectively, were 
determined in unstimulated whole blood and after ex vivo stimulation with the platelet 
agonists adenosine-diphosphate (ADP; 7.8 µM and 31.2 µM) (Sigma-Aldrich, Zwijndrecht, 
The Netherlands) or PAR-1 agonist thrombin receptor-activating peptide (TRAP; 39 µM 
and 156.25 µM or 625 µM) (Sigma-Aldrich, Zwijndrecht, the Netherlands). VWF binding to 
platelets in whole blood was measured as previously described [32]. Briefly, whole blood 
was incubated with a mixture of HEPES-buffered saline and saturating concentrations of 
FITC-labeled anti-VWF (Abcam, Cambridge, UK) and PC7-labeled anti-CD61 (eBioscience), 
with or without the addition of ristocetin (0.433 µM, 0.577 µM and 0.77 µM) (American 
biochemical & pharmaceuticals). After incubation for 20 minutes at room temperature, 
a fixative solution (0.2% paraformaldehyde) was added. Samples were measured on a BD 
FACS Calibur (Bandung) or BD FACS Canto II (Jepara). Platelets were gated based on their 
forward- and sideward-scatter (FSC/SSC) properties and positivity for CD42b or CD61, 
which was defined as a median fluorescence intensity (MFI) exceeding the MFI of the 
matched isotype control.
Platelet surface sialic acid. Citrated whole blood was immediately centrifuged after blood 
drawing for 15 minutes at 300 g without brake to obtain platelet-rich plasma (PRP).  Four 
million platelets were resuspended in 100 µl PBS in an Eppendorf tube and centrifuged for 
8 minutes at 600 g. The platelet pellet was then stained with the platelet identification 
marker CD61 (anti-61 PC7, Beckman Coulter, Woerden, Netherlands) and streptavidin 
labelled sialic acid binding lectins Sambucus nigra lectin (SNA) and Maackia amurensis 
lectin II (MAL-II) (both obtained from Vector Laboratories, California, USA) for 30 minutes 
at room temperature (RT). Cells were then washed, fixated using 0.2% paraformaldehyde 
(PFA) and analyzed using flow cytometer.
Plasma markers. Plasma VWF antigen (VWF:Ag) and active VWF levels were determined 
with ELISA, as described previously [33]. Nunc maxisorb 96 wells ELISA plates were coated 
overnight at 4˚C with 0.775 µg/ml anti-total VWF IgG (DAKO, A0082) or 5 µg/ml of anti-
active VWF VHH (AU/VWF-a11). Diluted plasma samples were incubated for one hour at 
room temperature. Plates were washed three times and incubated with 0.55 µg/mL 
polyclonal rabbit anti-human VWF to capture VWF and active VWF for one hour at 37˚C. 
Binding was detected with HRP-conjugated rabbit anti-mouse antibody. HRP activity was 
measured using OPD as a substrate after 30 minutes incubation at 37˚C. Normal pooled 
plasma (NPP) was used as a standard in every assay. ADAMTS-13 activity was determined 
using the fluorescence resonance energy transfer (FRETS) assay for ADAMTS-13 activity 
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(Peptides International, Inc. USA) whereby the ADAMTS-13 activity of NPP of the healthy 
Dutch donors was set at 100% [34]. Values obtained in the study participant samples were 
expressed as a percentage of NPP. 
Plasma neuraminidase activity and transferrin glycosylation. Sialidase activity in plasma 
of participants in the Jepara cohort was determined with a fluorometric method with 
0.45 mM 2-(4-methylumbelliferyl) keringα-D-N-acetylneuraminic acid as a substrate, 
as previously described [35]. In this assay, 30 µl plasma was mixed with equal volumes of 
substrate and reaction buffer of pH 7.0 and incubated at 37°C for 2 hrs. After incubation 
400µl of stop solution (containing glycine and trisol) was added. The mixture was vortexed 
and centrifuged at 10,000 x g for 10 minutes. 300µl of the supernatant was transferred to 
a clean reaction plate and fluorescence was measured. Enzymatic activity was calculated 
in moles of substrate hydrolyzed per unit per time (hours). Plasma sialidase activity was 
also investigated by mixing platelet rich plasma (PRP) from healthy Dutch volunteers with 
platelet poor plasma (PPP) from participants in the Jepara cohort in a volume ratio of 1:1 for 
two hours at 37°C. Desialylation of platelets was analyzed by staining platelets with sialic 
acid binding lectins SNA and MAL-II as described above. 
Transferrin glycosylation in plasma of dengue patients was analyzed using high-resolution 
nano liquid chromatography-chip (C8) quadrupole time of flight mass spectrometry 
(nanoLC-chip [C8]-QTOF MS) as previously described [35]. Briefly, plasma samples were 
diluted 1:10 with 0.9% NaCl solution and loaded onto a pierce spin column (Thermo Fisher) 
containing anti-transferrin conjugated beads. Samples were incubated for 15 minutes 
at room temperature, followed by 6 washing steps of 700 µl 10 mM Tris-HCl, pH 7 and a 
single elution (50 µl, 100 mM glycine-HCl, pH 2.7). The eluted fraction was neutralized 
with 1–1.5 µl 1.0 M Tris-HCl, pH 9.0 and analyzed on a microfluidic 6540 HPLC-chip-QTOF 
instrument (Agilent Technologies). Peak abundances were listed by Agilent BioConfirm 
Software and were used to calculate the ratio of sialylation by expressing the percentage 
of trisialotransferrin in comparison with tetrasialotransferrin (the most abundant 
transferrin isorform in controls).
In vitro studies 
Platelet preparation. PRP and washed platelets were isolated from 3.2% sodium-citrate-
anticoagulated whole blood from healthy volunteers as previously described [36]. Briefly, 
whole blood was centrifuged for 15 minutes at 156xg without a brake to obtain PRP. PRP 
was further centrifuged at 330xg for 15 minutes to obtain platelets poor plasma (PPP) and 
platelet pellets, which were resuspended in HEPES tyrode buffer at 4x108 platelets/ml.
Dengue NS1 and dengue virus. Washed platelets (1x107 plt/ml) were exposed to different 
concentrations (1.25–10 µg/ml) of DENV2 NS1 protein (strain Thailand/16681/84) (Native 
Antigen, Oxfordshire, United Kingdom) and incubated for 4 hours at 37°C. This NS1 protein 
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is in its native hexamer folding state and possess all post-translational modifications. It 
is shown to be > 95% pure and oligomeric, as demonstrated by native PAGE and Western 
blot analysis [37-38] and as certified by the manufacturer. In addition, washed platelets 
were exposed to DENV2 strain 16681 (kind gift from Claire Huang, Centers for Disease 
Control, Fort Collins, CO, USA). Virus stock was prepared in the Aedes albopictus mosquito-
derived C6/36 cell line to exclude the possibility that mammalian cytokines and other 
inflammatory products in the virus stock would influence the results. Virus was cultured 
using Leibovitz’s L-15 medium (Thermo Fisher) supplemented with 10% heat-inactivated 
fetal calf serum (Thermo Fisher), 2% Tryptose Phosphate Broth Solution (Sigma), 1x 
MEM Non-Essential Amino Acids (Thermo Fisher), and 50 U/ml penicillin and 50 µg/ml 
streptomycin (Thermo Fisher). Briefly, cells were infected with DENV2 and after 2 hours of 
incubation at 28°C, the medium was replaced with fresh L-15 medium. The infected cells 
were incubated at 28°C and the supernatant was harvested 4 days post-infection, stored 
in aliquots at −80 °C, and titrated on BHK-15 cells by end-point dilution. Supernatant of 
uninfected C6/36 cells was harvested in parallel to virus stocks, for use in mock infections. 
Washed platelets (1x107 plt/ml) were inoculated with DENV2 at a multiplicity of infection 
(MOI) of 3.7, or with an equal volume of mock medium, incubated for 3 or 6 hours, followed 
by fixation with 1% PFA to inactive DENV. Surface sialic acid was measured as described 
above. PFA fixation had no effect on lectin binding to sialic acid on the platelet membrane. 
Purified neuraminidase (NA; 200µM) from Clostridium perfringens (Sigma-Aldrich, 
Zwijndrecht, Netherlands) was used as positive control.
Induction of VWF-platelet binding and effect of oseltamivir. Binding of VWF to platelets 
was induced by exposing PRP to different concentrations of ristocetin (0-1.6 mg/ml) 
(American Biochemical & Pharmaceuticals, Epsom, UK) for 1hr at 37°C. VWF-platelet 
binding was inhibited in selected experiments by pre-incubation of PRP with 5µg/ml 
anti-GP1b antibodies (Abbiotec, San Diego, CA) for 30 minutes. In selected experiments, 
inhibition of platelet desialylation by neuraminidase inhibitors was investigated by 
incubation of PRP with 1-50 µM oseltamivir acid (Santa Cruz Biotechnology, Texas, 
USA) for 30 minutes. Plasma-derived VWF was purified from Haemate P by gel filtration 
chromatography as previously described [39]. The VWF was quantified using VWF antigen 
ELISA.
Flow cytometry. Surface sialic acid was measured using the lectins SNA and MAL-II as 
described above. In selected experiments, surface galactose expression was analyzed 
by incubation with streptavidin labeled Ricinus communis agglutinin 1 (RCA-1) lectin 
(vector laboratories, California, USA). Neuraminidase expression on the platelet surface 
was measured using antibodies against human neuraminidase-1 (anti-neu-1, Fisher 
scientific, Landsmeer, The Netherlands) as primary antibody and Goat-anti-rabbit IgG – 
Alexa Fluor 488 (Fischer scientific) as secondary antibody. Platelet VWF and expression 
of the lysosomal marker CD63 were measured with the following antibodies: anti-VWF 
FITC (Abcam, Cambridge, UK), anti-CD63 FITC, (Biolegend, San Diego, CA) and anti-CD61 
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PC7 (Beckman Coulter) as platelet identification marker. Platelets were incubated with 
saturating amounts of these antibodies for 25 minutes, fixated with 0.2% PFA for 15 
minutes and measured on a Cytomics FC500 flow cytometer or a Cytoflex flow cytometer 
(both Beckman Coulter).
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 software. Data are presented 
as geometric mean with 95% confidence intervals unless stated otherwise. The Kruskal 
Wallis test was used to determine significance between multiple groups. Differences 
between individual groups were analyzed with the Mann-Whitney test or Student’s T-test. 
Correlations were tested using either the Spearman correlation test (for non-normally 
distributed data) or Pearson correlation test (normally distributed data). A P value <0.05 
was considered a statistically significant difference. Flow cytometry data were analyzed 
with Beckman Coulter Kaluza software, version 1.2. Data on transferrin glycosylation were 
analyzed with Agilent Mass Hunter Qualitative Analysis Software B.04.00.
Results
Clinical characteristics and platelet number and reactivity
In Bandung, a total number of 40 patients with acute dengue and 10 healthy adult controls 
were enrolled. Three patients were children aged ≤14 years old. Samples collected were 
divided into four groups based on the day of fever; day 1-3 (n=20), day 4-6 day (n= 54), 
day 7-13 (n=24) and day >13 days (n=24). In Jepara, 40 patients with dengue were enrolled, 
together with 15 patients with non-dengue illness (acute gastroenteritis n=9, acute 
respiratory tract infection n=6) and 25 healthy controls. Ten and three of the patients with 
dengue or non-dengue febrile illness respectively were children. Clinical characteristics 
are given in Table 1. Hemorrhagic manifestations were common in both dengue cohorts 
(35% in Bandung and 38% in Jepara) and manifested predominantly as skin or mucosal 
bleeding. Ultrasonography was performed routinely in the Bandung cohort during the 
critical phase showing ascites, pleural effusion or a thickened gallbladder in 33 (82.5%) of 
the enrolled patients. 
Fig 1A-B shows platelet numbers in the Bandung and Jepara cohorts. Platelets numbers 
in healthy controls were not determined. As expected, platelet numbers were lowest on 
day 4-6 after onset of fever, which roughly corresponds with the critical phase of dengue. 
Fig 1C-F shows data of platelet activation and reactivity to ex vivo stimulation with the 
platelet agonist ADP. Compared with healthy controls, circulating platelets of dengue 
patients were activated on day 1-3 and day 4-6 after fever onset, as shown by increased 
expression of P-selectin and fibrinogen binding to integrin αIIbβ3. In conjunction with 
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this, ex vivo reactivity to stimulation with ADP was significantly reduced on these days 
compared with later phases and healthy controls, indicating platelet dysfunction. Similar 
findings were found for platelet reactivity towards the platelet agonist TRAP (Fig S1). These 
findings confirm our earlier findings that platelets in patients with dengue are activated, 
but also functionally impaired [15].
Table 1 – Clinical characteristics cohorts Bandung and Jepara.
Bandung Jepara
Variable Dengue Controls Dengue Non-dengue 
illness
Controls
Number 40 10 40 15 25
Male, n, (%) 27 (68) 4 (40) 21 (53) 6 (40) 14 (56)
Age, years, median (IQR) 22 (17-35) 27 (17-35) 20 (15-39) 26 (12-33) 28 (26-34)
Days of fever at presentation, 
median (IQR)
4 (3-5) NA 4.0 (2-6) 4.1 (2-6) NA
NS1 positive, n (%) 38 (95) NA 16 (40) 0 (0) NA
Bleeding manifestations, n (%) 14 (35) NA 15 (38) 0 (0) NA
Bleeding type, n (%) NA NA
   Petechia 3 (7.5) 7 (17.5)
   Gum bleeding 8 (20.0) 5 (12.5)
   Epistaxis 5 (12.5) 6 (15)
   Melena 2 (5.0) 3 (7.5)
   Hypermenorrhea 1 (2.5) 0 (0)
Classification, n (%)#
   DF 8 (20) NA 25 (62) NA NA
   DHF 32 (80) NA 15 (38) NA NA
Full blood count at presentation,  
median (IQR)
   Hemoglobin, gr/dL 14.2 (13.5-15.2) 13.4 (12.7-16.1) 13.8 (12.4-14.1) 13.6 (12.8-13.9) 13.9 (12.9-14.2)
   Platelet count, 109/L 62 (34-101) 265 (237-312) 46 (29-72) 152 (104-211) 261 (197-309)
   Hematocrit, % 42.0 (40.0-44.8) 41.0 (38.3-46.3) 41.7 (38.1-41.8) 42.2 (37.7-42.8) NA
#  DF, dengue fever; DHF, dengue hemorrhagic fever (defined as dengue with hemorrhagic manifestations, plasma 
leakage, and platelet count <100x109/L). 
NA, not applicable.
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Figure 1 – Platelet number and platelet activation with impaired reactivity in patients with dengue 
infection. (A, B) Platelet number at enrolment in cohorts from Bandung and Jepara. Binding of 
fibrinogen (C, D) to platelets and platelet P-selectin expression (E, F) in unstimulated samples and 
after ex vivo stimulation with two concentrations of ADP. Platelet P-selectin expression and binding of 
fibrinogen were measured using flow cytometry and are expressed as median fluorescence intensity 
(MFI) in arbitrary units. Data depicted as geometric mean with 95% confidence interval. Differences 
between groups were analyzed using the Mann-Whitney U test, *P < 0.05, ** P<0.01, ***P<0.001.
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Increased VWF binding to platelets
Plasma levels of active VWF levels are increased in patients with dengue [19], but it is 
unknown whether this results in higher binding of VWF to platelets. We, therefore, 
determined the binding of VWF to platelets in the Bandung cohort using flow cytometry. 
We observed a significantly (P<0.001) higher binding of VWF to circulating platelets of 
patients in the acute or critical phase of dengue compared to healthy controls (Fig 2A; 
gating strategy shown in Fig S2). When plasma VWF was further activated by ex vivo 
incubation of whole blood with different concentrations of ristocetin, VWF-platelet 
binding increased. Higher values were obtained in the febrile and critical phase than in 
the convalescence phase and in healthy controls (Fig 2B). Median plasma VWF antigen 
(VWF:Ag) concentrations were approximately three fold higher in patients in the acute 
phase than in controls (median, (IQR); 27.9 µg/ml (21.6 – 38.8 µg/ml) vs. 8.4 µg/ml (4.4 – 
14.1 µg/ml); P< 0.01) and remained elevated throughout the convalescent phase (Fig 2C). 
Plasma concentrations of active VWF, which means VWF in which the platelet binding 
epitope on the A1 domain is exposed, were two-fold higher in the acute phase than in 
controls (median (IQR) 629 ng/ml (461 – 860 ng/ml) vs. 300 ng/ml (151 – 319 ng/ml); P<0.01) 
(Fig 2D). Levels of ADAMTS-13, an enzyme that cleaves prothrombotic ultra-large VWF, 
was significantly lower in patients around the critical phase (day 4-6 after fever onset) 
compared with the convalescent phase (day >13) and healthy controls (Fig S3). 
Platelet-VWF binding was inversely correlated with platelet numbers in enrolment 
samples (Pearson R= -0.59; P< 0.001) (Fig 2E). Increased VWF-platelet GP1b interaction was 
reported to be associated with inhibition of platelet αIIbβ3 [21], but we found no correlation 
between platelet-VWF binding and TRAP- or ADP-induced platelet fibrinogen binding 
(Fig 2F, data high dose TRAP shown). There was also no correlation between platelet-VWF 
binding and plasma VWF levels (R= -0.09; P= 0.68), active VWF levels (R= 0.08; p= 0.69) or 
ADAMTS-13 levels (R= -0.19; P= 0.39) (Fig S3). These results show for the first time that VWF 
binding to platelets is a feature of dengue which may contribute to dengue-associated 
thrombocytopenia.  
Finally, we compared platelet parameters between patients with and without bleeding, 
as well as those with and without plasma leakage. No significant differences in platelet 
count, platelet-VWF binding, plasma VWF and active VWF levels were found between 
subjects with or without bleeding complications and between those with or without 
plasma leakage, except for a significantly higher plasma VWF in the in the plasma leakage 
group (Fig S4).  
 
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 41
2
Desialylation mediates platelet clearance in dengue
41
Figure 2 – Increased VWF-platelet binding and plasma VWF:Ag and active VWF levels in dengue 
patients. (A) Platelet-VWF binding measured by flow cytometry in unstimulated samples (line is 
geometric mean with 95% confidence interval) and (B) after ex vivo stimulation with increasing 
concentrations of ristocetin in participants with acute dengue and healthy volunteers. (C) Time 
course of plasma VWF:Ag levels and (D) active VWF levels in the same participants. (E) Pearson 
correlation between platelet-VWF binding and platelet number in enrolment samples and (F) 
fibrinogen binding after ex vivo stimulation with high dose (156µM) TRAP in enrolment samples. Data 
shown are individual values or aggregated data as geometric mean with 95% confidence interval. 
Differences between groups were analyzed using the Mann-Whitney U test, *P < 0.05, ** P<0.01, 
***P<0.001.
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Platelet desialylation in dengue infection
Next, in the Jepara cohort, we determined whether there was also loss of sialic acid from 
the platelet membrane in dengue infection. Platelet surface sialic acid was measured 
in patients in the critical or early recovery phase of dengue (median 7 days after fever 
onset) using the lectins SNA and MAL-II, which primarily binds α-2,6-sialoglycans and 
MAL-II α-2,3-sialoglycans, respectively. The median (IQR) platelet count at the time of 
measurement was 57 (37-81) x109/L. Binding of both lectins to sialic acid residues was 
significantly reduced in patients with dengue, compared with patients with non-dengue 
febrile illness and healthy controls (Figs 3A and 3B; gating strategy shown in Fig S5). In 
12 participants, SNA and MAL-II binding was also measured in the convalescence phase 
when platelets numbers had normalized. Both platelet SNA and MAL-II had increased 
significantly compared with the early dengue phase with median MFI values for SNA of 
762 (663 – 857) vs. 537 (439 – 752; P=0.003; Wilcoxon signed rank test) and for MAL-II of 
6246 (5171 – 7188) vs. 5096 (4435 – 6004; P=0.001). In the early dengue phase, platelet count 
correlated significantly with SNA binding (Spearman R 0.48; P= 0.002), but not with MAL-II 
binding (R 0.28; P=0.08). In addition, there was also no correlation between SNA or MAL-
II binding and levels of VWF:Ag (SNA R= -0.2; P= 0.25 and MAL-II R= 0.13; P= 0.46)  or of 
active VWF (SNA R= -0.2; P= 0.25 and MAL-II R= 0.13; P= 0.46). We compared dengue patients 
with and without bleeding in the Jepara cohort and did not find statistically significant 
differences in platelet sialic acid expression or platelet reactivity (Fig S6).
Next, we investigated mechanisms underlying desialylation. First, we tested whether 
plasma sialidase activity was increased in acute dengue with a functional sialidase activity 
assay. As shown in Fig 3C, sialidase activity in the plasma of acute dengue patients was not 
increased in comparison to the other groups. Further proof that platelet desialylation in 
dengue infection does not result from increased plasma sialidase activity was provided 
by mixing PRP from healthy Dutch volunteers with PPP (1:1 volume ratio) from randomly 
selected patients with dengue (sample from acute and convalescent phase), non-dengue 
febrile illness or healthy controls (n=6 each group). As shown in Fig 3D, no differences in 
platelet desialylation across the groups were observed. Finally, to further confirm these 
results, we performed glycoprofiling of intact plasma transferrin using mass spectrometry 
in five dengue patients with the highest plasma sialidase activity in the functional 
assay [35]. Loss of sialic acid was calculated using the ratio of the undersialylated trisialo-
glycosylated transferrin form and this ratio was below the upper reference of normal (<5%) 
in all five patients (table 2).
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Table 2 – Sialidase activity and plasma transferrin glycosylation of patients with dengue.
Sialidase activity (pmol/hr) Sialic acid loss (%)
Dengue patient 1 99 2.8
Dengue patient 2 101 2.6
Dengue patient 3 103 1.9
Dengue patient 4 106 3.6
Dengue patient 5 123 2.8
Sialic acid loss upper reference of normal: <5%
Figure 3 – Platelet desialylation in acute dengue and plasma sialidase activity. Binding of the 
lectins (A) SNA and (B) MAL-II to platelet sialic acid residues measured by flow cytometry, in patients 
with acute dengue (n=40), non-dengue febrile illness (n=15) and healthy controls (n=20) in Jepara. 
(C) Plasma sialidase activity measured as moles of substrate (2-(4-methylumbelliferyl) α-D-N-
acetylneuraminic acid) hydrolyzed per hour. (D) Binding of SNA and MAL-II lectins to platelets 
following incubation of platelet rich plasma from healthy Dutch volunteers with platelet poor plasma 
from patients with dengue (acute and convalescence sample), non-dengue febrile illness and healthy 
controls (n=6 per group). Data expressed as geometric mean with 95% CI. Samples depicted in panels 
A-B were analyzed on a BD FACS Calibur in Jepara, and samples in panel D on a Beckman coulter FC500 
flow cytometry in The Netherlands, which explains the differences in MFI values. Differences between 
groups were analyzed using the Mann-Whitney U test, *P < 0.05, ** P<0.01, ***P<0.001. NS depicts 
statistically non-significant result across groups using Kruskal-Wallis test.
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In vitro studies
Other possible mechanisms responsible for removal of sialic acid from platelets in 
dengue infection were further explored in a series of in vitro experiments. A recent study 
showed that dengue virus NS1 protein is able to induce the expression of sialidase and 
heparanase in endothelial cells, leading to desialylation of the endothelial glycocalyx 
layer [38]. We, therefore, investigated whether NS1 also induces desialylation of platelets. 
Incubation of washed platelets or PRP with different concentrations of NS1 up to four 
hours did, however, not reduce binding of SNA or MAL-II lectins to sialic acid residues, nor 
did it increase the binding of RCA to galactose residues or surface expression of Neu1 on 
platelets indicating that NS1 did not induce platelet desialylation (Figs 4A, 4B and S7A). 
As expected, desialylation was observed using purified neuraminidase from C.perfringens 
as a control. NS1 did induce platelet activation, as indicated by increased P-selectin 
expression (Fig 4C). Next, we investigated whether DENV itself would induce removal of 
sialic acid. DENV is known to activate platelets [12], which we confirmed in our experiments 
by finding increased platelet P-selectin expression (Fig 4D). However, removal of sialic 
acid, as evidenced by a reduction in the binding of SNA or MAL-II, or increased binding 
of RCA lectin, which is a lectin that binds to desialylated β-galactose residues, was not 
observed following incubation of washed platelets with DENV2 for 3 or 6 hours (Figs 4E, 4F, 
and 4G; only data at 3 hours are shown). 
Next, because our clinical data showed that platelet-VWF binding is increased in dengue 
infection, we explored whether VWF binding to platelets could be responsible for 
desialylation of platelets. To induce VWF binding to platelets, we exposed PRP of healthy 
volunteers to increasing concentrations of ristocetin, which indeed resulted in a dose-
dependent increase in VWF-platelet binding (Fig 5A). In the same time, surface sialic acids 
were reduced as evidenced by a reduction in binding of the lectins SNA and MAL-II. These 
effects were dependent on VWF binding to GPIbα as blocking the VWF with anti-GPIbα 
antibodies prevented desialylation (Fig 5B and 5C). VWF-mediated platelet desialylation 
was confirmed using washed platelets and purified VWF whereby addition of ristocetin 
resulted into exposure of galactose residues (detected by RCA lectin binding) in a dose 
response manner (Fig S7B). We further show that ristocetin-induced VWF-platelet binding 
increases the expression of Neu1 on the platelet surface (Fig 5D). Neu1 is stored in platelet 
lysosomes and the Neu1 expression on the membrane correlated strongly (R 0.95; P=0.01) 
with the lysosomal marker CD63 (Fig 5E). Previous studies showed that the neuraminidase 
inhibitor oseltamivir is able to inhibit Neu1 activity in platelets [40]. We confirmed these 
findings by showing that ristocetin induces the binding or RCA lectin to platelets (Fig 
5F), which can be inhibited by oseltamivir acid in a concentration as low as 1µM, which 
is equivalent to plasma levels of the drug [41] (Fig 5G). Lower concentrations of oseltamivir 
resulted into inconsistency in the RCA lectin binding.
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Figure 4 – Dengue non-structural protein 1 (NS1) nor dengue virus (DENV) induce platelet 
desialylation. Binding of (A) SNA or (B) MAL-II lectins to washed platelets or (C) the expression of 
P-selectin after incubation with two concentrations of DENV2 NS1 protein for 4 hrs at 37°C (n=7 
platelet donors). (D) shows expression of platelet P-selectin and (E-G) the binding of SNA, MAL-II, 
or RCA lectins to washed platelets following incubation with dengue virus type 2 (DENV 2) for 3 hrs 
at 37°C (n=8 platelet donors). Purified neuraminidase from C. perfringens (100 mU) and the platelet 
agonist adenosine diphosphate (ADP) at 125 µM were used as positive controls. Mock infection 
with supernatant of uninfected C6/36 cells harvested at the same time as DENV2 stocks was used 
as negative control. Data are shown as geometric mean with 95% confidence interval. Samples 
depicted in panels A-C were analyzed on a Beckman coulter Cytoflex, and samples in panel D-G on a 
FC500 flow cytometer, which explains the differences in MFI values. Differences between groups were 
analyzed using the Mann-Whitney U test, *P < 0.05, ** P<0.01, ***P<0.001.
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Figure 5 – Binding of VWF to platelets induces platelet desialylation which can be inhibited by 
oseltamivir. Binding of (A) von Willebrand factor (VWF), (B) SNA and (C) MAL-II lectins to platelets and 
(D) platelet membrane expression of Neuraminidase-1 (Neu-1) after exposing platelet rich plasma 
(PRP) of healthy volunteers to ristocetin for 1 hr at 37°C in presence and absence of GPIb receptor 
blocking antibodies. (E) Pearson correlation between the expression of Neu-1 and the lysosomal 
marker CD63 on the platelet membrane after incubation PRP with ristocetin (1.6mg/ml for 1 hour). (F) 
Binding of RCA lectin to galactose or N-acetylgalactosamine residues on platelets after exposing PRP 
to ristocetin (G) with and without the addition of increasing concentration of oseltamivir. Purified 
neuraminidase from C. perfringens (100mU) was used as a positive control. Data were analyzed using 
Student’s T-tests and presented as geometric mean with 95% confidence interval. *** P < 0.001, ** P 
< 0.005, * P < 0.05; ### P < 0.001 when samples were compared with ristocetin-treated samples that 
were unexposed to oseltamivir. Data were from on 5-7 platelet donors in  2 independent experiments.
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Discussion
In this study, we describe a new mechanism of platelet clearance and thrombocytopenia 
in dengue infection. The release of VWF by activated endothelial cells results in excessive 
VWF binding to platelets, leading to loss of surface sialic acid. We show for the first time 
that a dengue infection induces a marked increase in VWF binding to circulating platelets, 
which was inversely related to platelet number. We further show for the first time that 
circulating platelets in dengue patients have lost surface sialic acid. This occurred in the 
absence of increased plasma sialidase activity. We further investigated the mechanisms 
underlying platelet desialylation in dengue infection in vitro and identified increased VWF 
binding to platelets as the most likely mechanism. Platelets are important in preservation 
of endothelial integrity [10]. We speculate that the course of events in dengue infection 
is that endothelial cell activation in the setting of dengue infection leads to release and 
activation of VWF. The resulting VWF-mediated platelet clearance may in turn contribute 
to the vascular leakage syndrome that is characteristic of severe dengue.
We and other groups have previously shown that patients with acute dengue have higher 
VWF plasma levels [19, 42]. Under normal circumstances, VWF does not bind to GPIbα on 
platelets, but does so only after a conformational change exposing its active A1 domain. 
Active VWF can be measured using a specific nanobody, and here, we confirm our earlier 
findings that the amount of active VWF in the circulation is markedly increased in dengue 
infection [19]. Our present study adds to these earlier data that we now also show directly, 
using a novel flow cytometry assay, that more VWF has bound to circulating platelets. 
It thereby supports the notion that VWF is important in the etiology of dengue-induced 
thrombocytopenia, as binding of VWF to platelets is expected to result in platelet 
clearance. It is also in concordance with our earlier observations that VWF:Ag is being 
consumed in children with severe dengue [19]. In contrast to our current findings, VWF:Ag 
levels in these children admitted to the ICU with severe dengue showed an increasing trend 
towards discharge, while levels of VWF:propeptide decreased . Because VWF:propeptide 
is secreted in equimolar amounts as VWF:Ag, this time course was suggestive for VWF 
consumption. In the current study, VWF consumption was probably less pronounced as 
most participants had dengue disease without severe complications. 
Another important finding of our study was that circulating platelets in dengue patients 
contained less surface sialic acid. Removal of sialic acid exposes terminal β-galactose 
and β-GlcNAc resulting in accelerated platelet clearance via Ashwell–Morell receptor [25-
28]. Removal of 8-10% of platelet sialic acid was reported to be sufficient to cause platelet 
clearance from the circulation [43]. Recently, VWF binding to platelets by botrocetin or by 
platelet refrigeration was shown to induce unfolding of the mechanosensory domain 
of the GPIbα subunit, leading to GPIb-IX–mediated signaling in the platelet, including 
calcium mobilization, phosphatidylserine exposure, and likely trafficking of Neu1 to the 
platelet surface and subsequent desialylation of platelet glycoproteins [44], [29]. We confirm 
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these findings in vitro by demonstrating that induction of VWF binding to platelets with 
ristocetin results in increased expression of Neu1 on the platelet surface and platelet 
desialylation. We cannot exclude that ristocetin may execute a VWF-independent effect 
on platelet desialylation, as previous studies suggested that ristocetin has direct effects 
on GPIbα and other platelet receptors [45, 46]. However, our findings that ristocetin did not 
induce platelet desialylation in the presence of GPIbα blocking antibodies or in washed 
platelets in absence of VWF supports the conclusion that the effects of ristocetin on 
platelet desialylation are through induction of VWF binding to platelet GP1bα. In addition, 
the snake venom protein botrocetin, which induces VWF binding to platelets but does not 
bind GPIbα, also triggers platelet desialylation [44]. 
Our present study also supports findings from previous studies that platelets are activated 
during a DENV infection [12, 15]. Despite our observation that activating platelets ex vivo 
using ADP did not result in removal of sialic acid from the platelet membrane, we cannot 
exclude that in vivo platelet activation results in trafficking of Neu1 to the membrane 
where it may desialylate GP1b, leading to increased binding of VWF to the platelet.
We also investigated other possible mechanisms of platelet desialylation in dengue 
infection. NS1 was recently shown to induce sialidase in endothelial cells, leading to 
degradation of endothelial bound sialic acid [47], but we did not find platelet desialylation 
upon exposure of platelets to NS1. In addition, dengue virus does not express 
neuraminidase, in contrast to other viruses as influenza or bacteria as Streptococcus 
pneumoniae. Incubation of platelets with cultured dengue virus did induce platelet 
activation, as previously reported [12-14], but did not induce platelet desialylation. This was 
further supported by the fact that sialidase activity in plasma of dengue patients was 
not increased, that plasma of dengue patients failed to induce desialylation of platelets 
of healthy volunteers and that plasma proteins (transferrin) of dengue patients were 
not desialylated. The latter is in contrast to an earlier study by Rajendiran et al. [48], who 
reported increased desialylation of plasma proteins in patients with dengue.
In vitro, VWF-induced platelet desialylation could be circumvented by the neuraminidase 
inhibitor oseltamivir acid, which is widely used worldwide in the treatment of influenza 
infections. Interestingly, over the past years, different authors have reported that 
oseltamivir may increase platelet counts in conditions such as immune thrombocytopenic 
purpura [49, 50], sepsis [51] and suspected influenza [52]. We are currently carrying out a phase 
2 randomized clinical trial to study the effect of oseltamivir on thrombocytopenia and 
plasma leakage in dengue infection (ISRCTN35227717). In addition, antagonists of VWF, 
such as the anti-VWF aptamer ARC1779 are nowadays available. ARC1779 was able to 
reverse thrombocytopenia in VWD type 2B. a condition characterized by excessive binding 
of VWF to platelets [53]. This reinforces the importance of VWF in platelet clearance and 
supports the possible use of VWF antagonists as adjunctive therapy for dengue-associated 
thrombocytopenia.  
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Our present study confirms our earlier finding that acute dengue infections are not only 
associated with thrombocytopenia but also platelet dysfunction with hyporeactivity 
to ex vivo activation [15]. This platelet dysfunction, which may contribute to bleeding 
complications, may be a consequence of profound platelet activation in the circulation 
resulting in secondary loss of function. Additional proof for the occurrence of platelet 
exhaustion in dengue infection was recently provided by a quantitative proteomics 
study of platelet contents showing exhaustion of the granule-stored PF4/CXCL4 [54]. Gain 
of function mutations in VWF, as seen in von Willebrand disease type 2B were shown 
to impair activation of the αIIbβ3 integrin. However, this mechanism appears to be less 
important in dengue infection, as there was no inverse correlation of platelet-VWF binding 
with platelet-fibrinogen binding in our cohort.
Different limitations of our studies should also be acknowledged. First, VWF binding to 
platelets and platelet sialic acid were measured in different cohorts, preventing us to 
analyze a direct correlation between both parameters. We were able to correlate platelet 
SNA and MALII lectin binding with plasma levels of active VWF, but this did not show a 
significant correlation. In our opinion, however, this does not disprove the hypothesis 
that excessive platelet-VWF binding is responsible for platelet desialylation in dengue 
infection, because VWF binding to platelets did not correlate with active VWF plasma 
levels in our cohort. Second, it was not possible to measure the expression of neu1 on the 
platelet membrane in the patient samples.  Third, the proposed mechanisms for platelet 
desialylation were analyzed using in vitro studies and samples from healthy individuals, 
rather than dengue-infected patients due to limited availability of patient material.
In conclusion, acute dengue infections induce the binding of VWF to platelets, which 
results in the removal of sialic acids from the platelet surface by the actions of endogenous 
neuraminidase. Neuraminidase inhibitors such as oseltamivir might represent a novel 
therapeutic option for dengue-associated thrombocytopenia.   
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Supplemental materials
Figure S1 – Platelet activation with impaired reactivity to TRAP in patients with acute dengue. 
Binding of fibrinogen to platelets and platelet P-selectin expression in unstimulated samples and 
after ex vivo stimulation with two concentrations of TRAP. (A, B) Data from Bandung cohort with 
longitudinal data from the different days of fever in dengue patients and in healthy controls. Platelet 
P-selectin expression and binding of fibrinogen were measured using flow cytometry and are 
expressed as median fluorescence intensity (MFI) in arbitrary units. Data depicted as geometric mean 
with 95% confidence interval. Differences between groups were analyzed using the Mann-Whitney U 
test, *P < 0.05, ** P<0.01, ***P<0.001.
A       B        Based on Gate P0
   
C        Based on Gate P1    D         Based on Gate P1
   
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 55
2
Desialylation mediates platelet clearance in dengue
55
E         Based on Gate P1 
Figure S2 – Flow cytometry gating strategy for determination of VWF binding to platelets. Platelets 
were gated based on forward and side scatter characteristics (A), followed by positivity for the 
platelet marker CD61-PC7 (B). The Median fluorescence intensity (MFI) of anti-VWF after stimulation 
(C) without agonist and (D) after ex vivo VWF-activation with ristocetin (0.777 µM). (E) Observed 
differences in VWF binding to platelet with marker Anti-VWF-FITC in unstimulated sample and after 
ex vivo stimulation of platelets with ristocetin.
Figure S3 – ADAMTS-13 activity in Bandung cohort.  (A) Data from different days of fever in dengue 
patients and in healthy controls. Data are shown as geometric mean with 95% confidence interval. 
Differences between groups were analyzed using the Mann-Whitney U test. (B-D) The correlation 
between VWF binding to platelets without any agonist stimulation and plasma VWF, VWF activation 
factor and ADAMTS13 activity is shown. Analysis were done using Pearson correlation coefficient.  *P 
< 0.05, ** P<0.01.
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Figure S4 – Differences in platelets and VWF parameters between dengue patients with and 
without bleeding, and patients with and without plasma leakage. Data shown are platelet numbers 
(A and B), VWF binding to platelets in the absence of an agonist (MFI) (C and D), Plasma VWF:Ag levels 
(E and F) and plasma active VWF levels (G and H). Differences between groups were analyzed using the 
Mann-Whitney U test, *P < 0.05, ** P<0.01, ***P<0.001.
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Figure S5 – Flow cytometry gating strategy for determination of sialic acid expression on platelets. 
Platelets were gated in P0 based on forward and side scatter characteristics (A) followed by positivity 
of the platelet marker CD61-PC7 in P1 (B). The median fluorescence intensity (MFI) of PE-labeled SNA 
lectin on platelets is determined from gate P1 (C, higher expression, and D, lower expression of sialic 
acid).
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Figure S6 – Sialic acid expression and platelet reactivity in dengue patients with or without 
bleeding. Binding of the lectins (A) SNA and (B) MAL-II to platelet sialic acid residues were measured 
by flow cytometry in dengue patients with (n=22) and without bleeding (n=18). Platelet P-selectin 
expression and binding of fibrinogen to platelets in unstimulated samples and after ex vivo 
stimulation with two concentrations of ADP (C, D). Platelet P-selectin expression and binding of 
fibrinogen were measured using flow cytometry and are expressed as median fluorescence intensity 
(MFI) in arbitrary units. Data are expressed as geometric mean with 95% confidence interval. 
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Figure S7 – Platelet desialylation is mediated by VWF binding to platelets. (A) Expression of 
Neuraminidase 1 (Neu-1) and binding of RCA lectin and VWF to platelets after incubation with two 
concentrations of DENV NS1 protein for 4 hrs at 37°C (n=7 platelet donors). (B) Binding of VWF and 
RCA to platelets after incubating washed platelets with increasing concentrations of purified VWF 
and 1.6mg/ml of ristocetin for 1 hr at 37°C (n=5 platelet donors). Purified neuraminidase from C. 
perfringens (100 mU) was used as positive control. Samples were analyzed using Beckman coulter 
Cytoflex flow cytometry. Data are shown as geometric mean with 95% confidence interval.
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 60
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 61
CHAPTER 3
 
Desialylation of platelets by 
pneumococcal neuraminidase A 
induces ADP-dependent platelet  
hyper-reactivity
Vesla Kullayaa,b,c,#, Marien I. de Jongeb,d, Jeroen D. Langereisb,d, Christa E. van der Gaast – de 
Jonghb,d, Christian Bülle, Gosse J. Ademae, Dirk Lefeberf, Amelieke J. Cremersg, Blandina T. 
Mmbagac, Phillip G. de Grooth, Quirijn de Masta,b, Andre J. van der Vena,b
 
Affiliations
a  Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
b   Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The 
Netherlands
c   Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
d   Laboratory of Pediatric Infectious Diseases, Radboud University Medical Center, Nijmegen, The 
Netherlands
e   Department of Radiation Oncology, Radiotherapy & Oncoimmunology Laboratory, Radboud University 
Medical Center, Nijmegen, The Netherlands
f   Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen, The Netherlands
g  Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands
h   Department of Clinical Chemistry and Haematology, University Medical Centre, Utrecht, The 
Netherlands
Infect immun. 21;86(10). Pii: e00213-18.
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 62
Chapter 3
62
Abstract
Platelets are increasingly recognized to play a role in the complications of Streptococcus 
pneumoniae infections. S. pneumoniae expresses neuraminidases, which may alter 
glycans on the platelet surface. In the present study, we investigated the capability of 
pneumococcal neuraminidase A (NanA) to remove sialic acid (desialylation) from the 
platelet surface, the consequences for the platelet activation status and reactivity, and the 
ability of neuraminidase inhibitors to prevent these effects. Our results show that soluble 
NanA induces platelet desialylation. Whereas desialylation itself did not induce platelet 
activation (P-selectin expression and platelet fibrinogen binding), platelets became 
hyper-reactive to ex vivo stimulation by adenosine diphosphate (ADP) and crosslinked 
collagen-related peptide (CRP-XL). Platelet aggregation with leukocytes also increased. 
These processes were dependent on the ADP-pathway as inhibitors of this pathway 
(apyrase and ticagrelor) abrogated platelet hyper-reactivity. Inhibition of NanA-induced 
platelet desialylation by neuraminidase inhibitors (e.g. oseltamivir acid) also prevented 
the platelet effects of NanA. 
Collectively, our findings show that soluble NanA can desialylate platelets leading to 
platelet hyper-reactivity which can be prevented by neuraminidase inhibitors.
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Introduction
Streptococcus pneumoniae is a major cause of community acquired pneumonia 
and invasive infections [1]. S. pneumoniae is known to activate platelets via different 
mechanisms, including through engagement of immune receptor FcγRIIA and integrin 
αIIbβ3, and activation of Src and Syk tyrosine kinases [2]. The role of Toll like receptor (TLR)-
2 in pneumococcal-induced platelet activation has also been proposed [3], however with 
contradictory results [4]. Thrombocytopenia, which may result from platelet activation, 
is an independent predictor of mortality in severe pneumonia [5]. Whether platelet 
desialylation by pneumococcal NanA is another mechanism of platelet activation by S. 
pneumoniae is still unknown.
The  importance of platelets in processes beyond hemostasis and coagulation is 
increasingly appreciated [6]. Activated platelets release different immune molecules, 
modulate the response of leukocytes and contribute to the formation of neutrophil 
extracellular traps (NETs) that trap bacteria in the circulation avoiding their further 
dissemination [7,8]. Furthermore, platelet activation may also increase the risk for 
cardiovascular complications which are common during S. pneumoniae infections [9]. 
Three genes encode for neuraminidase activity in S. pneumoniae - nanA, nanB and nanC - of 
which only nanA is expressed by all pneumococci. The NanA protein is located at the cell 
surface of pneumococci where it is involved in the facilitation of mucosal colonization 
[10, 11]. Platelet surface glycoproteins (GPs) are decorated with N-acetylneuraminic acid 
(Neu5Ac) type of sialic acid [12] of which about 60% is liable to cleavage  by neuraminidase 
[13]. Desialylation of platelets exposes galactose residues and leads to platelet apoptosis, 
phagocytosis and clearance from the circulation by the Ashwell-Morel receptor (AMR) in 
the liver [14,15]. Grewal et al. showed in a mouse model of pneumococcal sepsis that removal 
of desialylated platelets by the AMR protected against disseminated intravascular 
coagulation [16]. 
Although NanA is well studied as a surface virulence factor [11, 17, 18], its effect on platelet 
activation and function remains unclear, as well as whether neuraminidase inhibitors 
such as oseltamivir acid are able to prevent these effects [19]. Recently, two main variants 
of NanA, containing the amino acids ‘KGI’ or ‘RAV’ at the catalytic site, were reported to 
differ in enzyme kinetics and susceptibility to neuraminidase inhibitors [20]. It is unknown 
whether infection with either variant will result into a different clinical outcome. 
The current study aimed to investigate the effects of soluble NanA on platelet 
desialylation, platelet activation status and platelet reactivity and characterize involved 
pathways. Furthermore, the propensity of neuraminidase inhibitors and platelet function 
inhibitors to prevent these NanA effects on platelet were explored. Finally, we studied 
whether the KGI and RAV variants of NanA had a different effect on platelets and whether 
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these variants were associated with platelet count in a cohort of individuals with invasive 
pneumococcal infections.
Results
Soluble NanA from S. pneumoniae desialylates platelets.
To determine whether NanA was released in the medium, supernatants from wild-type 
(WT) and nanA mutant (DnanA) pneumococci were analyzed by SDS-PAGE. This analysis 
showed a NanA band of the expected size in the WT derived supernatant, whereas this 
band was absent in the mutant (figure S1). 
To study the effect of soluble NanA on platelet surface sialic acid content, washed platelets 
were exposed to supernatant with and without NanA, derived from WT and DnanA mutant 
respectively. Platelets incubated with NanA resulted in reduced interaction of the sialic 
acid binding lectins SNA and MALII compared with platelets incubated without NanA, 
indicating that NanA cleaved sialic acids from platelet surface glycoproteins (figure 1A, 
1B, S2). Binding of SNA lectin on platelets exposed to lower dilutions of DnanA-derived 
supernatant tended to be higher than in those exposed to PBS (figure 1A). This may be 
due to factors in the supernatant that enhance binding of SNA to glycoproteins of non-
desialylated platelets. The different binding specificity of MALII, which binds to α-2,3-
sialoglycans, and SNA, which binds to α-2,6-sialoglycans, likely explains the differences in 
binding patterns of the two lectins. Neuraminidase activity in the supernatants was 441.2 
µMol/min/l and 58.9 µMol/min/l for supernantants with and without NanA respectively 
as measured by the substrate hydrolysis assay. Based on the concentration curve in figure 
1, we chose to use the 1:400 dilution point in the subsequent experiments. This dilution 
point is equivlent to 1.10µMol/min/l and 0.14µMol/min/l for supernantants with and 
without NanA respectively. 
 
Figure 1 – Binding of SNA and MAL II lectins to NanA exposed platelets. Binding of SNA (A) and MALII 
(B) lectins to platelet surface sialic acid after treating washed platelets with serial dilutions (1:80 – 
1:10000) of pneumococcal culture supernatants with (+NanA) and without NanA (-NanA) for 1 hour 
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at 37°C. PBS and purified neuraminidase from C. perfringens (NA) were used as negative and positive 
controls respectively. Data are presented as mean with SD of mean fluorescent intensity in arbitrary 
units (MFI-AU) of two independent experiments with 3 replicates each; (n=6). Differences between 
the supernatants with and without NanA (+NanA vs –NanA) were analysed using t-test **p<0.01, 
*p<0.03, ns = not significant. Increase in desialylation with decrease dilution of supernatants was 
analysed using 1-way ANOVA with post test for linear trend. For +NanA supernatant; r2=0.73, p<0.001 
for SNA and r2=0.44, p<0.001 for MALII while for –NanA supernatant r2=0.18, p=0.06 for SNA and 
r2=0.65, p<0.001 for MALII. 
 
NanA exposure results in platelet hyper-reactivity that is largely ADP 
signalling dependent. 
Next, we studied the effects of NanA on platelet activation status and platelet reactivity to 
ex vivo stimulation. Platelet rich plasma was exposed to NanA for 1 hour to assess platelet 
activation with subsequent determination of platelet reactivity by addition of increasing 
concentrations of the platelet agonists ADP, CRP-XL and TRAP. There was no difference in 
the expression of the alpha-granule protein P-selectin and binding of fibrinogen following 
exposure to supernatant with or without NanA. In contrast, following ex vivo stimulation 
with ADP and low dose of CRP-XL, platelets exposed to NanA showed higher P-selectin 
expression and fibrinogen binding compared with the control without NanA (figure 2A, 
2B, S3). Stimulation with TRAP also induced higher fibrinogen binding, but not P-selectin 
expression in NanA exposed platelets. Similar results in fibrinogen binding were observed 
using washed platelets indicating that plasma factors had no effects to the observed 
outcome (figure S4A). However, unlike in PRP, fibrinogen binding was also slightly 
increased in desialylated platelets without secondary stimulation probably as a result of 
minimal platelet activation due to the platelet isolation procedure. In order to identify 
involved mechanisms of NanA-induced platelet hyper-reactivity, we focused on the ADP 
pathway, because the platelet effects of NanA were more pronounced when ADP or CRP-XL 
were used as platelet stimuli compared to TRAP. The effect of CRP-XL (collagen pathway) is 
also known to depend on secondary ADP release (21). ADP-signalling was inhibited using 
apyrase, which hydrolyses soluble ADP, and by ticagrelor, an inhibitor of the ADP receptor 
P2Y12. Both apyrase and ticagrelor reduced the NanA-induced platelet hyper-reactivity 
upon ex vivo stimulation with either CRP-XL or TRAP (figure 3), confirming the importance 
of the ADP signalling pathway. 
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Figure 2 – Reactivity of NanA exposed platelets to various platelet agonists. P-selectin (A) and 
fibrinogen (B) expression on platelets after treating PRP with PBS (negative control), 200 mU purified 
neuraminidase from C. perfringens (NA), or supernatant with (+NanA) and without NanA (-NanA) for 1 
hour at 37°C followed by stimulation with increasing concentrations of ADP, CRP-XL or TRAP. Data are 
presented as mean with SEM of mean fluorescent intensity (MFI) in arbitrary units, (n=10). Differences 
between +NanA and –NanA were analysed using t-test. 
 
Figure 3 – Effect of apyrase and ticagrelor to platelet hyper-reactivity of NanA exposed platelets. 
P-selectin (A,B) and fibrinogen (C,D) expression on platelets after treating PRP with PBS or 
supernatant containing NanA (+NanA) for 1 hour at 37°C followed by hydrolysing ADP using 10µg/
ml apyrase (A,C) or blocking ADP receptor using 50 µg/ml ticagrelor (B,D) for 30 minutes before 
stimulation with increasing concentrations of CRP-XL or TRAP. Data are presented as mean with 
SEM of mean fluorescent intensity (MFI) in arbitrary units of two independent experiments with 3 
replicates each; (n=6) and analysed using t-test. ***p<0.001 *p<0.05 +NanA vs +NanA with apyrase or 
ticagrelor.
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NanA promotes dense granule secretion and increases surface 
expression of GPIIIa.
Platelets contain large quantities of ADP in their dense granules, together with other 
molecules such as ATP, calcium and serotonin. Secretion of ADP from dense granules 
activates P2Y12, inducing amplification of platelet activation. We show that NanA 
promotes ADP-induced dense-granule secretion, as suggested by a higher expression of 
the dense granule marker CD63 on the platelet surface together with a reduction in intra-
platelet mepacrine concentrations (figure 4A).  Exposure of platelets to NanA without a 
platelet agonist did not change mepacrine concentrations or CD63 expression, indicating 
that exposure to NanA alone is insufficient for inducing dense granule secretion.
Figure 4 – Degranulation of dense granules and binding of monoclonal antibodies to platelet 
surface receptors in NanA exposed platelets. (A) shows CD63 expression and intra-platelet 
concentrations of mepacrine after treating PRP with PBS (negative control), purified neuraminidase 
(NA) or supernatants with (+NanA) and without (-NanA) followed by stimulation with increasing 
concentrations of ADP. Data are presented as mean with SEM of mean fluorescent intensity (MFI) in 
arbitrary units of two independent experiments with 3 replicates each; (n=6). Differences between 
+NanA and –NanA were analysed using t-test.  (B) shows binding of monoclonal antibodies against 
P2Y12, GPVI, GPIIIa and GPIb on platelet surface after treating PRP with increasing concentrations of 
supernatant containing NanA (+NanA) for 1 hour at 37°C. Data are presented as mean with SD of mean 
fluorescent intensity (MFI) in arbitrary units of three independent experiments with 3 replicates each. 
Increase in expression levels with decrease dilution of the supernatant was analysed using 1-way 
ANOVA with post test for linear trend. ns = not significant
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Exposing platelet rich plasma to increasing concentrations of NanA did not increase binding 
of antibodies directed against the ADP receptor P2Y12, the collagen receptor GPIV or the VWF 
receptor GP1b (figure 4B). In contrast, a significant increase in the binding of antibodies 
against GPIIIa was observed (P<0.001) probably due to increased exposure of antibody 
binding sites as a consequence of removal of sialic acid. When associated with GPIIb, GPIIIa 
constitutes the receptor for fibrinogen and other adhesive proteins such as VWF. 
Neuraminidase inhibitors prevent NanA-induced platelet hyper-reactivity. 
Next, we explored whether neuraminidase inhibitors could prevent NanA-induced platelet 
hyper-reactivity. Both oseltamivir acid and DANA prevented NanA-induced platelet hyper-
reactivity in a dose dependent manner (figure 5).
 
Figure 5 – Inhibition of NanA by oseltamivir acid and DANA. P-selectin and fibrinogen expression on 
platelets after treating PRP with PBS or supernatant containing NanA in the presence of increasing 
concentrations of oseltamivir acid or DANA for 1 hour at 37°C and then stimulated with 125 µM 
ADP. Data shows mean with SEM of mean fluorescent intensity in arbitrary units (MFI-AU) of two 
independent experiments with 3 replicates each; (n=6). Decrease in P-selectin and fibrinogen 
expression levels with increase concentrations of oseltamivir acid or DANA in +NanA samples were 
analysed using 1-way ANOVA with post test for linear trend.
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NanA induces platelet interaction with leukocytes.
Sialic acid is negatively charged, which gives a cell high electronegative surface charge. 
Removal of sialic acid from platelet surface reduces the overall electronegative charge 
and this may increase intercellular interactions. Analysis of whole blood exposed to 
NanA showed increased aggregates of platelets with monocytes, neutrophils and T-cells 
as compared with the control without NanA (figure 6). Addition of oseltamivir showed 
a reduction in platelet-leukocyte interaction although differences were not statistically 
significant (figure S4C).
 
Figure 6 – Interaction of NanA exposed platelets with leukocytes. Levels of platelet interaction with 
monocytes, neutrophils and T-cells after treating whole blood with PBS as negative control, 200mU 
purified neuraminidase from C.perfrigens (NA), or supernatants with (+NanA) and without NanA 
(-NanA) for 1 hour at 37°C. Data are presented as mean with SEM of mean fluorescent intensity (MFI) 
in arbitrary units of two independent experiments with 3 replicates each (n=6), and analysed using 
t-test.
Variation in the catalytic site of NanA had no effect on platelet hyper-
reactivity.
Despite the highly conserved activity of NanA, a recent study revealed the evolutionary 
diversity of this enzyme (20). Two semi-conserved epitopes were identified in the catalytic 
site of NanA ‘KGI’ (Lys-Gly-Ile) and ‘RAV’ (Arg-Ala-Val), which differed in Km (Michaelis 
constant), the substrate concentration at 1/2 the maximum velocity. The Km of the RAV 
variant was found to be significantly lower than the KGI variant, suggesting that the RAV 
variant has a higher activity. In a cohort of 281 patients with S. pneumoniae bacteremia, 
239 had the KGI and 42 the RAV variant. Platelet counts measured at hospital admission 
did not differ between these two groups (figure 7A). Unfortunately, nadir platelet counts 
were available for few patients in the KGI group only and were therefore not used in this 
analysis. Type of disease manifestation and severity of disease were also comparable 
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between the groups (data not shown). A subset of S. pneumoniae isolates from patients in 
either group were cultured and the supernatants were used to study the effect of NanA-
KGI and NanA-RAV on platelet desialylation. There were no differences in binding of SNA 
and MALII lectins to platelets sialic acid between platelets exposed to supernatant of 
KGI or RAV variants (figure 7B, 7C). In addition, there was no difference in neuraminidase 
activity between the two NanA variants as measured by a substrate-based assay (figure 
7D). These observations suggest no difference in the enzymatic activity of NanA variants, 
and no difference in clinical outcome after infection with S. pneumoniae producing either 
variants.
Figure 7 – Differential effect of NanA-RAV and NanA-KGI on platelet function. (A) shows platelet 
count of patients infected with S. pneumoniae containing the KGI or RAV NanA variants at admission 
(KGI (n=239) or RAV (n=42)). (B and C) show binding of SNA and MALII lectins to surface sialic acid 
after treating platelets with supernatant derived from culture of isolates producing either RAV or KGI 
NanA. +NanA and –NanA were used as positive and negative controls respectively. The RAV and KGI 
groups consist of four isolates each tested in three platelet donors. (D) shows enzymatic activity of 
the RAV versus the KGI NanA variants in hydrolyzing sialic acid substrate (2-(4-methylumbelliferyl)
α-D-N-acetylneraminic acid). Data are presented as mean with SD and analysed using t-test. ns = not 
significant.
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Discussion
In this study, we demonstrate that pneumococcal NanA induces removal of sialic acid from 
the platelet surface, resulting in platelet hyper-reactivity. These effects were dependent 
on ADP signaling and could be prevented by ADP receptor antagonists such as ticagrelor, 
as well as neuraminidase inhibitors, such as oseltamivir acid.  
Sialic acid on the platelet surface was determined using the lectins SNA and MALII, 
which both bind N-acetylneuraminic acid found on platelet glycoproteins. Pneumococci 
also harbor other neuraminidases than NanA, e.g. NanB and NanC, explaining why also 
supernatant from αnanA induced some sialic acid depletion. While NanA can cleave α-2,3, 
α-2,6, and α-2,8-linked sialic acids, NanB exhibit preferences for α-2,3-linked sialic acids 
[17]. In our experiments, only NanA gene was mutated. Traces of NanB and NanC could 
still be present in the supernatant, cleaving some of the α-2,3 links that can be detected 
by MALII but not SNA. This account for the low binding of MALII but not SNA lectin to 
platelets exposed to supernatant of the mutant strain. However, NanA is the strongest 
neuraminidase and virulence factor for sialic acid removal. NanB on the other hand is only 
involved in metabolic activities [17, 18].  In our experiments, we carefully selected the dilution 
point of the supernatant where the effect of NanB was minimal diminishing any potential 
effects of this contaminant to the observed outcomes on platelet reactivity.
Our findings show that NanA-induced sialic acid removal does not directly lead to platelet 
activation, but has an indirect effect, as it leads to increased sensitivity for platelet 
activation by other platelet agonists. These findings are in line with a 1975 report of 
Greenberg and colleagues, who found increased agonist-induced platelet aggregation 
after removal of sialic acid by neuraminidase [22]. However, they conducted a non-
controlled experiment with the ADP hydrolyzing agent apyrase leading to inconclusive 
result on the role of ADP. Our study clearly identified the importance of ADP signaling 
in NanA-induced platelet hyper-reactivity and show that both ADP receptor antagonists 
as well as neuraminidase inhibitors may prevent these effects. Although oseltamivir 
acid is designed for influenza neuraminidase, it can effectively inhibit S. pneumoniae 
neuraminidase due to close similarities in the active site of the two proteins [19]. 
Different mechanisms may explain why NanA-desialylated platelets are hyper-reactive, as 
also shown in Figure S5: First, the plasma membrane Orai1 channels contain α-2,6–linked 
sialic acids [23] which can be cleaved off by NanA. Orai1 mediates calcium influx into the 
cell and its desialylation has been associated with increased calcium uptake [23], a process 
known to enhance platelet activation [24]. Secondly, desialylation may lead to a reduction 
in the negative charge of the cell membrane, which may enhance transport of positively 
charged calcium ions over the cell membrane. Thirdly, binding of desialylated VWF (asialo 
VWF) to platelets is known to induce degranulation of platelet dense granules [25], an effect 
that can be blocked by apyrase and Ticagrelor [26]. 
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Neuraminidase could act on platelets as well as on sialylated plasma proteins such as 
fibrinogen in the PRP. However, several studies have reported that the sialic acid content 
of fibrinogen does not affect its interactions with platelets [27, 28]. The observed increase 
fibrinogen binding in our assay are therefore unlikely to have been influenced by desialylated 
fibrinogen molecule. Although aggregation of NanA exposed platelets was not measured 
but is expected as platelet aggregation correlates with fibrinogen binding to platelets.
Platelet activation is an important process in inflammation and host defence [29–31], 
however, hyper-reactive platelets may also increase the risk for cardiovascular events. The 
importance of cardiovascular complications of pneumococcal infections is increasingly 
recognized [9, 32]. ADP receptor antagonists are among the most commonly used drugs 
in cardiovascular medicine and neuraminidase inhibitors are frequently prescribed 
to patients with pneumonia during the influenza season, therefore it is important to 
better understand the effects of NanA-mediated desialylation of platelets. From studies 
in murine models it is known that neuraminidase inhibitors may ameliorate sepsis by 
dampening inflammation  [33]. Grewal et al. found that clearance of desialylated platelets 
protects the host from streptococcal-associated coagulopathy [16]. Interestingly, loss of 
sialic acid is a well-known platelet clearance mechanism and over the past years, different 
authors have reported that oseltamivir acid may increase platelet counts in conditions 
such as immune thrombocytopenia [15, 34], sepsis [35] and suspected influenza [36].
Platelet-monocyte clusters which we observed in vitro, are also observed during S. 
pneumoniae infections [37], and are known to mediate development of cardiovascular events 
[38]. We observed increased platelet-leukocyte aggregates in whole blood exposed to NanA, 
however, desialylation of other sialylated blood components [39] apart from platelets may 
have promoted the observed intercellular aggregation. Platelets engage with leukocyte 
mainly through its surface P-selectin receptor expressed on activated platelets. Platelet-
leukocyte interactions therefore increase with increased platelet activation. Removal of 
sialic acid from cell surfaces reduce cell surface electronegative charge allowing for more 
cell-cell interactions to occur. Our results show that desialylated platelets are hyper-
reactive to stimulation. We hypothesize that during pathological conditions where the 
vasculature is rich with mediators with potential to activate platelets, platelet-leukocyte 
interactions will also be enhanced.
NanA may influence the binding of agonists to other platelet receptors however only 
anti-GPIIIa binding increased significantly when exposing platelets to NanA, while no 
increased binding of anti-P2Y12, anti-GPIV or anti-GP1b antibodies was found. Fibrinogen 
binding to platelets only occurs after a formation of GPIIb/GPIIIa complex that is driven 
by activating agents such as ADP [40], which explains the increase in availability of GPIIIa 
receptor without fibrinogen binding in unstimulated samples. This observation is 
contrary to that of Grewal and colleagues [16] who did not observe a change in binding of 
anti-CD61 (GPIIIa) in desialylated platelets. Our results are in line with previous studies 
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that indicate that glycosylation of P2Y12 receptor (41) or GPVI [42] affects function and ligand 
binding (only GPVI) but not their surface expression. Conversely, amplification of platelet 
hyper-reactivity through ADP signaling may be blunted by neuraminidase as Zhong et al. 
[41] further showed using CHO cells that non-glycosylated P2Y12 receptors are defective in 
the P2Y12-mediated inhibition of adenylyl cyclase activity.
Xu et al. showed with a molecular simulation model and with purified NanA variants 
containing ‘KGI’ and ‘RAV’ motifs in the catalytic domain, that NanA-RAV has a higher 
enzymatic activity than the NanA-KGI variant [20]. We could not confirm this result as 
neither evidence for a difference in clinical outcome nor in the in vitro platelet activation 
assays between the two variants was found. Our findings suggest therefore that the 
exposure to either variants may have similar clinical consequences. Although we were not 
able to demonstrate removal of asialoglycoproteins from the circulation of pneumonia 
patients in our cohort, Grewal et al has shown using a mouse model that intravenous 
administration of pneumococcal sialidase leads to platelet desialylation and subsequent 
removal from the circulation [16]. These observations suggest that a similar effect could 
occur in human patients with streptococcus bacteremia.
Siglecs are sialic acid-binding receptors on cell surfaces involved in the transduction of 
inhibitory signals. Siglec-7 is expressed on platelet surface following platelet activation 
where engagement of purinergic receptors as well as integrin αIIbβ3 is crucial [43]. Siglec-7 
binds to α-2,3, α-2,6 and α-2,8 linkages which can all be cleaved by NanA. Engagement of 
Siglec-7 to its ligand leads to platelet apoptosis by the intrinsic and an extra-mitochondrial 
pathway but has no effect on platelet activation, aggregation, or secretion [43, 44]. Although 
platelet desialylation particularly of the GP1b receptor has been associated with platelet 
apoptosis, the role of siglec-7 was not discussed [15]. Since siglec-7 induces apoptosis after 
engangement to its ligand, the gangliosides, it would be expected that removal of platelet 
sialic acid would affect this apoptotic pathway. Whether platelet desialylation by NanA 
interferes with siglec inhibitory signals requires further investigation. Given the existing 
information, it is unlikely that interference of neuraminidase with siglec-7 ligands would 
affect platelet activation.
One limitation of our study is that we did not purify NanA from culture supernantants 
used. However, we controlled for possible effects of other pneumococcus-derived products 
in the supernatant,  by using a control NanA mutant strain with the same biological 
properties as the NanA producing strain except for NanA secretion. We are therefore 
confident that the effects we observed are caused by NanA and not by other streptococcal 
exoglycosidases such as BgaA (a β-galactosidase) and StrH (a β-acetylglucosaminidase), 
which are primarily membrane bound [45].
Collectively, our findings show that exposure of platelets to soluble NanA induces removal 
of sialic acid from the platelet surface, which in turn, leads to platelet hyper reactivity 
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and increased interaction with leukocytes. Neuraminidase inhibitors may prevent these 
effects on platelets caused by NanA, but the clinical consequences are currently unknown.
Materials and Methods
Ethical statement
Clinical data were obtained from a cohort of adult patients with first episode of bacteremic 
pneumococcal pneumonia admitted at two Dutch hospitals, namely the Canisius-
Wilhelmina Ziekenhuis in Nijmegen and Maasziekenhuis Pantein in Boxmeer between 
2000 and 2011. This cohort study was approved by the Local Medical Ethics Committees 
of both participating hospitals. Analyses of the current study were within the goal of the 
cohort and no additional institutional approval was required. All data and samples used 
were anonymous.
Construction of a DnanA mutant
A directed deletion of nanA was made in the pneumococcal TIGR4 strain by allelic 
replacement of the target gene with an antibiotic resistance marker as described 
previously (46). Briefly, overlap extension PCR was used to insert the spectinomycin 
resistance cassette of the pR412 plasmid between the two 500-bp flanking sequences 
adjacent of the target gene. The resulting PCR products were introduced by competent 
stimulating peptide (CSP-2)-induced transformation into TIGR4. Directed mutants were 
obtained by selective plating and were checked for correct integration of the antibiotic 
resistance cassette into the target gene by PCR using control primers located inside the 
gene. Subsequently, the WT TIGR4 strain was transformed with chromosomal DNA isolated 
from the mutants to prevent the accumulation of inadvertent mutations elsewhere on 
the chromosome. In addition, loss of the target gene was confirmed by qPCR. The primers 
(Biolegio, Nijmegen, Netherlands) used in this study are listed in supplemental Table1.
Alignment of pneumococcal NanA variants
A total of 281 pneumococcal isolates were obtained from an unbiased cohort of patients 
with invasive pneumococcal disease in Nijmegen, the Netherlands, between 2001 and 
2011. All patients gave written consent to participate. The study was approved by the Local 
Medical Ethics Committees of participating hospitals. Details of clinical data on patient 
characteristics, comorbidities, severity of disease and clinical outcome are described 
in Cremers et al. [47]. Genomic DNA preparation and whole genome sequencing are 
described in Cremers et al. [48]. The NanA sequences were aligned using multiple sequence 
comparison by log-expectation (MUSCLE) [49] software. 
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Development of culture supernatants and NanA protein quantification
A single bacterial colony of TIGR4 WT and DnanA were cultured in casein tryptone (CAT) 
medium supplemented with 0.015M K2HPO4, 5µl catalase (Sigma ) and 0.02 g ManNac, and 
harvested at an OD of 0.2. After removal of remnant bacterial and culture components, 
supernatants were concentrated using microcon 30 kDa centrifugation filter devices 
(Merck Millipore).
Concentrated supernatants were incubated at 100˚C for 5 minutes in sample buffer (60 
mM Tris-HCl pH 6.8, 2% SDS, 2% β-mercaptoethanol, trace bromophenol blue), analysed 
on Tris-glycine SDS- PAGE gel in a Protean II xi cell electrophoresis system (Bio-Rad) and 
visualized by Coomassie staining. Densitometry analysis was performed with ImageJ 
[50]. Average spot intensity of NanA (~80 kDa) and BSA (~55 kDa) used as loading control 
(marker) were determined. The absence of the ~80 kDa in the NanA mutant confirms the 
presence of the protein at this size in the gel. Average spot intensity of NanA was corrected 
with the average spot intensity of BSA and depicted as relative corrected spot intensity 
compared to WT TIGR4. Enzymatic activity of NanA in the supernatant was confirmed by a 
fluorometric method using 0.45 mM 2-(4-methylumbelliferyl)α-D-N-acetylneraminic acid 
as substrate. 30µl sample was mixed with equal volumes of substrate and reaction buffer 
of pH 7.0 and incubated at 37°C for 2 hours followed by 400µl of stop solution (containing 
glycine and trisol). After centrifugation, supernatant was transferred into a clean reaction 
plate and fluorescence was measured. Total enzymatic activity was calculated in moles of 
substrate hydrolyzed per unit per time (hours).
Platelet sialic acid assays
Washed platelets were isolated from 3.2 % sodium-citrate-anticoagulated whole blood 
(Becton Dickinson) as previously described [51], and resuspended in HEPES tyrode buffer 
at 4x108 platelets/ml. Platelets were exposed to serial dilutions of culture supernatant 
for 1 hour at 37αC, and washed twice with TPBS (PBS +0.05% Tween™ 20) supplemented 
with 0.01% prostaglandin. PBS or 200 µM purified neuraminidase (NA) from Clostridium 
perfringens (Sigma-aldrich) were used as negative and positive controls respectively. 
Purified neuraminidase was used to demonstrate that observed effects with supernatant 
containing NanA are similar to those induced by other neuraminidases. Cells were then 
stained with the platelet identification marker CD61 (Beckman Coulter) and sialic acid 
binding lectins Sambucus nigra lectin (SNA) and Maackia amurensis lectin II (MALII) (both 
from vector laboratories) for 30 minutes at room temperature (RT). Cells were washed 
twice, fixated using 0.2% paraformaldehyde and analysed using a Cytomics FC500 flow 
cytometer and CXP acquisition software (Beckman Coulter).
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Platelet function assays and platelet-leukocyte complexes
Platelet function was determined using a flow cytometry assay as previously described 
[52]. Whole blood or PRP were incubated with 200 mU purified neuraminidase, and 
supernatants with and without NanA for 1 hour at 37αC followed by stimulation with 
increasing concentrations of adenosine diphosphate (ADP), crosslinked collagen-related 
peptide (CRP-XL) or Thrombin Receptor Activation Peptide (TRAP). Cells were labelled 
with antibodies directed against CD61, P-selectin (Biolegend) as marker of platelet 
degranulation and fibrinogen (Dako) as marker of integrin αIIbβ3 activation. The ADP 
stimulatory pathway was blocked by hydrolysing ADP using 10 µg/ml of apyrase (Sigma-
aldrich) or by blocking the ADP receptor P2Y12 with 50ug/ml ticagrelor (Bio connect B.V) 
for 30 minutes before addition of stimuli. These concentrations of apyrase and Ticagrelor 
reduced about 40% of secondary stimulation with 7.8µM ADP for both P-selectin and 
fibrinogen binding (figure S4B). This observation indicates that apyrase and ticagrelor 
give adequate inhibition of the CRP and TRAP induced ADP positive feedback loop as 
activated platelets are expected to release smaller amounts of ADP than the 7.8µM 
used in our experiments. Quantification of platelet dense granule was determined by 
incubating NanA exposed PRP with 50µM mepacrine for 10 minutes followed by a flow 
cytometry analysis to determine intra-platelet mepacrine content. Furthermore, dense 
granule degranulation was analysed by measuring the expression of CD63 (Biolegend) on 
the platelet membrane. Platelet-leukocyte interactions were determined by gating CD45 
positive cells that were also positive for both platelet (anti-CD42b, BD Biosciences) and 
monocyte (CD14), neutrophil (CD56) or T-cell (CD3) markers (Beckman Coulter). 
Surface expression of platelet glycoproteins
To study whether desialylation of platelets affects the surface expression of glycoproteins, 
PRP was treated with increasing concentrations of WT supernatant for 1 hour at 37αC. Cells 
were labeled with antibodies against the VWF receptor GPIbα (anti-CD42b, BD Biosciences), 
fibrinogen receptor GPIIIa (anti-CD61, Beckman Coulter), collagen receptor GPVI (anti-
GPVI, BD Biosciences) and the ADP receptor P2Y12 (Fabgennix). The effect of neuraminidase 
inhibitors to platelet function was assessed by treating PRP with supernatant containing 
NanA in the presence of increasing concentrations of oseltamivir acid (Bio connect B.V) 
and 2,3-didehydro-2-deoxy-N-acetylneuraminic acid (DANA) (Sigma-aldrich) followed by 
stimulation with 125 µM ADP. 
Statistical analysis
Statistical differences were analysed using Student’s t-test or one-way analysis of 
variance (1-way ANOVA) with post-tests as indicated. Data are presented as means with 
SD or mean with SEM of independent measurements. Statistical analysis was done using 
Graphpad prism 6 software. Flow cytometry analysis was done using Beckman Coulter 
Kaluza software, version 1.2.
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 77
3
NanA induces platelet hyper-reactivity
77
Acknowledgement
The authors thank Marc Eleveld, Erika van der Maten, Astrid van Rens and Rahajeng 
Tunjungputri for laboratory assistance. This project was funded by a grant from the 
Netherlands Fellowship Programme awarded to V.K.
Author contributions
M.D.J, Q.D.M. and A.V. conceived the study; V.K, J.L and C.E.G performed the experiments; 
V.K, J.L and A.J.C analyzed the data; C.B, G.A, P.D.G, B.T.M and D.L provided technical advice 
and support; V.K, M.D.J, Q.D.M, J.L and A.V. wrote the manuscript. All authors contributed 
significantly to the final version of the manuscript.
Conflict of interest
All authors declare no conflict of interest.
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 78
Chapter 3
78
References
1 Kadioglu A, Andrew PW. 2004. The innate immune response to pneumococcal lung 
infection: the untold story. Trends Immunol. 25(3):143–9. 
2 Arman M, Krauel K, Tilley DO, Weber C, Cox D, Greinacher A, Kerrigan, Steven W, 
Watson, Steve P. 2014. Amplification of bacteria-induced platelet activation is 
triggered by FcγRIIA, integrin αIIbβ3, and platelet factor 4. Blood. 123(20):3166–74. 
3 Keane C, Tilley D, Cunningham A, Smolenski A, Kadioglu A, Cox D, Jenkinson HF, 
Kerrigan SW. 2010. Invasive Streptococcus pneumoniae trigger platelet activation via 
Toll-like receptor 2. J Thromb Haemost. 8(12):2757–65. 
4 de Stoppelaar SF, Claushuis TAM, Schaap MCL, Hou B, van der Poll T, Nieuwland R, van 
‘t Veer C. 2016. Toll-Like Receptor Signalling Is Not Involved in Platelet Response to 
Streptococcus pneumoniae In Vitro or In Vivo. PLoS One. 11(6):e0156977. 
5 Brogly N, Devos P, Boussekey N, Georges H, Chiche A, Leroy O. 2007. Impact of 
thrombocytopenia on outcome of patients admitted to ICU for severe community-
acquired pneumonia. J Infect. 55(2):136–40. 
6 Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA. 2012. Platelets: 
versatile effector cells in hemostasis, inflammation, and the immune continuum. 
Semin Immunopathol. 34(1):5–30. 
7 Semple JW, Italiano JE, Freedman J. 2011. Platelets and the immune continuum. Nat 
Rev Immunol. 11(4):264–74. 
8 Schrottmaier WC, Kral JB, Badrnya S, Assinger A. 2015. Aspirin and P2Y12 Inhibitors 
in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost. 
114(20150423). 
9 Rae N, Finch S, Chalmers JD. 2016. Cardiovascular disease as a complication of 
community-acquired pneumonia. Curr Opin Pulm Med. 22(3):212–8. 
10 Trappetti C, Kadioglu A, Carter M, Hayre J, Iannelli F, Pozzi G, Andrew PW, Oggioni 
M. 2009. Sialic acid: a preventable signal for pneumococcal biofilm formation, 
colonization, and invasion of the host. J Infect Dis. 199(10):1497–505. 
11 Brittan JL, Buckeridge TJ, Finn A, Kadioglu A, Jenkinson HF. 2012. Pneumococcal 
neuraminidase A: an essential upper airway colonization factor for Streptococcus 
pneumoniae. Mol Oral Microbiol. 27(4):270–83. 
12 Crook M. 1991. Sialic Acid: its importance to platelet function in health and disease. 
Platelets 2(1):1–10. 
13 Madoff Ma, Ebbe S, Baldini M. 1964. Sialic Acid Of Human Blood Platelets. J Clin 
Invest. 43(5):870–7. 
14 Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H, Hoffmeister KM. 2015. 
The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-
STAT3 signaling. Nat Med. 21(1):47–54. 
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 79
3
NanA induces platelet hyper-reactivity
79
15 Zhang X-H, Wang Q-M, Zhang J-M, Feng F-E, Wang F-R, Chen H, Han W, Xu L, Liu 
K, Huang X. 2015. Desialylation is associated with apoptosis and phagocytosis of 
platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. J 
Hematol Oncol. 8(1):116. 
16 Grewal PK, Aziz P V, Uchiyama S, Rubio GR, Lardone RD, Le D, Varki NM, Nizet V, Marth 
JD. 2013. Inducing host protection in pneumococcal sepsis by preactivation of the 
Ashwell-Morell receptor. Proc Natl Acad Sci U S A. 110(50):20218–23. 
17 Xu G, Kiefel MJ, Wilson JC, Andrew PW, Oggioni MR, Taylor GL. 2011. Three 
Streptococcus pneumoniae Sialidases: Three Different Products. J Am Chem Soc. 
133(6):1718–21. 
18 Gualdi L, Hayre JK, Gerlini A, Bidossi A, Colomba L, Trappetti C, Pozzi G, Docquier 
J, Andrew P, Ricci S, Oggioni MR. 2012. Regulation of neuraminidase expression in 
Streptococcus pneumoniae. BMC Microbiol. 12:200. 
19 Gut H, Xu G, Taylor GL, Walsh MA. 2011. Structural Basis for Streptococcus 
pneumoniae NanA Inhibition by Influenza Antivirals Zanamivir and Oseltamivir 
Carboxylate. Journal of Molecular Biology. 409.
20 Xu Z, von Grafenstein S, Walther E, Fuchs JE, Liedl KR, Sauerbrei A, Schmidtke M. 
2016. Sequence diversity of NanA manifests in distinct enzyme kinetics and inhibitor 
susceptibility. Sci Rep. 6:25169. 
21 Nieswandt B, Bergmeier W, Eckly A, Schulte V, Ohlmann P, Cazenave J-P, Zirngibl H, 
Offermanns S, Gachet C. 2001. Evidence for cross-talk between glycoprotein VI and 
Gi-coupled receptors during collagen-induced platelet aggregation. Blood. 97(12). 
22 Greenberg J, Packham MA, Cazenave JP, Reimers HJ, Mustard JF. 1975. Effects on 
platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest. 
32(4):476–84. 
23 Dörr K, Kilch T, Kappel S, Alansary D, Schwär G, Niemeyer BA, Peinelt C. 2011. 
Cell type–specific glycosylation of Orai1 modulates store-operated Ca 2+ entry. 
8;9(418):ra25.
24 Varga-Szabo D, Braun A, Nieswandt B. 2011. STIM and Orai in platelet function. Cell 
Calcium. 50:270–8. 
25  De Marco L, Girolami A, Russell S, Ruggeri ZM. 1985. Interaction of asialo von 
Willebrand factor with glycoprotein Ib induces fibrinogen binding to the 
glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest. 
75(4):1198–203.
26 Iyú D, Glenn JR, White AE, Fox SC, van Giezen H, Nylander S, Heptinstall S.. 2010. Mode 
of action of P2Y12 antagonists as inhibitors of platelet function. Thromb Haemost. 
105(1):96–106. 
27 Harfenist E, Packham M, Mustard J. 1984. Effects of variant gamma chains and sialic 
acid content of fibrinogen upon its interactions with ADP-stimulated human and 
rabbit platelets. Blood. 1984 64(6). 
28  Park K, Gerndt SJ, Cooper SL. 1986. The effect of fibrinogen sialic acid residues on ex 
vivo platelet deposition on biomaterials. Thromb Res. 43(3):293–302. 
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 80
Chapter 3
80
29  Jenne CN, Kubes P. 2015. Platelets in inflammation and infection. Platelets. 26(4):286–
92. 
30 Barbara J, Waltraud K, Schrottmaier C, Salzmann M, Assinger A. 2016. Platelet 
Interaction with Innate Immune Cells. Transfus Med Hemother. 43:78–88. 
31 Thomas MR, Storey RF. 2015. The role of platelets in inflammation. Thromb Haemost 
114(3):449–58. 
32 Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM,Taliani G, Falcone 
M, Palange P, Bertazzoni G, Farcomeni A, Grieco S, Pignatelli P, Violi F, Albanese F, 
Biliotti E, Carnevale R, Catasca E, Celestini A, Esvan R, Fazi L, Marinelli P, Mordenti 
M, Napoleone L, Palumbo, Pastori, Perri, Proietti M, Capparuccia MR, Russo A, 
Russo R, Sarallo V, Salvatori G, Scarpellini MG, Ullo I. 2014. Platelet activation is 
associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol. 
64(18):1917–25. 
33 Chen G-Y, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Yu H, Qu J, Fang D, Wu W, 
Bai X-F, Liu J-Q, Woodiga SA, Chen C, Sun L, Hogaboam CM, Kunkel SL, Zheng P, Liu Y. 
2011. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-
SiglecG interaction. Nat Biotechnol. 29(5):428–35.
34 Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Carrim N, Grozovsky 
R, Ruan M, Zhu L, Zeng Q, Tao L, Zhai Z-m, Peng J, Hou M, Leytin V, Freedman J, 
Hoffmeister KM, Ni H. 2015. Desialylation is a mechanism of Fc-independent platelet 
clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 
6:7737. 
35 Paulson JC, Kawasaki N. 2011. Sialidase inhibitors DAMPen sepsis. Nat Biotechnol. 
29(5):406–7. 
36 Jansen AJG, Peng J, Zhao H-G, Hou M, Ni H. 2015. Sialidase inhibition to increase 
platelet counts: A new treatment option for thrombocytopenia. Am J Hematol 
90(5):E94–5. 
37 uis, Theodora A. M.Stoppelaar SF, Claushde, Schaap MCL, Hou B, van der Poll T, 
Nieuwland R, van ‘t Veer C. 2016. Toll-Like Receptor Signalling Is Not Involved in 
Platelet Response to Streptococcus pneumoniae In Vitro or In Vivo. Freson K, editor. 
PLoS One. 11(6):e0156977. 
38 Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese 
P, Frelinger AL, Goldberg RJ, Michelson AD. 2001. Circulating monocyte-platelet 
aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 
38(4):1002–6. 
39 Varki A. 2008. Sialic acids in human health and disease. Trends Mol Med.14(8):351–60. 
40 Bennett JS, Vilaire G. 1979. Exposure of platelet fibrinogen receptors by ADP and 
epinephrine. J Clin Invest. 64(5):1393–401.
41  Zhong X, Kriz R, Seehra J, Kumar R. 2004. N-linked glycosylation of platelet P 2 Y 12 
ADP receptor is essential for signal transduction but not for ligand binding or cell 
surface expression. FEBS Lett. 562(1–3):111–7. 
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 81
3
NanA induces platelet hyper-reactivity
81
42  Kunicki TJ, Cheli Y, Moroi M, Furihata K. 2005. The influence of N-linked glycosylation 
on the function of platelet glycoprotein VI. 15;106(8):27744-9. 
43 Nguyen KA, Hamzeh-Cognasse H, Palle S, Anselme-Bertrand I, Arthaud C-A, Chavarin 
P,Pozzetto B, Garraud O, Cognasse F. 2014. Role of Siglec-7 in apoptosis in human 
platelets. PLoS One. 9(9):e106239. 
44 Cognasse F, Nguyen KA, Damien P, McNicol A, Pozzetto B, Hamzeh-Cognasse 
H,Pozzetto B, Hamzeh-Cognasse H, Garraud O. 2015. The Inflammatory Role of 
Platelets via Their TLRs and Siglec Receptors. Front Immunol. 6:83. 
45 King SJ, Hippe KR, Weiser JN. 2006. Deglycosylation of human glycoconjugates by the 
sequential activities of exoglycosidases expressed by Streptococcus pneumoniae. 
Mol Microbiol. 59(3):961–74.
46 Burghout P, Bootsma HJ, Kloosterman TG, Bijlsma JJE, de Jongh CE, Kuipers 
OP,Kuipers OPM. 2007. Search for genes essential for pneumococcal transformation: 
the RADA DNA repair protein plays a role in genomic recombination of donor DNA. J 
Bacteriol. 189(18):6540–50. 
47 Cremers AJH, Meis JF, Walraven G, Van Der Gaast-De Jongh CE, Ferwerda G, Hermans 
PWM. 2014. Effects of 7-valent pneumococcal conjugate 1 vaccine on the severity of 
adult 2 bacteremic pneumococcal pneumonia. Vaccine. 32:3989–94. 
48  Cremers AJH, Mobegi FM, De Jonge MI, Van Hijum SAFT, Meis JF, Hermans PWM, 
Ferwerda G, Bentley SD, Zomer AL. 2015. The post-vaccine microevolution of invasive 
Streptococcus pneumoniae. Nat Publ G. 23;5:14952
49  Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high 
throughput. Nucleic Acids Res. 32(5):1792–7. 
50 Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image 
analysis. Nat Methods. 9(7):671–5. 
51 Tunjungputri RN, van der Ven AJ, Riksen N, Rongen G, Tacke S, van den Berg TNA, 
Fijnheer R, Gomes ME, Dinarello CA, van de Veerdonk FL, Gasem M, Netea MG, 
Joosten LAB, De Groot PG, de Mast Q. 2015. Differential effects of platelets and 
platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory 
responses. Thromb Haemost. 113(5):1035–45. 
52 Tunjungputri RN, van de Heijden W, Urbanus RT, de Groot PG, van der Ven A, de Mast 
Q. 2016. Higher platelet reactivity and platelet-monocyte complex formation in 
Gram-positive sepsis compared to Gram-negative sepsis. Platelets 1–7. 
 
 
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 82
Chapter 3
82
Supplemental materials
Supplemental Table 1 – Primers used for the construction of a ΔnanA mutant.
Primers for mutant generation:
Target region Primer sequence
spn1693_L1_NanA  5’-GTTCGATAAGGATTGAGCAGG-3’
spn1693_L2_NanA  5’-CCACTAGTTCTAGAGCGGCCGTTCCAAATACCACTGCTC-3’
spn1693_R1_NanA  5’-GGATCGAAAGTCTCATGAATAC-3’
spd1504_R2 5’-GCGTCAATTCGAGGGGTATCGCTTCACTAGGACTAACAGC-3’
spd1504_C 5’-TGGCATCTGGCTTAAACTCC-3’
Primers for qPCR:
Target region Primer sequence
Sp_NanAF 5’-TTGGAACGTCTCCTGTTTTAGCT-3’
Sp_NanAR 5’-CCCCGAAAGTTGAGTTTCATTT-3’
gyrAF 5’-AATGAACGGGAACCCTTGGT-3’
gyrAR 5’-CCATCCCAACCGCGATAC-3’
MrTn9 5’-CAATGGTTCAGATACGACGAC-3’
pR412_L 5’-GCCGCTCTAGAACTAGTGG-3’
pR412_R 5’-GATACCCCTCGAATTGACGC-3’
Abbreviations: Spec, spectinomycin resistance cassette; L1 and L2, primers downstream of the open 
reading frame of the target gene; R1 and R2, primers upstream of the open reading frame of the target 
gene; C, control primer within the target gene.
 
Figure S1 – Coomassie staining of SDS-PAGE gel
Coomassie staining of SDS-PAGE gel showing presence of NanA protein in the pneumococcal culture 
supernatant of WT and DnanA mutant TIGR4 strain, relative to the BSA marker.
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Figure S2 – Representative plots showing binding of SNA and MALII lectins to platelet surface sialic 
acid.
A: Histograms showing binding of SNA and MALII lectins to platelet surface sialic acid after treating 
PRP with PBS (negative control), 200 mU purified neuraminidase from C. perfringens (NA), or culture 
supernatants with (+NanA) and without (-NanA) NanA.
B: Overlays of histograms showing dose response effect of the binding of SNA and MALII lectins 
to platelet surface sialic acid after treating washed platelets with serial dilutions (0 - 1:80) of 
supernatants with and without NanA for 1 hour at 37°C.
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Figure S3 – Representative plots showing reactivity of NanA exposed platelets to ADP.
A: The platelet gating strategy used in identifying platelet population. Platelets (CD61 positive cells) 
were selected on their forward (FS) and side (SS) scatter characteristics.
B: Observed differences in platelet P-selectin expression after treating PRP with PBS (negative 
control), 200 mU purified neuraminidase from C.perfringens (NA), or culture supernatants with 
(+NanA) and without (-NanA) NanA for 1 hour at 37°C followed by stimulation with 125µM ADP.
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Figure S4 – (A) Fibrinogen binding following incubation of washed platelets with PBS (negative 
control), 200 mU purified neuraminidase from C. perfringens (NA), or supernatant with (+NanA) and 
without NanA (-NanA) for 1 hour at 37°C followed by stimulation with increasing concentrations of 
ADP. (B) Fold change in % of P-selectin and fibrinogen expression on platelets after treating PRP with 
supernatant containing NanA for 1 hour at 37°C followed by hydrolysing ADP using 10µg/ml apyrase 
or blocking ADP receptor using 50 µg/ml Ticagrelor for 30 minutes before stimulation with 7.8µM of 
ADP. (C) Levels of platelet interaction with monocytes and neutrophils after treating whole blood with 
PBS as negative control, 200mU purified neuraminidase from C.perfringens (NA), or supernatants 
with (+NanA) and without NanA (-NanA) for 1 hour at 37°C in the presence and absence of 50µM 
oseltamivir. Data are presented as mean with SEM of two independent experiments with 3 replicates, 
(n=6). MFI-AU; mean fluorescent intensity in arbitrary units. 
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Figure S5 – Proposed mechanism for pneumococcal NanA-induced platelet hyper-reactivity. 
Increased surface expression of alpha granule protein P-selectin, and binding of VWF and fibrinogen 
to glycoproteins GPIbα and GPIIbIIIa respectively are hallmarks of platelet activation, which is 
accompanied by degranulation of cytosolic alpha and dense granules containing ADP, serotonin 
and ionized Ca2+ (iCa2+). These events are enhanced in desialylated platelets stimulated with platelet 
agonists. We propose three mechanisms for increased platelet reactivity of NanA exposed platelets. 
First, desialylation of Orai1 channels by NanA increases re-uptake of iCa2+ into the cell promoting 
platelet activation. Second, calcium flux over the cell membrane is facilitated by the decrease in the 
overall surface negative charge following removal of surface sialic acid. Thirdly, desialylated plasma 
VWF, asialo VWF, binds to platelets leading to enhanced degranulation of dense granules. Released 
ADP from dense granules provide autocrine stimulation of platelets. Blocking of the ADP stimulatory 
pathway by apyrase or Ticagrelor inhibits the hyper-reactivity of desialylated platelets to stimulation 
with platelets agonists emphasizing on the role of ADP on NanA-mediated effects. 
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Abstract
Detection of respiratory syncytial virus (RSV) in blood, including mononuclear leukocytes 
and organs other than the lung, suggests that RSV disseminates outside the respiratory 
tract. In this study, the role of platelets in host defense against RSV was explored using 
an in vitro model. Platelets, also produced in the lungs, are increasingly recognized as an 
important part of host immune responses and may therefore play a role in modulating 
lung infections and clearing RSV viremia. In human peripheral blood mononuclear 
cells (PBMCs), platelets significantly reduced RSV infection of monocytes, monocyte 
activation, and interferon (IFN)a/g production. Direct contact of platelets with PBMCs 
modulated the immune response when stimulated with Poly I:C (TLR3) and R848 (TLR7/8), 
Toll-like receptors (TLRs) involved in the recognition of RSV, and led to an enhanced 
IFNa/g production. This suggested that reduction in RSV infection of monocytes in the 
presence of platelets could be IFN dependent; blocking IFNa receptor 2 (IFNAR2) on PBMCs 
indeed increased RSV infection. In addition, IFNs were not detected when PBMCs were 
stimulated with inactivated RSV, indicating that infection of monocytes was important 
for the induction of IFN responses and that the platelet-mediated reduced RSV infection 
was responsible for the decreased IFN levels. Furthermore, platelets could internalize RSV 
reducing the amount of viral particles that could infect monocytes. Our findings suggest 
that platelets may play a role in the clearance of RSV viremia by internalizing viral particles 
and by enhancing type I IFN production from PBMCs, which subsequently exert antiviral 
effect on host cells.
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Introduction
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections 
(LRTI) in young children and immune compromised patients [12]. The extrapulmonary 
manifestations, which especially occur in patients with severe disease, suggest that RSV 
may also infect organs other than the lung [4]. The detection of RSV RNA in blood of young 
children and immune compromised patients [16, 23, 24], the presence of RSV in various organs 
apart from the lung [4] and in circulating mononuclear leukocytes [13], as well as the capacity 
of RSV to infect monocytes [3], all suggest RSV dissemination outside the respiratory tract. 
Blood RSV RNA loads have been correlated with disease severity in mice (20); however, data 
from humans are scarce.
While the host immune response to RSV has been studied before [1, 8], no data on the 
putative role of platelets in RSV pathogenesis are available. Increasing evidence indicates 
that platelets play an important role in host defense in general and more specific in the 
pathogenesis of viral infections through various mechanisms [5]. Recently, the lung has 
been identified as second site, apart from bone marrow, of platelet biogenesis from 
megakaryocytes [10] and may therefore have a function in modulation of lung infections. 
The interaction between platelets and leukocytes and the subsequent alteration in 
cytokine production [19] may be one of the mechanisms that also play a role in host defense 
against RSV. Of special importance is the role of type I interferons (IFNs), which play a 
crucial role in RSV host defense [6, 18].
Although many viral infections are accompanied by thrombocytopenia, thrombocytosis 
is commonly found in children with RSV infection [9]. In contrast, thrombocytopenia was 
found to be a risk factor for viremia and increased mortality from RSV infection in patients 
with hematopoietic cell transplantation [23]. Interestingly, analysis of gene expression 
profiles from infants with LRTI of different viral etiologies showed that overexpression of 
platelet related genes is specific for RSV [11]. All these data indicate that significant changes 
in platelets occur during RSV infection while we have no insight whether this also affects 
host defense against RSV. The aim of our present study was therefore to determine the role 
of platelets and platelet–leukocyte interaction in innate immune responses against RSV 
infection.
Materials and Methods
Isolation of peripheral blood mononuclear cells and platelets
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained 
from the Sanquin blood bank Nijmegen while platelets were isolated from citrate-
anticoagulated venous blood collected from healthy adult volunteers as described 
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 92
Chapter 4
92
previously (21). Briefly, PBMCs were isolated by density gradient centrifugation on Ficoll-
Hypaque (Pharmacia Biotech, Uppsala, Sweden). PBMCs were washed five times with 
normal saline then resuspended in RPMI-1640 Dutch Modification culture medium (ICN 
Biomedicals, Costa Mesa, CA) and adjusted to 5 × 106 cells/mL.
For platelet isolation, 3.2% sodium-citrate-anticoagulated whole blood (Becton Dickinson, 
Franklin Lakes, NJ) was centrifuged for 15 min at 156 g without brake to obtain platelet-rich 
plasma (PRP). PRP was further centrifuged at 330 g for 15 min to obtain platelet pellets and 
resuspended in HEPES tyrode buffer.
Culture of RSV (GFP-RSV)
Green fluorescent protein (GFP) expressing RSV-A2 (rgRSV30) was kindly provided by Dr. 
M.E. Peeples [7] and was cultured on HeLa cells. Subsequently the virus was purified by 
ultracentrifugation over 30% sucrose cushion as described previously [22]. To quantify the 
number of infectious virus particles, HeLa cells (80–90% confluent) were infected with 
fivefold viral dilutions for 20–22 h. The virus titer was determined by counting wells with 
≥10 and ≤100 infected cells/view (Olympus CKX41 microscope) where each data point 
was the average of an experimental duplicate [22]. Inactivated rgRSV30 was produced by 
incubating the virus with 0.025% beta-propiolactone (BPL) (Acros Organics) for 16 h at 
4°C under continuous gentle shaking. Next, the stock was incubated for 4 h at 37°C to 
hydrolyze the BPL and stored at −80°C until further use.
RSV infection and stimulation of PBMCs
PBMCs at a concentration of 5 × 106 cells/mL were dispensed into a round-bottomed 96-
well plate (Thermo scientific, Roskilde, Denmark) and infected with live or BPL inactivated 
rgRSV30 at multiplicity of infection (MOI) of 10 in the presence and absence of platelets. 
For the transwell system assay, PBMCs were dispensed into the lower compartment 
of a flat-bottomed 24-well plate with a 0.4 µm filter membrane (Greiner Bio-one, 
Frickenhausen, Germany) and stimulated with 100 µg/mL Poly I:C (InvivoGen, Toulouse, 
France) or 5 µg/mL R 848 (InvivoGen) in the presence of platelets or physically separated 
platelets dispensed into the upper compartment of the transwell. PBMC to platelet ratio 
used was 1:150. Negative controls included stimulated PBMCs with Roswell Park Memorial 
Institute medium (RPMI) in presence or absence of platelets. IFNa receptors on PBMCs 
were blocked using anti-IFNAR2 antibodies (PBL assay science, Piscataway, NJ) or IgG2A 
isotype control (eBioscience, San Diego, CA) for 1 h at 37°C before adding platelets or RSV. 
Cells were incubated for 48 h at 37°C and 5% CO2, and supernatant was collected after 
centrifugation and stored at −20°C.
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Flow cytometry
To determine the percentage of monocytes infected with RSV and expression of CD16 on 
monocytes, PBMCs were cultured with RSV for 48 h in presence and absence of platelets as 
described above. Cells were washed with cold PBS and then labeled for monocyte markers 
with anti-CD14 (anti-CD14 ECD; Beckman Coulter, Fullerton, CA) and anti-CD16 (anti-CD16 
PE; eBioscience) antibodies for 30 min, washed again, and fixated with paraformaldehyde 
(1%). Cells were analyzed using the FC500 flow cytometer with CXP software (Beckman 
Coulter). Mean fluorescent intensity (MFI) or percentage of RSV infection and expression of 
CD16 on monocytes were determined by gating on the population of cells double positive 
for CD14 and RSV and CD14 and CD16, respectively.
To study whether platelets internalize RSV, washed platelets at a concentration of 5 × 105 
cells/mL were incubated with RSV-A2 that does not express GFP at MOI of 5 for 2 h at 37°C, 
5% CO2 on a shaker.
After incubation cells were washed twice using bovine serum albumin (BSA) buffer and 
then stained for CD61 (anti-CD61; Beckman Coulter) as platelet identification marker and 
for surface expression of platelet alpha granule protein P-selectin (anti-CD62p; BioLegend, 
San Diego, CA) as platelet activation marker for 30 min at 4°C. Thereafter cells were washed 
and resuspended in fixation/permeabilization solution for 20 min followed by perm/wash 
buffer (both obtained from BD Biosciences, Breda, The Netherlands) for 10 min at 4°C. Cells 
were then stained for intracellular expression of RSV nucleoprotein (NP) using FITC labeled 
anti-NP antibodies (Abcam, San-Francisco) diluted in perm/wash buffer for 30 min at 4°C. 
After a wash step cells were analyzed on a BD LSR II flow cytometry machine. Platelets were 
identified based on their forward and side scatter characteristics, from which populations 
double positive for platelet marker anti-NP and CD62p were identified.
Cytokine determination
Cytokines in collected supernatants were quantified using commercially available 
enzyme-linked immunosorbent assay (ELISA) for IFN gamma (IFNg) (obtained from 
Sanquin, Amsterdam, Netherlands) and IFN alpha (IFNa) (obtained from R&D, Abingdon, 
United Kingdom) according to the manufacturer’s instructions.
Statistical analysis
Statistical analysis was done using GraphPad prism 5 software. Data were analyzed using 
Kruskal–Wallis and Mann–Whitney tests or student t-test (data on expression of RSV NP in 
platelets). Data are presented as mean of independent samples unless stated otherwise. 
Flow cytometry analysis was done using Beckman Coulter Kaluza software, version 1.2.
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Results
We first investigated whether platelets modulated RSV infection of monocytes. PBMCs 
were infected with RSV at MOI of 10 in the presence and absence of platelets. Addition of 
platelets significantly decreased RSV infection of monocytes after 48 h of incubation (Fig. 
1A and Supplementary Fig. S1; Supplementary Data are available online at www.liebertpub.
com/vim). CD16 expression on monocytes, a marker for monocyte activation, also tended 
to be lower when PBMCs were incubated with RSV in the presence of platelets although 
the effect was not significant (Fig. 1B, C and Supplementary Fig. S2).
 
Figure 1 – RSV infection of monocytes and expression of CD16 on monocytes (CD14+ cells) after 
stimulation of PBMCs with RSV. (A) Median MFI (in arbitrary units) of RSV infecting monocytes, (B) 
percentages of monocytes (CD14+ cells) expressing CD16, and (C) median MFI of CD16 expression on 
monocytes after culturing PBMC with RSV for 48 h in the presence and absence of platelets. Data were 
analyzed using Mann–Whitney test and presented as mean with SEM (n = 6). MFI, mean fluorescent 
intensity; PBMC, peripheral blood mononuclear cell; RSV, respiratory syncytial virus.
We next explored whether the reduced monocyte infection and activation rate resulted 
from increased production of antiviral cytokines IFNa and IFNg. Concentrations of these 
cytokines in the culture supernatant were lower when PBMCs were stimulated with RSV 
in the presence of platelets. In addition, BPL inactivated RSV did not induce production 
of IFNa/g from PBMCs (Fig. 2). To avoid confounding by monocyte infection rate, we 
stimulated PBMCs with the synthetic TLR3 and TLR7/8 ligands poly I:C and R848. RSV is a 
known ligand for these Toll-like receptors (TLRs) [8]. IFNa and IFNg production by PBMCs 
upon stimulation with these TLR ligands was increased in the presence of platelets (Fig. 
3); however, differences were not significant for IFNg production after stimulation with 
R848. These effects could be reversed by physical separation of PBMCs and platelets by 
a transwell system (Fig. 3). Blocking IFNAR2 on PBMCs using anti-IFNAR2, but not IgG2A 
isotope control, increased RSV infection of monocytes and monocyte activation (CD16 
expression) (Fig. 4 and Supplementary Figs. S1 and S2).
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Figure 2 – IFN production after stimulation of PBMCs with RSV. (A) IFNa and (B) IFNg produced after 
PBMCs were stimulated with live RSV (n = 12) or BPL inactivated RSV (n = 6) for 48 h in the presence and 
absence of platelets. Data were analyzed using Mann–Whitney test and presented as mean with SEM. 
Lower detection levels of IFNa and IFNg were 25 and 7.8 pg/mL, respectively. BPL, beta-propiolactone; 
IFN, interferon; SEM, standard error of the mean.
 
Figure 3 –  IFN production after stimulation of PBMCs with Poly I:C and R848. IFNa and IFNg produced 
after stimulation of PBMCs using Poly I:C (TLR3 ligand) (A, C) and R848 (TLR7/8 ligand) (B, D) for 48 h 
in the presence or absence of platelets or platelets physically separated by a transwell system. Data 
were analyzed using Mann–Whitney test and presented as mean with SEM. Lower detection levels of 
IFNa and IFNg were 25 and 7.8 pg/mL, respectively. (n = 14). **p < 0.01, *p = 0.03.
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Figure 4 – RSV infection of monocytes and expression of CD16 on monocytes (CD14+ cells) after 
blocking IFNAR2 on PBMCs. (A) Median MFI (in arbitrary units) of RSV infecting monocytes, (B) 
percentages of monocytes (CD14+ cells) expressing CD16, and (C) median MFI of CD16 expression on 
monocytes after culturing PBMCs with RSV for 48 h in the presence and absence of platelets, with RSV 
and platelet in combination with anti-IFNAR2 or IgG2A control antibodies, and BPL inactivated RSV for 
48 h. Data were analyzed using Kruskal–Wallis test followed by Mann–Whitney test and presented as 
mean with SEM. (n = 6). IFNAR2, IFNa receptor 2.
Figure 5 – Expression of RSV NP and P-selectin on platelets. MFI-AU of and percentages of platelets 
expressing RSV NP (A) (n = 5) and surface P-selectin (B) (n = 3) after incubating washed platelets with 
RSV at MOI of 5 for 2 h. Data were analyzed using student t-test and presented as mean with SD. MFI-
AU, median fluorescent intensity in arbitrary units; MOI, multiplicity of infection; NP, nucleoprotein.
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To study whether the reduced monocyte infection with RSV resulted also from 
internalization of RSV by platelets, washed platelets were incubated with RSV for 2 h. 
Platelets incubated with RSV had significantly higher MFI of intracellular RSV NP and 
higher percentages of platelets expressing RSV NP (Fig. 5A and Supplementary Fig. S3). 
Surface P-selectin expression was also increased in RSV exposed platelets (Fig. 5B and 
Supplementary Fig. S3). These results indicate that platelets can internalize RSV, a process 
that leads to platelet activation and degranulation.
Discussion
Increasing evidence supports the idea that platelets play a role in host defense against 
infections. Our data show that platelets can reduce RSV infection of monocytes and 
monocyte activation by enhancing IFN production from leukocytes and by internalizing 
viral particles.
IFNs induce antiviral responses when pattern recognition receptors in the cytoplasm of 
host cell detect viral associated motifs and are dependent on the capacity of the virus 
to infect a host cell [17]. Our results show that platelets can enhance antiviral responses 
by enhancing production of IFNs from PBMCs following stimulation with viral antigen. 
This IFN dependent antiviral effect was exhibited by reduced RSV infection of monocytes 
in the presence of platelets and confirmed by increased infection after blocking IFNa 
receptor2 on PBMCs. RSV infection of monocytes is a well-known inducer of IFNa/g [6, 17]. 
This observation explains the simultaneous reduction of IFN production with reduced 
RSV infection of monocytes observed in our study. In addition, inactivated RSV could not 
induce production of IFNa/g from PBMCs. Increased IFN production from PBMCs following 
stimulation of TLR3 and TLR7/8 in the presence of platelets provides further evidence of 
the link between RSV infection rate and IFN production. The transwell system portrays the 
importance of direct contact between platelets and leukocytes in these effects. Platelet 
effects mediated by direct platelet–leukocyte interaction have also been described earlier 
[15, 21].
Platelets can also have inherent ability to directly recognize and clear pathogens and 
release immune mediators [14]. Platelet mediated reduction of monocyte infection with 
RSV could also be explained by the internalization of RSV by platelets [2]. Put together, 
our findings indicate that platelets enhance type I IFN production from PBMCs exerting 
antiviral effect on host cells; and second, platelets internalize viral particles and, hence, 
reduce the number of particles that can infect monocytes, a process that may play a role 
in clearing RSV viremia.
RSV primarily infects the lung and it is possible that platelets also interact with alveolar 
macrophages. A limitation of our study is that we did not use alveolar macrophages. 
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However, PBMCs have been proposed as a robust and reproducible in vitro model to study 
both innate and adaptive responses to RSV [22]. Furthermore, platelet mediated reduction 
of monocyte activation and IFNa during RSV infection as observed in our study may be an 
important factor in preventing lung inflammation in vivo.
Data presented are based on an in vitro model using a recombinant RSV strain and isolated 
PBMCs. The protective effect of platelets to alveolar macrophages and epithelial cells, 
which are the main targets for RSV in vivo, poses need for further studies.
Conclusion
Collectively, our current study shows that platelets play an important role in host innate 
defenses against RSV by reducing RSV infection of monocytes and monocyte activation 
in a type I IFN dependent manner. Platelets can also internalize viral particles and may 
therefore be important in preventing RSV dissemination and disease exacerbation.
Acknowledgments
The authors thank Jop Jans and Wouter van der Heijden for laboratory assistance. This 
project was funded by the Netherlands Fellowship Programme.
Author Disclosure Statement
No competing financial interests exist.
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 99
4
Platelets modulate immune response against hRSV
99
References
1 Arruvito L, Raiden S, Geffner J. Host response to respiratory syncytial virus infection. 
Curr Opin Infect Dis. 2015;28(3):259–66. 
2 Chabert A, Hamzeh-Cognasse H, Pozzetto B, Cognasse F, Schattner M, Gomez RM, et 
al. Human platelets and their capacity of binding viruses: meaning and challenges? 
BMC Immunol. 2015;16:26.
3 Domurat F, Roberts NJ, Walsh EE, Dagan R. Respiratory syncytial virus infection of 
human mononuclear leukocytes in vitro and in vivo. J Infect Dis. 1985;152(5):895–902. 
4 Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus 
infection; a systematic review. Crit Care. 2006;10(4):R107.
5 Flaujac C, Boukour S, Cramer-Bordé E. Platelets and viruses: an ambivalent 
relationship. Cell Mol Life Sci. 2010;67(4):545–56. 
6 Goritzka M, Makris S, Kausar F, Durant LR, Pereira C, Kumagai Y, et al. Alveolar 
macrophage-derived type I interferons orchestrate innate immunity to RSV through 
recruitment of antiviral monocytes. J Exp Med. 2015;212(5):699–714.
7 Hallak LK, Collins PL, Knudson W, Peeples ME. Iduronic acid-containing 
glycosaminoglycans on target cells are required for efficient respiratory syncytial 
virus infection. Virology. 2000;271(2):264-75. 
8 Kim TH, Lee HK. Innate immune recognition of respiratory syncytial virus infection. 
BMB Rep. 2014;47(4):184–91.
9 Kubota M, Maeda H, Yoshimoto J, Kobayashi K, Usami I, Yamaoka K. Thrombocytosis 
at an early stage of respiratory tract viral infection. Acta Paediatr. 2005;94(3):364–6.
10 Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, et al. The 
lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. 
Nature. 2017;544(7648):105–9.
11 Mejias A, Dimo B, Suarez NM, Garcia C, Suarez-Arrabal MC, Jartti T, et al. Whole blood 
gene expression profiles to assess pathogenesis and disease severity in infants with 
respiratory syncytial virus infection. PLoS Med. 2013;10(11):e1001549.
12 Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden 
of acute lower respiratory infections due to respiratory syncytial virus in young 
children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55.
13 O’Donnell DR, McGarvey MJ, Tully JM, Balfour-Lynn IM, Openshaw PJ. Respiratory 
syncytial virus RNA in cells from the peripheral blood during acute infection. J 
Pediatr. 1998;133(2):272–4.
14 Ostrowski SR, Johansson PI. Rethinking platelet function: thrombocytopenia 
induced immunodeficiency in critical illness. Med Hypotheses. 2011;77(5):798–802.
15 Passacquale G, Vamadevan P, Pereira L, Hamid C, Corrigall V, Ferro A. Monocyte-
platelet interaction induces a pro-inflammatory phenotype in circulating 
monocytes. PLoS One. 2011;6(10):e25595.
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 100
Chapter 4
100
16 Rohwedder A, Keminer O, Forster J, Schneider K, Schneider E, Werchau H. Detection 
of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction. 
J Med Virol. 1998;54(4):320–7.
17 Schijf MA, Lukens M V, Kruijsen D, van Uden NOP, Garssen J, Coenjaerts FEJ, et al. 
Respiratory syncytial virus induced type I IFN production by pDC is regulated by 
RSV-infected airway epithelial cells, RSV-exposed monocytes and virus specific 
antibodies. PLoS One. 2013;8(11):e81695. 
18 Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector 
functions. Curr Opin Virol. 2011;1(6):519–25.
19 Schrottmaier WC, Kral JB, Badrnya S, Assinger A. Aspirin and P2Y12 Inhibitors in 
platelet-mediated activation of neutrophils and monocytes. Thromb Haemost. 
2015;114(20150423). 
20 Torres JP, Gomez AM, Khokhar S, Bhoj VG, Tagliabue C, Chang ML, et al. Respiratory 
syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in 
mice. Respir Res. 2010;11:125. 
21 Tunjungputri RN, van der Ven AJ, Riksen N, Rongen G, Tacke S, van den Berg TNA, et 
al. Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and 
TLR4-mediated inflammatory responses. Thromb Haemost. 2015;113(5):1035–45.
22 Vissers M, Habets MN, Ahout IML, Jans J, de Jonge MI, Diavatopoulos DA, et al. An in 
vitro model to study immune responses of human peripheral blood mononuclear 
cells to human respiratory syncytial virus infection. J Vis Exp. 2013;(82):e50766.
23 Waghmare A, Campbell AP, Xie H, Seo S, Kuypers J, Leisenring W, et al. Respiratory 
syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: 
viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect 
Dis. 2013;57(12):1731–41.
24 Yui I, Hoshi A, Shigeta Y, Takami T, Nakayama T. Detection of human respiratory 
syncytial virus sequences in peripheral blood mononuclear cells. J Med Virol. 
2003;70(3):481–9.
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 101
4
Platelets modulate immune response against hRSV
101
Supplemental material
 
Supplemental figure 1 – RSV infection of monocytes.
Dot plots showing flow cytometry analysis of CD14+ cells (monocytes) infected by RSV after culturing 
PBMC with RSV for 48 hrs in the presence and absence of platelets, or with RSV and platelet in 
combination with anti-IFNAR2 or Ig  G2A control.
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Supplemental figure 2 – Expression of CD16 on monocytes mediated by RSV and platelets.
Dot plots showing flow cytometry analysis of CD14+ cells (monocytes) expressing CD16 after PBMCs 
were stimulated with platelets alone, with RSV in the presence and absence of platelets, with RSV and 
platelet in combination with anti-IFNAR2 or IgG2A control antibodies, or BPL inactivated RSV for 48 hrs.
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Supplemental figure 3 – Expression of RSV nucleoprotein and P-selectin on platelets after 
stimulation of platelets with RSV.
(A) Gating strategy used to identify platelet population. (B) Dot plots showing flow cytometry 
analysis of platelets expressing RSV nucleoprotein (NP) and platelet P-selectin after incubating 
washed platelets with RSV at MOI of 5 for 2 hours. Data shown is representative of three (for 
P-selectin) and five (for NP) donors. 
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Abstract
The immune effects of platelets and platelet-leukocyte aggregation are increasingly 
recognized. We studied the occurrence of platelet-monocyte aggregation (PMA) in patients 
with pulmonary tuberculosis (TB), the processes underlying PMA and consequences for 
cytokine responses. 
In a cross-sectional study involving 65 Tanzanian TB patients in different phases of 
treatment and 29 healthy controls, TB patients had a significantly higher PMA. This 
increased PMA in TB patients was associated with increased monocyte CCR5, CD16 
expression and PF4, but not with increased membrane-expressed or soluble P-selectin 
expression. These findings were confirmed in vitro: whereas incubation of whole blood 
with Mycobacterium tuberculosis (Mtb) did not activate platelets, monocytes became 
activated with higher CD11b, CD16 and CCR5 expression, but this was independent of 
platelet-monocyte interaction. Still, platelets had an anti-inflammatory effect on 
cytokine responses as peripheral blood mononuclear cells (PBMC) incubated with Mtb in 
the presence of platelets produced less interleukin (IL)-1β, tumor necrosis factor-α, IL-6 
and interferon-γ and more IL-10. 
In conclusion, increased PMA during TB infection is caused by monocyte and not platelet 
activation. By counteracting the Mtb-induced pro-inflammatory leukocyte response, 
platelets may protect against excessive tissue damage, but may also compromise the 
production of protective cytokines, such as IFNg and TNFa. 
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Introduction
Tuberculosis (TB) is one of the major global health problems, claiming about 1.5 million 
lives every year worldwide [1].  The complexity of the disease arises from inflammatory 
responses which serve both as a protective tool to the host and as an immune evasion 
strategy for the pathogen [2, 3].
Macrophages and interferon (IFN) gamma producing T-lymphocytes are key cells in 
the protection against TB [4]. Emerging evidence also identified important roles for 
other cell types, including platelets, in antimycobacterial immunity [5]. Traditionally 
known for their role in hemostasis, platelets are increasingly recognized to have many 
functions in inflammation and host defence [6]. They contain hundreds of mediators with 
immune properties and interact intensively with leukocytes changing their phenotype 
and function [7, 8]. This interaction primarily involves ligation of platelet P-selectin 
with monocyte P-selectin glycoprotein ligand-1 (PSGL-1) [9]. Feng et al. recently showed 
that platelets are important players in the formation and function of granulomas and 
macrophage transformation in TB [10]. Platelets steer macrophages into multinucleated 
giant foam cells, which have increased capacity to phagocytose mycobacteria and exhibit 
an anti-inflammatory phenotype with reduced ratio of tumor necrosis factor alpha (TNFα) / 
interleukin (IL)-10 production upon challenge with Mycobacterium tuberculosis (Mtb). 
Human monocytes can be subdivided based on surface expression of CD14 and CD16. 
Monocytes expressing CD16 are heterogeneous in function depending on the intensity of 
CD16 expression [11]. While monocyte expressing high CD16 (CD16high) are considered to be 
fully matured and more pro-inflammatory, monocytes expressing low CD16 (CD16low) are 
at a transitory stage of differentiation with a both pro- and anti-inflammatory phenotype 
[12]. In general, CD16 expressing monocytes, here referred to as CD16+ monocytes, are pro-
inflammatory and are known to migrate more efficiently into inflamed tissues [11, 13]. TB 
patients have increased numbers of circulating CD16+ monocytes and recent evidence 
suggests that a shift of the CD16- monocyte population toward a CD16+ subpopulation 
may represent an immune evasion strategy that ultimately favors persistence of Mtb 
[14]. Monocyte CCR5 expression has also been implicated in the pathophysiology of TB 
infection [15]. CCR5, a chemokine receptor for platelet RANTES (Regulated on Activated, 
Normal T-cell Expressed and Secreted), is mostly expressed on CD16+ monocytes [15, 16]. CCR5 
is upregulated during TB infection and plays role in facilitating migration of monocytes 
into tissues15. Moreover, CCR5 is also an entry co-receptor for Human Immunodeficiency 
Virus (HIV) on CD4+ T-cells and macrophages [17, 18]. Platelets preferentially bind to CD16+ 
monocytes19, and can also induce CD16 expression on monocytes [20]. Whether platelet-
monocyte interaction also influences monocyte CCR5 expression is unknown.  
In summary, platelet-monocyte crosstalk in TB may play a so far unsuspected role in the 
pathogenesis and immune responses against Mtb. Patients with TB often have increased 
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circulating numbers of platelets [21, 22], but it is not well known whether TB patients also 
have increased platelet-monocyte aggregation (PMA). The aim of our present study 
was to investigate whether patients with pulmonary TB indeed have increased PMA 
and whether this is due to platelet activation and/or monocyte activation. Using whole 
blood and isolated peripheral blood mononuclear cells (PBMC) stimulated with Mtb, 
we subsequently studied the effects of Mtb on platelets and monocyte activation and 
the role of PMA in CD16 and CCR5 expression. Finally, we studied how platelets and PMA 
modulate innate cytokine responses to Mtb.
Materials and Methods
A: PATIENT STUDY
Study population and design
We performed a cross-sectional study involving 65 adult patients with XpertMTB/RIF 
(Cepheid, USA) Mtb positive test attending Kibongóto Infectious Diseases Hospital and 
Mawenzi Reginal referral Hospital between January and March 2015. Exclusion criteria 
included use of aspirin or other platelet function inhibitors, and presence of HIV or 
any other known concurrent infection. The patient group included 25 newly diagnosed 
patients about to start treatment, 24 patients who had been treated for one month and 16 
patients who had been treated for 5 months. Patients were treated according to national 
guidelines with a combination of rifampicin, isoniazid, pyrazinamide and ethambutol 
for 2 months, followed by rifampicin and isoniazid. A group of 29 healthy controls of 
comparable age and sex selected from hospital staff was also included. The study was 
approved by the Kilimanjaro Christian Medical University College ethical committee 
(CRERC). All participants provided written informed consent to participate in the study. 
Monocyte phenotyping, platelet-monocyte aggregation and platelet 
reactivity assays
Venous blood was collected in Vacutainer tubes containing 3.2% sodium citrate (Greiner 
Bio-one, Kremsmünster, Austria). Monocytes phenotyping was done by incubating whole 
blood for 25 minutes with saturating concentrations of antibodies directed against CD14 
(anti-CD14 PerCP, BD biosciences, San Jose, CA) as monocyte identification marker, CD16 
(anti-CD16 FITC, BD biosciences, San Jose, CA), CD195 (anti-CD195 FITC, Biolegend, San 
Diego, CA, USA) as marker of CCR5 expression and CD61 (anti-CD61 PE, BD biosciences, 
San Jose, CA) as platelet identification marker followed by addition Optilyse B (Beckman 
Coulter, Fullerton, California, USA) and distilled water. Monocytes were gated based on 
their forward and sideward scatter properties and surface expression of CD14 (Fig S1). 
PMA formation and expression of CD16 and CCR5 on monocytes were determined using 
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the median fluorescence intensity (MFI) of CD61, CD16 and CD195 on CD14+ cells. Platelet 
membrane expression of the alpha-granule protein P-selectin (CD62P) was measured as 
marker of platelet activation in unstimulated samples and after ex vivo platelet stimulation 
with low dose (7.8µmol/l) and high dose (31.2µmol/l) of the platelet agonist adenosine 
diphosphate (ADP) or with low dose (39µmol/l) and high dose (625µmol/l) of thrombin 
receptor activating petptide-6 (TRAP). Whole blood was incubated with saturating 
concentrations of APC-labelled anti-CD62P (P-selectin; BD biosciences, San Jose, CA), and 
anti-CD61. After 20 minutes incubation at room temperature, 0.2% paraformaldehyde was 
added and samples were analysed using Becton Dickinson flow cytometer. Platelets were 
gated based on their forward and sideward scatter properties followed by determination 
of the MFI of CD62P on CD61-positive cells (Fig S1). Soluble P-selectin (sPsel) and platelet 
factor 4 (PF4) were measured in plasma samples of health controls and TB patients at the 
start of treatment using ELISA (R&D, Abingdon, UK and Dako, Denmark A/S).
 
B: IN VITRO STUDY
Whole blood stimulation assay
Venous blood from adult healthy volunteers was collected in vacutainer tubes containing 
3.2 % sodium-citrate (Becton Dickinson, Franklin Lakes, NJ, USA) and stimulated with 
20µg/ml of killed Mtb (Mtb-H37Rv strain) for four hours at 37°C, 5% CO2 humidified 
atmosphere. Platelet-monocyte interaction was inhibited by 10µg/ml of anti-P-selectin 
or IgG1 isotype control antibodies (both obtained from R&D systems, Minneapolis, USA) 
for 30 minutes before addition of Mtb. Platelet p-selectin expression, PMA and expression 
of monocyte CD16 and CCR5 were determined by flow cytometry as described above (Fig 
S2). In addition, cells were also labelled with antibodies directed against CD11b (anti-CD11b 
FITC, Beckman Coulter, Fullerton, California, USA) as marker of monocyte activation. 
P-selectin was determined after stimulation of Mtb treated blood with 39µMol/ml of TRAP. 
Isolation of peripheral blood mononuclear cells (PBMC) and platelets
PBMCs were isolated from buffy coats obtained from the Sanquin bloodbank Nijmegen 
while platelets were isolated from citrate-anticoagulated venous blood collected from 
healthy adult volunteers as described previously [23]. Briefly, PBMCs were isolated by 
density gradient centrifugation on Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). 
PBMCs were washed five times with normal saline then resuspended in RPMI-1640 Dutch 
Modification culture medium (ICN Biomedicals, Costa Mesa, CA, USA) and adjusted to 
5x106 cells/ml. 
For platelet isolation, 3.2 % sodium-citrate-anticoagulated whole blood (Becton Dickinson, 
Franklin Lakes, NJ, USA) was centrifuged for 15 minutes at 156 x g without brake to obtain 
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platelet-rich plasma (PRP). PRP was further centrifuged at 330 x g for 15 minutes to obtain 
platelet pellets and resuspended in HEPES tyrode buffer. Prostacyclin (PGI2) 10ng/ml was 
added to inhibit platelet activation after the isolation procedure. Platelets were let to rest 
for 30 min before being used in the experiments.
PBMCs stimulation assay
PBMCs at a concentration of 5x106 cells/ml were dispensed into a flat-bottomed 96well 
plate (Thermo scientific, Roskilde, Denmark) and stimulated with 1µg/ml and 5µg/ml 
of killed Mtb in the presence and absence of washed platelets. PBMC to platelet ratio 
used was 1:50 and 1:100. Cells were incubated for 24 hrs and 48 hrs at 37°C and 5% CO2. 
Supernatant was collected after centrifugation and stored at -20αC. In another set of 
similar experiments, wells were washed three times with sterile PBS to remove floating 
cells. TRIzol reagent (Invitrogen, USA) was added into the wells containing adhering 
monocytes and stored at -80C for isolation of RNA.
Cytokine determination
Cytokines in collected supernatants were quantified using commercially available 
ELISAs for Interferon gamma (IFNγ), IL-6 and IL-10 (obtained from Sanquin, Amsterdam, 
Netherlands) and tumor necrosis factor alpha (TNFα) and IL-1β (obtained from R&D, 
Abingdon, UK) according to the manufacturer’s instructions. Next, RNA from stored 
monocytes was precipitated with isopropanol and washed with 75% ethanol followed 
by reconstitution in RNAse-free water. RNA was subsequently reverse transcribed 
into cDNA by using iScript (Bio-Rad, Hercules, CA, USA). qPCR analysis was done by 
using StepOnePlus sequence detection systems with SYBR Green Mastermix (Applied 
Biosystems, Foster City, CA, USA). The following primers were used: TNFα forward 
5’-CCTCTCTCTAATCAGCCCTCTG-3’, and reverse 5’-GAGGACCTGGGAGTAGATGAG-3’; IL-10 
forward 5’-CAACCTGCCTAACATGCTTCG-3’, and reverse 5’-TCATCTCAGACAAGGCTTGGC-3’. 
Data were corrected for expression of the housekeeping gene GAPDH for which the primers 
forward 5’-CGCTCTCTGCTCCTCCTGTT-3’, and reverse 5’-CCATGGTGTCTGAGCGATGT-3’ were 
used.  
Statistical analysis
Data on PMA formation, monocyte phenotype and platelet reactivity obtained from 
the patient study were analysed using Mann-Whitney test and presented as medians 
with interquartile range (IQR).  Correlations between parameters were assessed with the 
Spearman correlation coefficient. Differences in patient characteristics across groups were 
compared using one-way analysis of variance (ANOVA) and chi-square test for proportions. 
In-vitro data were analysed using paired t-test or Wilcoxon signed-rank tests (cytokine 
data) for non-parametric data and presented as mean with SEM or geometric mean with 
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geometric SD respectively. Analyses were done using SPSS version 22.0 software (for 
demographic data) and Graphpad Prism 5. The level of significance was set at p< 0.05.
Results
PATIENT STUDY
A cross sectional study enrolling TB patients in different phases of treatment was 
performed in Kibongóto National Tuberculosis Hospital and Mawenzi Reginal Hospital in 
Tanzania. A total of 65 TB patients and 29 healthy controls were enrolled. In the patient 
group, 25 were about to start TB treatment, 24 had been treated for one month and 16 had 
been treated for five months. Characteristics of the study participants are presented in 
Table 1. The groups were well matched for age and sex. 
Table 1 – Characteristics of study population.
Tuberculosis patients Controls
 Start of treatment Month 1 Month 5
Number 25 24 16 29
Male, n (%) 20 (80) 21 (87.5) 13 (81.3) 20 (69)
Female, n (%) 5 (20) 3 (12.5) 3 (18.7) 9 (31)
Age in years, Mean (SD) 35.4 (9.5) 37 (9.3) 40.9 (14.9) 33.9 (9.4)
Platelet count in cellsx109/l, Mean (SD) 346 (169)a 329 (93)a 221 (89)a
Alcohol use, n (%) 13 (52) 2 (8.3) 4 (25) 21 (84)
History of hypertension, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
History of diabetes, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
Smoking, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
Gender distribution across groups was analysed using chi-square test (p=0.442) while age distribution 
was analysed using one-way ANOVA (p=0.191). n (%), number (percentage). 
a   n=5, n=4 and n=3 for patients at start of treatment, patients in month 1 and patients in month 5 of 
treatment respectively.
Figure 1 shows results of PMA formation, monocyte CD16 and CCR5 expression and their 
mutual correlations. PMA was significantly higher in all patient groups compared to 
controls and highest in patients at the start and at month 5 of treatment. TB patients at all 
stages of treatment also had significantly higher expression of monocyte CD16 expression 
with the highest values in those starting TB treatment. In contrast, CCR5 expression was 
only higher in the patients at month 5 of treatment compared with the other groups 
(figure 1A). CD16 and CCR5 expression correlated well with each other (Spearman r= 0.815, 
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P<0.001), and also with PMA (r=0.78, p<0.0001 PMA vs CD16 and r=0.694, p=0.0001 PMA vs 
CCR5) (figure 1B). The proportion of monocytes expressing surface CD16 at high intensity 
(CD16high) was higher in the TB patients compared to controls, whereas the proportion of 
monocyte expressing CD16 at low intensity (CD16low) was comparable between the two 
groups (figure 1C). No association was found between PMA formation or expression of 
CD16 and CCR5 on monocytes with gender, age or use of alcohol among the study subjects 
(data not shown).
 
Figure 1 –  Platelet-monocyte aggregates (PMA) and expression of CD16 and CCR5 on monocyte are 
increased in TB patients. (A) shows mean fluorescence intensity (MFI) in arbitrary units of platelet-
monocyte aggregates (PMA), CD16 expression and CCR5 expression on monocytes of TB patients at 
the start of treatment (n=25), patients treated for one month (n=24), patients treated for five months 
(n=16) and healthy controls (n=29). Parameters were measured in whole blood by flow cytometry 
using anti-CD14, anti-CD61, anti-CD16 and anti-CD195 for identification of monocytes, platelets, 
CD16 and CCR5 respectively.  (B) Spearman correlation between CCR5 and CD16, PMA and CD16, and 
PMA and CCR5 respectively. (C) Proportion of monocytes expressing surface CD16 at low intensity 
(CD16low) or at high intensity (CD16high). Data in (A) and (C) were analysed using Mann-Whitney test 
and presented as median with IQR. 
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Platelet activation with increased expression of P-selectin is a frequent cause of increased 
PMA [24, 25]. Nonetheless, the expression of P-selectin on the platelet membrane in 
unstimulated whole blood was similar across the control and TB groups indicating that 
increased platelet degranulation was not present in TB. In fact, P-selectin expression in 
response to a low concentration of TRAP was lower in TB patients than in controls, whereas 
P-selectin responses to ADP or high dose TRAP were similar (figure 2A). Lower response 
of platelets to stimulation with low concentration of TRAP among TB patients was not 
influenced by gender, age or use of alcohol. On the contrary, soluble P-selectin and platelet 
factor 4 (PF4) were higher in TB patients at start of treatment than in controls (P<0.001) 
(figure 2B). The plasma markers are dependent on platelet mass [26]. Unfortunately, platelet 
counts were unavailable in the majority of participants which hampered the calculation 
of levels per platelet. In addition, soluble P-selectin and PF4 did not correlate with each 
other (Spearman r=0.090, P=0.647) (figure 2B) or with platelet membrane P-selectin in 
unstimulated samples (Spearman r= -0.148, P=0.49 and r=0.098, P=0.648 respectively). 
 
Figure 2 – Agonist-induced P-selectin membrane expression, and plasma levels of soluble 
P-selectin (sPsel) and platelet factor 4 (PF4) in controls and TB-infected patients at different stages 
of treatment. (A) Mean fluorescence intensity (MFI) in arbitrary units of P-selectin expression before 
and after stimulation of platelet with low and high concentrations of ADP and TRAP in TB patients at 
the start of treatment (n=25), patients treated for one month (n=24), patients treated for five months 
(n=16) and healthy controls (n=29). P-selectin expression was determined by flow cytometry using 
anti-CD61 and anti-CD62p for identification of platelets and P-selectin respectively. (B) Levels of 
soluble P-selectin (sPsel) and platelet factor 4 (PF4) in plasma of TB patients at start of treatment and 
health controls; and Spearman’s correlation between sPsel and PF4 in TB patients. sPsel and PF4 were 
quantified by ELISA. Data were analysed using Mann-Whitney test and presented as median with IQR.
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IN VITRO STUDIES 
The effect of Mtb on platelet and monocyte phenotype
Next, a set of in vitro experiments were performed to test the hypothesis that monocyte 
activation and not platelet activation accounts for the increased PMA in TB. Whole blood 
from healthy donors was stimulated with 20µg/ml Mtb. The activation of monocytes 
was determined by monocyte expression of CD11b and platelet activation by expression 
of P-selectin. Mtb increased the expression of monocyte CD11b, but not of platelet 
P-selectin, nor did it alter the reactivity of platelets to stimulation by TRAP (figure 3A). Mtb 
stimulation of whole blood also increased the expression of CD16 and CCR5 on monocytes.
 
 
Figure 3 – Platelet-monocyte aggregates (PMA), expression of monocyte CD16, CCR5 and CD11b 
and expression of platelet P-selectin after stimulation of whole blood with Mtb. (A) shows mean 
fluorescence intensity (MFI) in arbitrary units of CD11b expression on monocytes and P-selectin 
expression on platelets (at baseline and after secondary stimulation with 39µMol/l TRAP) after 
stimulation of whole blood with 20µg/ml Mtb for four hours. Results are pooled from two 
independent experiments performed in triplicates. (B) shows platelet-monocyte aggregates (PMA) 
and expression of CD16 and CCR5 on monocytes. Platelet-monocyte interaction was blocked using 
10µg/ml anti-P-selectin antibodies or IgG1 isotype control for 30 min before stimulation. Results are 
pooled from three independent experiments performed in triplicates. All assays were performed 
by flow cytometry using anti-CD14, anti-CD61, anti-CD11b, anti-CD62p, anti-CD16 and anti-CD195 
for identification of monocytes, platelets, CD11b, P-selectin, CD16 and CCR5 respectively. Data were 
analysed using t-test and presented as mean with SEM. ns=not significant.
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In earlier studies, platelet binding to monocytes was shown to change the phenotype 
of monocytes including increase in CD16 expression [8]. We therefore tested whether 
inhibition of PMA using anti-P-selectin antibodies reduced Mtb-induced expression 
of CD16 and CCR5 on monocytes. Addition of anti-P-selectin strongly reduced PMA, but 
did not reduce the expression of CD11b, CD16 or CCR5 on monocytes, indicating that high 
monocyte CD16 and CCR5 was a result of direct activation of monocytes by Mtb and 
that higher platelet binding to these monocyte is a result rather than the cause of this 
phenotypic change in Mtb exposed monocytes (figure 3B).
The effect of platelets and platelet-monocyte aggregates on cytokine 
response
Figure 4 – Cytokines produced after stimulation of PBMCs with Mtb in the presence or absence of 
platelets. (A) shows levels of IL-1β, IL-6, IFNγ, TNFα and IL-10 produced after stimulation of PBMCs 
using 1µg/ml and 5µg/ml of Mtb for 24hrs and 48hrs in the presence and absence of platelets. 
Cytokines were quantified using ELISA. Data were analysed using Wilcoxon test and presented as 
geometric mean with geometric SD. + represent 50 platelets for every PBMC while ++ represent 100 
platelets for every PBMC. Results are pooled from three independent experiments performed in 
triplicates.  **p<0.01, *p<0.05. (B) shows PCR results in relative copy numbers of mRNA (corrected for 
housekeeping gene GAPDH) of TNFα and IL-10 in adherent monocytes after stimulation of PBMCs 
using 5µg/ml of Mtb for 48hrs in the presence and absence of platelets in a 100:1 platelet-PBMC ratio. 
Bars are geometric mean ± geometric SD of three replicates. 
Platelets binding to monocytes is also known to influence the production of cytokines [23, 
25]. To study the effect of platelets and PMA on innate cytokine responses in TB, we exposed 
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isolated PBMCs from healthy donors to low (1µg/ml) and high (5µg/ml) concentrations of 
Mtb with and without addition of platelets for 24 hrs and 48 hrs and measured cytokines 
in the supernatants. Addition of platelets to PBMCs (platelet-PBMC ratio 50:1 or 100:1) 
stimulated with Mtb significantly decreased the pro-inflammatory cytokines IL-1β, IL-6 
and IFNγ after 24hrs and 48hrs incubation and TNFα after 24 hrs incubation (figure 4A), 
whereas concentrations of the anti-inflammatory cytokine IL-10 were increased at 24 hrs. 
Concentrations of TNFα and IL-10 in the supernatant were lower at 48hrs of stimulation 
than 24hrs of stimulation. In addition, incubation of platelets with PBMC without Mtb 
stimulation or incubation of platelets with Mtb did not lead to detectable cytokine levels 
in the supernatant. To confirm these findings, a PCR on TNFα and IL-10 was performed on 
RNA isolated from adherent monocytes that were incubated for 48hrs with and without 
platelets. A similar opposite effect was observed with a decrease in TNFα copies with a 
concurrent increase in IL-10 copies although differences were not significant (figure 4B). 
Discussion
The current study shows that TB patients have increased PMA at presentation and during 
TB treatment. Platelet activation promotes PMA, but no increased platelet P-selectin 
expression was found in our cohort. In addition, PMA correlated with CD16 and CCR5 
expression on monocytes, which are markers for a pro-inflammatory and migratory 
phenotype. In a set of in vitro experiments, we confirmed that Mtb does not activate 
platelets and that inhibition of PMA does not reduce monocyte CD16 and CCR5 expression. 
This indicates that monocyte activation by Mtb and not platelets is primarily responsible 
for increased PMA, monocyte CD16 and CCR5 expression during TB infection. However, 
PMA and interaction of platelets with lymphocytes may still modulate the innate immune 
response against Mtb as co-culture of PBMCs with platelets shifted cytokine responses to 
Mtb into an anti-inflammatory direction.
To the best of our knowledge, our study is the first showing that circulating PMA are 
increased in TB and that they may change immune responses. In addition, we are the first 
to study platelet function in TB infection using flow cytometry to analyse the expression of 
P-selectin, which functions as a cell adhesion molecule and a marker of platelet activation 
and degranulation. Previous studies, sometimes using more indirect techniques to 
measure platelet reactivity, showed controversial results. Rosas-Taraco et al shows that 
RANTES, a protein that is among others released by activated platelets [27],  is reduced in 
pulmonary tuberculosis infection28. In contrast, Büyükaşik and colleagues [29] used elevated 
plasma concentrations of platelet factor 4, which is a protein present in alpha granules, as 
an indicator of increased  platelet activation in patients with pulmonary TB. These plasma 
markers are an indirect measure of platelet activation status and may be influenced by 
platelet number. Turken et al. used light aggregometry to study platelet activation and 
found increased aggregation in patients with pulmonary TB [21]. The high plasma fibrinogen 
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levels that are commonly observed in TB patients [30] may enhance platelet aggregation 
and therefore influence the results of light aggregometry. We do not report fibrinogen 
binding but measured P-selectin expression on the platelet membrane and found no 
increased expression in TB patients, also in the in vitro studies. In contrast, plasma levels of 
soluble P-selectin and PF4 were increased in the TB patients, as also previously reported by 
others [31, 29]. Interpretation of these higher values is not straight forward as plasma levels 
of these proteins are known to depend on platelet mass [26], which is usually higher in TB [31], 
and soluble P-selectin is also produced by activated endothelial cells [32, 33]. The observation 
that these plasma markers did not correlate with membrane P-selectin expression 
supports the notion that platelet activation does not account for the higher levels of these 
proteins in TB. Instead, platelet P-selectin expression in the TB patients was even reduced 
after stimulation with low concentrations of TRAP. The PI3k-Akt-mTOR signalling pathway 
was recently shown to be inhibited in T-lymphocytes of patients with active tuberculosis 
[34]. This pathway is also important in platelet activation [35] and Akt-1 knockout mice depict 
an attenuated platelet response to thrombin [36]. No differences were apparent when 
a high dosage of TRAP was used, suggesting that maximum platelet degranulation can 
still be achieved. Furthermore, no difference in platelet reactivity was observed between 
patients at different stages of treatment following stimulation of platelets with TRAP. It is 
therefore unlikely that TB medication had any effects on platelet function. The propensity 
of bacteria to activate platelets differs. We recently showed that bacteremia with common 
Gram positive bacteria elicit strong thrombotic platelet activation whereas common Gram 
negatives do not [37]. Our current data therefore provide evidence that the increased PMA in 
pulmonary tuberculosis, which is a localized infection, is primarily the result of monocyte 
activation and not driven by platelet activation. The same applies to CD16 and CCR5 
expression by monocytes. Increased CD16 expression in TB patients has repeatedly been 
reported [14, 15, 38] while one study showed increased CCR5 expression [15]. Our current study 
shows that formation of PMA during TB infection correlates strongly with CD16 and CCR5 
expression on monocytes. However we observed no correlation between monocyte CD16 
and CCR5 expression and platelet P-selectin expression indicating that platelet binding to 
monocytes in the context of TB infection was not the cause of increased CD16 and CCR5. 
In a set of in vitro experiments, we show that this effect was due to monocyte activation 
by Mtb rather than platelet degranulation. However, platelets are known to increase 
monocyte CD16 hence the contribution of platelets on CD16 expression on PMAs cannot 
be completely ignored. Monocytes expressing CD16 and CCR5 migrate into lung tissue [15] 
and may therefore be involved in the formation of granulomas. PMAs may consequently 
function as carriers of platelets into the lung. Indeed, platelet markers have been found in 
biopsies of lung granulomas [10].
Our data also confirm previous findings from Feng and colleagues that platelets change 
the immune responses to Mtb [10]. In their study, which focused on the biology of localized 
macrophages in lung granulomas, they showed that macrophages differentiating in the 
presence of platelets for five days produced a lower TNFα/IL-10 ratio when challenged with 
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Mtb10. In our study, we demonstrate the role of platelets to the immediate response of 
bloodstream leukocytes to Mtb using PBMCs and fresh platelets. We show that within 24 
hours of Mtb exposure, the presence of platelets result in reduced monocyte-derived pro-
inflammatory cytokine responses (IL-1β, IL-6 and TNFα) as well as IFNγ, which is largely 
derived from T-lymphocytes, whereas IL-10 increased. Altogether, our findings indicate that 
the Mtb driven pro-inflammatory characteristic of CD16+ monocytes are downregulated 
by platelets and as such play a role in the balance between pro- and anti-inflammatory 
responses in TB patients. However, since platelets did not affect the cytokine mRNA 
generation of the adherent monocytes, we hypothesize that platelet effects are mediated 
through post-transcriptional regulation. The exact mechanism at which platelets regulate 
anti-inflammatory responses in leukocytes needs to be explored in future studies.
As reviewed recently by Stocker et al, the anti-inflammatory effects of platelets have 
gained attention recently [39]. Importantly, platelets seems to protect against septic shock 
by inhibition of macrophage dependent inflammation [40]. The anti-inflammatory effects 
of platelets during TB infection may however have a dual effect. First, by inducing platelet-
leukocyte crosstalk, Mtb downregulates the production of critical cytokines in the host 
defence against Mtb, such as IFNγ and TNFα [41]. Secondly, the platelet induced shift to a 
more anti-inflammatory response, may prevent excessive tissue damage by Mtb.
Platelets downregulate IFNγ production from leukocytes. Given the importance of this 
cytokine in host defence against Mtb, reduction of platelet-leukocyte interaction in TB 
patients may be favourable. This notion is supported by a recent study in which platelet-
monocyte interaction was shown to promote the survival of intracellular MTb survival 
in vitro [31]. Antiplatelet drugs are among the most commonly prescribed drugs and our 
current data as well as data from other groups suggest that these might influence host 
responses to Mtb. Aspirin for instance, has received ample attention as an adjuvant in 
treatment of tuberculosis although with contradicting results [42–44]. In addition, although 
aspirin has anti-inflammatory effects and is an inducer of IFNγ production [45], this drug 
has only limited effect on PMA in contrast to ADP receptor antagonists, such as clopidogrel 
or ticagrelor, which are known to inhibit PMA to a much higher degree [8]. To the best of our 
knowledge, studies exploring the effects of these drugs on immune responses against 
Mtb are not yet available. These studies need careful consideration as these drugs may 
increase the risk for bleeding while platelet hyper-reactivity is absent in TB patients. 
Coinfection of HIV and TB is common. While HIV is well known risk factor for TB infection 
[46, 47], there are limited reports on the microenvironment of patients with TB that facilitates 
establishment of HIV infection. Our results on the increase of monocyte CCR5, which 
is a  co-receptor for HIV, are in line with those reported by Rosas-Taraco and colleagues 
who show that Mtb increase susceptibility to HIV infection of primary cells by increasing 
expression of CCR5, increasing pro-inflammatory cytokines and downregulating CCL5 [28].
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 119
5
PMA in TB infection
119
Finally, one surprising observation in our study was that patients treated for one month 
had lower PMA than patients treated for five months. TB therapy is reported to reverse 
phenotypic changes of monocytes [48] and hemostatic and plasmatic [21] changes that 
occur during TB infection. The interpretation of this finding is hampered by the fact that 
participants were not followed longitudinally. Nonetheless inflammation and tissue 
damage are hallmarks of TB infection and we hypothesize that monocyte activation state 
induced by the infection is quickly reverted upon initiation of anti-TB therapy and reoccur 
later in the course of treatment due inflammation resulting from necrotic tissues.
Our study has different limitations. First, participants were not followed in time 
which hampers comparison across the different time points of TB treatment. Second, 
information on blood cell counts was not available for all patients as this was not part of 
the routinely ordered tests. Third, we used CD61 as platelet marker for determination of 
PMA. Although CD61 has been widely used for this purpose, some studies have reported 
that there is low expression of this marker on monocytes as well [49, 50].
In conclusion, PMA is increased during TB infection and this occurs in the absence 
of marked platelet activation. This suggests that monocyte activation is primarily 
responsible for the increased PMA. Platelet crosstalk with leukocytes counteracts the Mtb 
induced pro-inflammatory response of leucocytes, which may on the one hand protect 
against excessive tissue damage, but on the other hand compromise the production of 
essential protective cytokines, such as IFNγ and TNFα.
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Supplemental figures
Supplemental Figure 1 – Gating strategy for platelets and monocytes.
Plots showing the gating strategy for platelets (A) and monocytes (B). Both platelets (CD61 positive cells) 
and monocytes (CD14 positive cells) were selected on their forward (FS) and side (SS) scatter characteristics.
 
 
Supplemental Figure 2 – Representative plots showing platelet and monocyte phenotypes after 
exposure to Mtb.
P-selectin expression on platelets (CD61 positive cells) (A), platelet-monocyte aggregates (B), CD11b 
expression on monocytes (CD14 positive cells) (C), CD16 expression on monocytes (D), and CCR5 expression 
on monocytes after stimulation of whole blood with culture media (negative control) or 20µg/ml Mtb.
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Abstract
Background and methods  Platelets are key cells in coagulation and inflammation and 
as such play an important role in the development of ischemic cardiovascular diseases 
(CVD) such as myocardial infarction and ischemic stroke. Stroke is a leading cause of 
death in Sub-Saharan Africa (SSA). The incidences of CVD are rising due to lifestyle changes 
affected partly by global urbanization. To date, no data are available on determinants of 
platelet activation and reactivity in populations in SSA. The aim of our study was to study 
environmental and non-genetic host determinants of platelet reactivity in a cohort of 
319 healthy Tanzanian adults with a special focus on differences between those living in 
urban or rural areas. In addition, we studied the associations of platelet parameters with 
circulating inflammatory markers and cytokine production capacity.
Results  While measures of platelet activation/reactivity were similar between urban 
and rural subpopulations, their associations with both host and environmental factors 
showed distinct patterns between urban and rural subpopulations. Only in the urban 
population, platelet activation/reactivity was associated with traditional risk factors 
for CVD including advanced age, high systolic blood pressure, alcohol use and smoking 
of tobacco. Other factors associated with platelet activation/reactivity were use of pit 
latrine or smoke emitting cooking fuel. Important differences between urban and rural 
subpopulations were also found in associations of platelet reactivity with inflammatory 
markers: platelet reactivity correlated positively with plasma levels of alpha-1-antitrypsin 
(AAT) and negatively with interleukin (IL)-1β and IL-18 levels in the urban but not in the 
rural subpopulation, whereas only in the rural subpopulation platelet reactivity was 
strongly correlated with IL-1Ra and IL-18BPa levels. In addition, platelet numbers were 
inversely associated with whole blood cytokine production capacity in general, whereas 
platelet activation had predominantly negative correlations with TNFα production in the 
rural subpopulation. 
Conclusion  Associations between platelet reactivity with environmental and non-genetic 
host factors and plasma inflammatory markers differ between individuals from healthy 
rural and urban subpopulations in Tanzania. These differences provide novel insights in 
the possible health consequences of urbanization and lifestyle changes in SSA. 
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Introduction
Platelets are key cells in thrombosis and hemostasis. They are also increasingly recognized 
as important effector cells of inflammation and atherosclerosis [1–3]. Changes in platelet 
numbers and reactivity are associated with the risk for cardiovascular events and mortality 
[4, 5]. Recently, data from the community based Framingham Heart Study (FHS) identified 
intrinsic platelet hyper-reactivity to adenosine diphosphate (ADP) to be associated with 
the incidence of myocardial infarction and stroke [5]. 
Platelet numbers and reactivity vary markedly between healthy individuals. Both genetic and 
non-genetic factors underlie this variation [6, 7]. So far, studies investigating determinants 
of these platelet parameters were predominantly performed in individuals of Caucasian 
ancestry or other ethnic groups living in the west [8–10]. We recently studied determinants 
of platelet number and reactivity in 500 healthy individuals with a Western-European 
genetic background as part of the Human Functional Genomics Project (HFGP; www.
humanfunctionalgenomics.org; also referred to as 500FG cohort [10]. One of the main findings 
of this study was that platelet numbers are associated with plasma interleukin (IL)-1β levels 
and platelet degranulation capacity with IL-1β and IL-6 cytokine production capacity [10]. This 
is especially relevant as results of the CANTOS (Canakinumab Anti-inflammatory Thrombosis 
Outcome Study) affirmed the importance of IL-1β in cardiovascular diseases (CVD) [11].
To the best of our knowledge, no data are available on non-genetic host and environmental 
determinants of platelet number and reactivity in a Sub-Sahara African (SSA) population. 
This information is needed as CVD, especially ischemic stroke, are common in this 
region [12]. Stroke is a leading cause of death in the elderly population in Tanzania and 
age-standardized stroke incidence rates in rural population were similar as seen in high-
income countries, while incidence rates from urban Dar es Salaam were even higher [13, 14]. 
High blood pressure is considered the most important risk factor for stroke. The incidence 
of myocardial infarction is still relatively low in SSA, but rising, especially in urban areas, 
as classical CVD risk factors are increasing [15, 16]. SSA is currently in the middle of the so-
called demographic transition, characterized by mass urbanization, sedentary lifestyles 
and increased availability of nutrient-poor processed foods [17]. A better insight in factors 
driving platelet reactivity may help to understand the epidemiology of CVD in SSA and the 
interventions that need to be taken. 
The aim of our study was to assess for the first time in a healthy population from a 
semi-urbanized region in Northern Tanzania the general pattern of platelet activation 
and reactivity. We explored relations with non-genetic host and environmental factors 
and compared subjects living in rural vs. urban areas. Next, given the interrelationship 
between platelets and inflammation and host defense, we studied associations between 
platelet parameters with different circulating inflammatory markers and cytokine 
production capacity to different synthetic and pathogen-derived ligands.
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Methods
Study area and population description
The 300 functional genomics (300FG) study is part of the Human Functional Genomics 
Project (www.humanfunctionalgenomics.org), which aims to characterize and 
understand inter-individual variation of human immune responses in healthy and 
diseased individuals [18]. A total of 319 Tanzanian healthy individuals aged between 18-65 
years residing within the Kilimanjaro region in Northern Tanzania were recruited between 
March and December 2017, at the Kilimanjaro Christian Medical Center and Lucy Lameck 
Research Center, in Moshi municipal.  Moshi is the administrative, commercial and 
educational centre of the Kilimanjaro region with over 200,000 inhabitants and 7 higher 
education institutions. Due to this regional function, there is significant diversity in ethnic 
groups, economic status and lifestyle, whereby most inhabitants have adopted a Western 
lifestyle.   In contrast, people living outside the municipality (urban zone) represent the 
rural population of Tanzania whereby economy depends mainly on subsistence farming 
and animal husbandry. Most individuals in the rural belong to the Chagga tribe and 
follow a traditional lifestyle whereby living in large family units, using a pit latrine and 
consumption of vegetable diet are common practices. Individuals from both urban and 
rural zones were enrolled with a higher number from the urban zone to correct for the 
higher genetic diversity. 
Information about the study was given through leaflets or announced during mass 
gatherings. Volunteers were interviewed by a member of the study team using a guided 
pre-screening questionnaire. Healthy participants above the age of 18 years were enrolled. 
Exclusion criteria included pregnancy, suffering from any acute or chronic disease, use 
of antibiotics or anti-malarial medication in the last three months before sampling, or 
suffering from tuberculosis infection in the past one year. Following written informed 
consent, screening tests were performed. These included a rapid test for HIV (SD-Bioline, 
Standard Diagnostics, Kenya, #03FK16), malaria (Malaria Pf/PAN (HRP2/pLDH) Ag Combo 
RDT kit, Accessbio, USA, #RMRM-02571) and random blood glucose (ACCU-CHECK glucose 
test strips, Roche Diabetes Care GmbH, Germany, #07124112036) and blood pressure 
measurements. Subjects who tested positive for HIV or malaria, or had blood pressure 
outside the defined range (< 90/60mmHg or > 140/90mmHg) or had high blood glucose 
(>8.0 mmol/L) were excluded. Demographic data were collected from included subjects 
using an extensive questionnaire about host factors, lifestyle, diet and disease history. 
Body weight and height measurements were also taken. 
Measurements of platelet function
Venous blood was collected in citrated tubes (3.2% sodium citrate; Becton Dickinson, USA). 
Platelet reactivity tests were determined by a whole blood flow cytometry assay within two 
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hours as described previously [19]. Briefly, platelet membrane expression of the α-granule 
protein P-selectin (CD62P) and the binding of fibrinogen to the activated integrin αIIbβ3 
were measured in unstimulated whole blood samples and recorded as baseline activation 
parameters of resting platelets. Platelet reactivity to agonists was determined by using 
the geometric mean of the median fluorescent intensity (MFI) of P-selectin expression on 
platelets after ex vivo stimulation with a low or high concentration of adenosine diphosphate 
(ADP, 1µM and 125µM, Sigma-Aldrich, USA), thrombin receptor activation peptide-6 (TRAP-
6, 5µM and 125µM, Sigma-Aldrich, USA) or Protease activated receptor-4 agonist AYPGKF 
(PAR4, 200µM and 625µM, synthesized at the department of Immunohematology and blood 
transfusion of the Leiden University Medical Center, The Netherlands). Baseline parameters 
in unstimulated samples were termed as Psel_un and Fibr_un while induction of platelet 
P-selectin by ADP, TRAP-6 and PAR4 were termed as Psel_ADP, Psel_TRAP and Psel_PAR4, 
respectively. Platelet agonists were selected based on their distinctive platelet stimulatory 
pathways. ADP mediates platelet activation and aggregation via the P2Y1 and P2Y12 receptors 
[20], while TRAP-6 and PAR4 agonists mediates thrombus formation via PAR1 and PAR4 
receptors respectively [21]. The PAR4 agonist was included as individuals of African decency 
were reported to have enhanced PAR4 signaling [9]. 
The following antibodies were used: PE-labelled anti-CD62P (P-selectin; Sysmex Partec, 
Görlitz, Germany), FITC-labelled anti-fibrinogen (DAKO Ltd., High Wycombe, UK) and 
PE_Cy7-labeled anti-CD61 (Sysmex). Samples were measured on a Sysmex Cube8 flow 
cytometer and data were analysed using Kaluza software (Beckman Coulter, France). Cells 
were gated based on their forward and sideward scatter properties and surface expression 
of their respective identification markers (Fig S2). Whole blood cell count was done on 
EDTA anticoagulated blood using a Sysmex XN450 analyzer.
Measurement of circulating mediators
The circulating plasma cytokines IL-6, IL-1β, IL-1 receptor antagonist (IL-1Ra), IL-18, IL-
18 binding protein (IL-18BPa) were measured in EDTA plasma using the Simple Plex™ 
cartridges run on the Ella™ platform (ProteinSimple, San Jose, USA) following the 
manufacturer’s instructions. Circulating adipokines (Leptin, resistin, and adiponectin) 
and α-1-antitrypsin (AAT) were also measured in EDTA plasma using the R&D Systems 
DuoSet ELISA kits following the manufacturer’s standard protocols.
Whole blood stimulation assays and cytokine quantification
Heparinized whole blood was stimulated with bacterial, fungal, viral, and non-microbial 
metabolic stimuli as follows;- 100µl of blood was added to a 48 wells culture plate 
and subsequently stimulated with 400µl of stimulus for 48 hours at 37°C and 5% CO2. 
Supernatants were collected and stored at -80°C. Concentrations of cytokines IL-1β, IL-
6, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and IL-10 were measured in stored 
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supernatants using enzyme-linked immunosorbent assay (ELISA) according to the 
instructions of the manufacturer (IL-1β, IL-6, IL-10, TNF-α: R&D Systems; IFN-γ: Sanquin). 
List of stimuli used and their respective concentrations are listed in table S1.
Ethics
The study was performed according to the principles of the Declaration of Helsinki. All 
participants provided written informed consent. The 300FG study was approved by the 
Ethical Committees of Kilimanjaro Christian Medical University College, the National 
Institute of Medical Research in Tanzania (NIMR/HQ/R.8a/Vol.IX/2290); and the Ethical 
committee of the Radboud University Medical Center Nijmegen (CMO Arnhem-Nijmegen 
(CMO:2016-2657)) in the Netherlands.
Statistical analysis
Data on platelet reactivity and cytokines were Log10 transformed. The associations 
between platelet count and platelet reactivity parameters with host and environmental 
factors, circulating mediators and ex vivo cytokine production were analyzed using 
Spearman correlation coefficient or linear regression controlling for age, gender and 
BMI as indicated. Differences between groups were analysed using Chi-square or Mann-
Whitney tests for categorical and continuous variables, respectively. In order to maximize 
on the use of data, missing values were handled on a pairwise basis for each comparison 
separately. Statistical significance was based on P-value below 0.05. Analyses were 
performed using SPSS version 25 and Graphpad prism 7.
Results
Cohort characteristics and platelet activation and reactivity
The characteristics of the study participants are summarized in table 1. A total number of 
319 subjects were enrolled, of whom 251 (78.7%) lived in an urban area and 68 (21.3%) in a 
rural area. The median (IQR) age of the population was 30.2 (23.4-40.2) years and 50.8% 
were females. In general, participants from the urban were younger than those from the 
rural. In contrast, people in the rural had a higher median blood pressure, had increased 
exposure to animals and used mostly pit latrines and smoke emitting fuel. 
Statistical comparison between urban and rural subpopulations was done using Chi-
square tests or Mann Whitney test with p-value=0.05; *, significantly higher in the rural 
population; #, types of cooking fuel include firewood, charcoal and kerosene (smoky), and 
electrical and gas (non-smoky). @ Smoking habit was analyzed in males only as women in 
this study population did not smoke.
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Table 1 – Characteristics of study participants. 
All (n=319) Urban (n=251) Rural (n=68) P-value
Gender (N, %)
 Male 157 (49.2) 116 (46.2) 41 (60.3) 0.039*
 Female 162 (50.8) 135 (53.8) 27 (39.7)
Age in years (median, IQR) 30.2 (23.4-40.2) 27.4 (22.2-38.3) 39.7 (32.6-49.5) <0.000*
Age categories (N, %)
 18-30 years 164 (51.4) 152 (60.6) 12 (17.6)
 31-45 years 96 (30.1) 66 (26.3) 30 (44.1)
 46-80 years 59 (18.5) 33 (13.1) 26 (38.2)
 Body Mass Index (median, IQR) 24.0 (21.5-27.3) 24.2 (21.5-27.3) 23.4 (21.4-27.2) ns
BMI categories (N, %)
 Underweight, BMI<18.5 15 (4.7) 13 (5.2) 2 (2.9)
Normal weight, BMI 18.5-24.9 177 (55.5) 136 (54.2) 41 (60.3)
 Overweight, BMI 25-30 79 (24.8) 64 (25.5) 15 (22.1)
 Obese, BMI>30 48 (15) 38 (15.1) 10 (14.7)
Systolic blood pressure, mmHg (median, IQR) 123 (113-136) 120 (110-135) 130 (120-139) 0.005*
Diastolic blood pressure, mmHg (median, IQR) 79 (70-81) 77 (70-80) 79.5 (72.2-86) 0.028*
Use of contraceptives (N, % of women)
 No 138 (85.2) 117 (86.7) 21 (77.8) ns
Cooking fuel (N, %) #
 Smoky 115 (36.1) 69 (27.5) 22 (32.4) <0.000*
 Non-smoky 204 (63.9) 182 (72.5) 46 (67.6)
Smoking (N, % of men)@
 Current or past smoker 45 (28.7) 31 (26.7) 14 (34.1) ns
 Never smoked 112 (71.3) 85 (73.3) 27 (65.9)
Alcohol use (N, %)
 No 201 (63.0) 159 (63.3) 42 (61.8) ns
 Yes 118 (37.0) 92 (36.7) 26 (38.2)
Toilet facility (N, %)
 Pit latrine 77 (24.1) 52 (20.7) 25 (36.8) 0.006r
 Water closet 242 (75.9) 199 (79.3) 43 (63.2)
Exposure to animals (N, %)
 No 178 (55.8) 162 (64.5) 16 (23.5)
 Yes 141 (44.2) 89 (35.5) 52 (76.5) <0.000r
Statistical comparison between urban and rural subpopulations was done using Chi-square tests or Mann 
Whitney test with p-value=0.05; *, significantly higher in the rural population; #, types of cooking fuel include 
firewood, charcoal and kerosene (smoky), and electrical and gas (non-smoky). @ Smoking habit was analyzed in 
males only as women in this study population did not smoke.
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Platelet activation status is expressed as P-selectin expression in unstimulated samples 
(Psel_un) and fibrinogen binding to the activated integrin αIIbβ3 (Fib_un); platelet 
reactivity is measured as P-selectin expression after ex vivo platelet stimulation with two 
concentrations of ADP, TRAP-6 or PAR4 agonist. Data distribution, representative platelet 
reactivity plots and gating strategy are shown in figure S1 and S2 respectively. Platelet 
responses to stimulation with PAR4 agonists had the highest variation as compared 
to responses to stimulation with ADP and TRAP. The associations between platelet 
parameters after correcting for age and gender are shown in figure S3. Psel_un correlated 
well with Fibr_un, and unlike Fibr_un also correlated well with agonist-induced P-selectin 
reactivity. Readouts of platelet reactivity correlated well with each other, except for Psel_
PAR4low which did not correlate with Psel_un or Psel_ADPlow. Likewise, Psel_PAR4high 
showed only a weak correlation with Psel_un.
Impact of environmental and non-genetic host factors 
We first analysed platelet parameters in relation to a set of host and environmental factors 
(Fig 1A). Females had a significantly higher mean (SD) platelet count than males (272.4 α 
70.7  vs 238.6 α 57.3; P<0.001), as also previously reported [22], [23]. Age had a strong positive 
association with platelet activation status and ADP-stimulated platelet reactivity. 
Surprisingly, BMI was not associated with increased Psel_un or platelet reactivity, and 
even negatively associated with Fibr_un. However, when subjects were divided according 
to their BMI levels into non-obese (BMI < 30, n = 271) and obese (BMI ≥ 30, n = 48), the 
median MFI of fibrinogen binding to platelets in obese subjects was not different from 
that of non-obese subjects (2138.0 versus 2187.8, p=0.636). Furthermore, the inverse 
relation between BMI and fibrinogen binding was only observed in male but not in female 
subjects. Of the environmental factors, we found positive associations between at least 
one platelet activation or reactivity parameter with use of alcohol, use of a pit latrine (as a 
measure of low economic status) and exposure to tobacco or smoke emitting fuel (Fig 1A 
and S4A).   
Even though overall values for platelet activation or reactivity did not differ between the 
urban and rural populations, we investigated whether the patterns of associations with 
environmental and non-genetic host factors differed between both subcohorts (Fig 1B). 
Interestingly, the positive association of age and platelet activation/reactivity was only 
seen in the urban subcohort, whereas only in the rural cohort, female sex had a strong 
negative association with Psel_un. Regarding classical cardiovascular risk factors, positive 
associations between platelet activation or reactivity parameters with blood pressure, 
alcohol use, smoking of tobacco or exposure to smoky fuel were only seen in the urban 
subcohort and not in the rural subcohort (Fig 1C). 
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Figure 1 – Relation between platelet parameters and host and environmental factors. (A) Correlation 
coefficients of associations between platelet parameters with gender (corrected for age) and age 
(corrected for gender), and with BMI, systolic blood pressure (PB); and other environmental factors 
corrected for gender and age in the general population (n=319) and in urban (n=251) vs rural (n=68) 
subcohorts separately. Figure legends indicates levels of correlation coefficients while significant 
associations are marked by asterisks (*). Red and blue colours indicate positive and negative 
associations respectively. Dotted lines mark specific clusters with outstanding differences between 
urban and rural subcohorts. Analysis was done using linear regression model. (B) Bar graphs showing 
geometric mean with 95% interval of differences in unstimulated P-selectin between different age 
categories; differences in ADP stimulated P-selectin between individuals using smoky or non-smoky 
emitting fuel; and differences in unstimulated fibrinogen binding to platelets between smokers and 
non-smokers in urban and rural subpopulations. Differences were calculated using Mann Whitney 
test. Psel_un and Fibr_un = P-selectin and fibrinogen binding to platelets in unstimulated samples 
respectively; Psel_ADPlow, Psel_ADPhigh, Psel_TRAPlow, Psel_TRAPhigh, Psel_PAR4low and Psel_
PAR4high = P-selectin expression after stimulation of platelets with low and high dose of ADP, TRAP-6 
or PAR4 agonists.
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Figure 2 – Associations between platelet parameters with circulating inflammatory mediators. 
(A) Heat map showing correlation coefficients of associations between platelet parameters and 
circulating inflammatory mediators corrected for gender, age and BMI in the general population 
(n=241) and in urban (n=182) vs rural (n=59) subcohorts separately. Figure legends indicates levels 
of correlation coefficients while significant associations are marked by asterisks (*). Red and blue 
colours indicate positive and negative associations respectively. Dotted lines mark specific clusters 
with outstanding differences between urban and rural subcohorts. Analysis was done using linear 
regression model. (B) Scatter plots showing differences in the direction of the highly significant 
correlations between urban and rural subpopulations. Psel_un and Fibr_un = P-selectin and 
fibrinogen binding to platelets in unstimulated samples respectively; Psel_ADPlow, Psel_ADPhigh, 
Psel_TRAPlow, Psel_TRAPhigh, Psel_PAR4low and Psel_PAR4high = P-selectin expression after 
stimulation of platelets with low and high dose of ADP, TRAP-6 or PAR4 agonists. AAT, alpha1-
antitrypsin; IL-1RA, IL-1 receptor antagonist; IL-18BPa, IL-18 binding protein.
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Associations between platelet parameters with circulating 
inflammatory mediators 
Inflammation and platelets were previously shown to have a bidirectional relationship [10, 
24–26]. We therefore investigated whether differences in adipokines or cytokines underlie 
the observed differences in platelet parameters. We correlated platelet parameters with 
the adipokines leptin, adiponectin, resistin, the inflammatory cytokines IL-1β, IL-6, IL-1 
receptor antagonist (IL-1ra), IL-18, IL-18 binding protein (IL-18BPa) and alpha-1-antitrypsin 
(AAT). Analyses were corrected for gender, age and BMI as these factors were independently 
associated with inflammatory mediators (Fig S4B). Overall, AAT had the strongest positive 
associations with platelet reactivity, whereas plasma IL-1β and IL-18 levels correlated 
negatively with platelet activation and reactivity (Fig 2). Platelet count correlated 
positively with IL-1Ra, IL-6, leptin and resistin in univariate analysis (Fig S4C), but, with the 
exception of resistin, associations disappeared following correction for gender and BMI. 
Next, we assessed whether these associations differed between the urban and rural 
subcohorts. Interestingly, in the urban population, the strongest positive and negative 
associations with platelet reactivity were with AAT and IL-1β and IL-18, respectively (Fig 
2B). Mean (SD) AAT levels were marginally higher in the urban than in the rural subcohort 
(1.44±0.25 vs 1.37±0.22, p=0.047). Conversely, in the rural population, the strongest positive 
correlations with platelet reactivity were found for the IL-1Ra, IL-6 and IL-18BPa. 
Correlations of ex vivo cytokine production with platelet parameters
Platelet reactivity and platelet leukocyte aggregation have been reported to influence 
cytokine production capacity [27–29]. We quantified the production of the pro-inflammatory 
cytokines IL-1β, IL-6, TNFα and IFNγ and the anti-inflammatory cytokine IL-10 following 
stimulation of whole blood with different synthetic TLR ligands and bacterial and fungal 
stimuli and related these to platelet numbers and reactivity (Fig 3). Gender, age and BMI 
were associated with several cytokine responses (Fig S4D), and were therefore corrected 
for in this analysis. Associations of cytokine production capacity to multiple stimuli with 
platelet counts were generally negative. In addition, in the rural but not in the urban 
cohort, P-sel_un had predominantly negative correlations with TNFα production to 
different ligands (Fig 3).
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Figure 3 – Association between platelet parameters with ex vivo cytokine production. Heat map 
showing correlation coefficients of association between platelet parameters and cytokines (IL-1b, 
IL-6, TNFα, IFNγ and IL-10) produced in whole blood in response to a range of pathogenic stimuli in the 
general population (n=241) and in urban (n=182) vs rural (n=59) subcohorts separately. Figure legends 
indicates levels of correlation coefficients while significant associations are marked by asterisks (*). 
Red and blue colours indicate positive and negative associations respectively. Analysis was done 
using linear regression model, correcting for age, gender and BMI. Psel_un = P-selectin expression in 
unstimulated samples; Psel_ADPhigh, P-selectin expression after stimulation of platelets with high 
dose of ADP.
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Discussion
In this study, environmental and non-genetic determinants of platelet activation and 
reactivity in a population of healthy adults in SSA were analyzed with special focus on 
differences between individuals living in an urban or rural environment. The overall 
degree of platelet activation and reactivity did not differ between urban and rural 
subpopulations, however, important differences in the regulation of platelet function 
and its interaction with inflammation were found.  First, especially age, but also systolic 
blood pressure, smoking and alcohol use were associated with platelet reactivity in the 
urban subpopulation, but not in the rural subpopulation. Second, in the urban and rural 
subpopulations, platelet reactivity was associated with a different cluster of plasma 
cytokines and inflammatory markers. Finally, platelet numbers and platelet reactivity 
were inversely correlated with ex vivo whole blood cytokine production capacity in this SSA 
cohort, which is in contrast to what was previously found in a West-European HFGP cohort 
(500FG cohort).  
To the best of our knowledge, this is the first study investigating determinants of 
interindividual variations in platelet reactivity in SSA. This is especially important in view 
of the current demographic transition in many areas in SSA, which is associated with 
ongoing mass urbanization with a shift towards sedentary lifestyles, unhealthy diet and 
increasing use of tobacco and alcohol. Ischemic stroke is a leading cause of death in SSA, 
also in rural areas but its incidence, as well as that of myocardial infarction is rising due to 
changing lifestyles [15]. Platelets are key cells in the initiation and progression of ischemic 
CVD [30] and ADP-induced platelet hyperreactivity was recently shown to predict CVD in the 
Framingham cohort [5]. Previous studies have related platelet hyperreactivity to classical 
cardiovascular risk factors, including increasing age, use of alcohol or tobacco and higher 
blood pressure [7, 31–33]. Our present findings that platelet reactivity was only related to 
classical risk factors in the urban but not in the rural subpopulation, support the notion 
that traditional cardiovascular risk factors are becoming more important with ongoing 
urbanization. Further studies, such as metabolome or microbiome analysis, may shed 
light on risk factors determining platelet reactivity in rural populations.
Our present study confirms data from other populations that females have higher platelet 
numbers than males [8, 22, 23]. Interestingly, women in the rural, but not in urban areas had 
significantly lower platelet P-selectin expression. The reason for this is uncertain. Gender-
specific differences in platelet activation and aggregation have been reported by other 
investigators (reviewed in [34]), and even though results are conflicting, most investigators 
reported enhanced platelet reactivity in women. 
Another unexpected finding was the absence of a positive association of BMI with platelet 
reactivity and even an inverse relation of BMI with platelet fibrinogen binding in males. 
Obesity is associated with platelet hyperreactivity [35–38], but the fact that obesity (BMI>30) 
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was relatively uncommon (15%) in our population probably explains why no relation was 
seen. This also explains why no correlation of adipocytokines with platelet reactivity was 
observed, in contrast to results from earlier studies [26, 37, 39, 40]. 
Besides traditional cardiovascular risk factors, specific determinants of platelet function 
specific for low income regions were also identified. These included exposure to smoke 
emitting fuel and use of a pit latrine. Use of firewood, charcoal and kerosene as cooking 
fuel is a common practice in low income countries and related to an increased risk for 
CVD and thrombotic complications [41]. A study done in Indian women suggested 
that chronic exposure to biomass smoke induces platelet activation and increase in 
formation of platelet-leukocyte aggregates [42]. How use of a pit latrine relates to platelet 
hyperreactivity is unclear. Possible mechanisms include exposure to microbes and/or 
bioaerosols originating from the pit, or pit latrines being a sign of poverty. Urbanization is 
also associated with changes in lifestyle and diet which are likely to influence microbiota 
and metabolic composition. As these may be important for platelet function, we are 
currently analyzing microbiome and metabolome data in connection with platelet 
activation from the same cohort in order to identify new, non-traditional determinants of 
platelet function in SSA. 
Another interesting observation in our cohort was the different clustering of platelet 
parameters with inflammatory markers. In the urban cohort, platelet reactivity was 
positively associated with AAT levels and inversely with plasma IL-1β levels, whereas in the 
rural cohort, reactivity was positively related to levels of IL-6 and of the anti-inflammatory 
proteins IL-1Ra and IL-18BPa. Although hepatocytes produce most of circulating AAT, many 
more cell types, including immune cells and platelets, were reported to contain AAT [43], 
[44]. AAT is an acute phase protein with strong anti-inflammatory and immunomodulatory 
properties independent of elastase inhibition [45]. Among others, AAT has been shown to 
induce IL-1Ra expression [46, 47] and suppress lipopolysaccharide-induced IL-1β, IL-8, and 
TNF-α [45]. Our present findings confirm data from the 500FG cohort in which AAT levels 
were also positively related to platelet reactivity, whereas IL-1β or IL-6 levels were not 
related to platelet reactivity [10]. Whether the association of AAT with platelet reactivity is 
truly causal remains unknown, also because earlier studies suggested that AAT inhibits 
platelets  [48, 49]. In contrast to the findings in the 500FG cohort, IL-1β plasma levels were 
not associated with circulating platelet counts in the present cohort. IL-1β is a known 
regulator of platelet production [50]. The ongoing GWAS analysis is expected to answer 
whether genetic variation in the IL-1β gene accounts for the absent correlation in the 
present cohort. In addition, our current study supports the notion that IL-1β is not an 
important regulator of platelet reactivity in healthy individuals, even though IL-1β was 
reported by some investigators to activate platelets [51]. The positive association of platelet 
reactivity with anti-inflammatory proteins IL-1Ra and IL-18BPa is in line with the results 
from the cytokine production capacity whereby platelet number and reactivity were 
inversely associated with cytokine production, especially TNFα in the rural population. 
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Numerous studies have shown that platelets are able to tune cytokine responses either 
in a stimulatory or inhibitory way [28, 29, 52, 53]. Interestingly, our present observations are 
opposite to those from the 500FG cohort in which platelet degranulation capacity 
(P-selectin reactivity) was positively associated with IL-1β and IL-6 production capacity 
[10], suggesting that anti-inflammatory properties of platelets are more dominant in 
individuals from SSA.
A wide variation in platelet responses to PAR4 stimulation was observed, supporting the 
notion that PAR4 signaling is affected by commonly occurring polymorphisms which are 
prevalent in individuals of African ancestry [9]. In addition, PAR1 and PAR4 differ in their 
signaling networks whereby PAR4 plays a role in the later phase of platelet activation and is 
dependent on the synergistic effect of P2Y12 receptor activation [21]. This could explain why 
low concentrations of PAR4 agonists did not correlate with platelet activation, whereas 
maximum stimulation could be achieved with high concentrations of PAR4 agonists.
Our study has different limitations. First, while the cohort included 319 individuals, 
measurements of circulating inflammatory mediators and ex vivo cytokine responses were 
only available in 241 individuals. Similarly, more subjects were enrolled from the urban 
than from the rural areas which may have weakened the power of some statistical tests 
performed. Secondly, due to the nature of this observational study, mainly associations 
are presented which does not imply causality. Thirdly, dyslipidemia, also a classical risk 
factors for CVD, was not measured. Finally, whereas the enrolment of healthy volunteers 
without comorbidities is a particular strength of our studies, it may not reflect the 
common and important relations between platelets and inflammatory parameters as may 
be observed in a diseased setting.
In conclusion, associations between platelet reactivity and environmental and non-
genetic host factors and plasma inflammatory markers differ between individuals from 
healthy rural and urban subpopulations in Tanzania. These findings provide novel insights 
in regulation of platelet numbers and reactivity, and the possible health consequences of 
urbanization and lifestyle changes in SSA. 
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Supplemental materials
Table S1 – Stimulation scheme for the whole blood stimulation assay.
 Stimuli Test concentration Strain/manufacturer
1 RPMI (1640 Dutch Modified)   Life technologies
2 PHA 10 µg/ml Sigma
3 Lipopolysaccharide (LPS) 100 ng/ml E.coli/Sigma
4 Poly I:C 50 µg/ml Sas Invivogen
5 Mycobacterium tuberculosis 5 µg/ml H37Rv/ In house
6 Coxiella burnetii 1 x 107 /ml nine mile, RSA493
7 Escherichia coli 1 x 106 /ml ATCC 35218 / In house
8 Staphylococcus aureus 1 x 106 /ml ATCC29213/ In house
9 Candida albicans conidia 1 x 106 /ml UC820/ In house
10 Streptococcus pneumonia 1 x 107 /ml TIGR4/ In house
11 Salmonella typhimurium 1 x 106 /ml Phage type 510/In house
12 Salmonella enteritidis 1 x 106 /ml In house
Figure S1 – Gating strategy and platelet reactivity plots. Platelets were first selected based on the 
forward and side scatter plots (SSC-H/FSC-H) followed by their positivity for CD61 expression. Box 
plots show platelet activation in resting platelets and platelet reactivity to agonists after stimulation 
of whole blood with low and high dose of ADP (1µM and 125µM), TRAP-6 (5µM and 125µM) and PAR4 
(200µM and 625µM) agonists. 
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Figure S2 – Data distribution of platelet count and platelet activation parameters. Platelet 
activation parameters were Log10 transformed. Normality of the distribution was tested using 
Shapiro-Wilk test for normality with a cut-off of p>0.05. Psel_un and Fibr_un = P-selectin and 
fibrinogen binding to platelets in unstimulated samples respectively; Psel_ADPlow, Psel_ADPhigh, 
Psel_TRAPlow, Psel_TRAPhigh, Psel_PAR4low and Psel_PAR4high = P-selectin expression after 
stimulation of platelets with low and high dose of ADP, TRAP-6 or PAR4 agonists.
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Figure S3 – Associations between platelet parameters. (A) P values of significant associations 
between platelet parameters (adjusted for age and gender). The colour legend indicates the ranges 
of P values of linear regression. Red colour indicates positive associations. The darker the colour, the 
greater the significance of the relation. (B) Scatterplots of highly significant correlations. The black 
line indicates the LOESS fit to the data. Psel_un and Fibr_un = P-selectin and fibrinogen binding to 
platelets in unstimulated samples respectively; Psel_ADPlow, Psel_ADPhigh, Psel_TRAPlow, Psel_
TRAPhigh, Psel_PAR4low and Psel_PAR4high = P-selectin expression after stimulation of platelets 
with low and high dose of ADP, TRAP-6 or PAR4 agonists.
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Figure S4 – Relationship between intrinsic host factors with other predictor variables. Heat maps 
shows P values of the relation between (A) gender and age with other demographic parameters; 
(B) between circulating mediators with each other and with gender, age and BMI; (C) between 
platelet parameters and circulating inflammatory mediators without correcting for gender, age and 
BMI; and (D) between gender, age and BMI with ex vivo cytokine levels. Data were analysed using 
Mann-Whitney test for categorical variables or spearman’s correlation for continuous variables. 
Associations between circulating mediators with each other were analysed using linear regression 
model and were corrected for gender, age and BMI. Psel_un and Fibr_un = P-selectin and fibrinogen 
binding to platelets in unstimulated samples respectively; Psel_ADPlow, Psel_ADPhigh, Psel_
TRAPlow, Psel_TRAPhigh, Psel_PAR4low and Psel_PAR4high = P-selectin expression after stimulation 
of platelets with low and high dose of ADP, TRAP-6 or PAR4 agonists.
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In this thesis, we studied the interaction of platelets with infectious diseases and 
inflammation. We performed studies in healthy individuals as well as in patients with 
infectious diseases that commonly present with altered platelet numbers and/or 
function, and validated our findings using in vitro models. Overall, we studied (1) how 
infectious diseases alter platelet numbers and function with a special focus on removal of 
platelet surface sialic acid, (2) how infectious diseases alter platelet function and platelet-
mediated inflammatory responses, and (3) determinants of variations in platelet number 
and function in healthy individuals in Sub Saharan Africa (SSA). This chapter provides the 
summary and the general discussion of the findings presented in this thesis.
Summary of the findings
Changes in platelet numbers are common in viral infections, particularly in viral 
haemorrhagic fevers. An infection with dengue virus is often associated with the 
development of thrombocytopenia and platelet dysfunction, which may contribute to a 
haemorrhagic diathesis and plasma leakage [1]. The decrease in platelet count in dengue is 
multifactorial [2]. One mechanism of increased platelet clearance is endothelial activation 
with release of von Willebrand factor (VWF). VWF is a protein that – upon activation – 
binds platelets, and excessive binding of VWF to platelets is a well-known mechanism of 
platelet clearance [3]. Increases in plasma levels of active VWF have also been described 
in patients with a severe dengue infection [4]. Another recently reported mechanism 
of platelet clearance is removal of sialic acid from the platelet membrane, also termed 
platelet desialylation. In chapter 2, we studied in two cohorts of Indonesian patients 
whether excessive VWF binding to platelets as well as platelet desialylation occur in 
dengue. We showed that circulating platelets of dengue patients indeed bind more VWF 
and that the degree of VWF-platelet binding correlated inversely with platelet counts. 
The amount of sialic acid on the platelet surface was simultaneously reduced in dengue 
patients compared to healthy controls. In a set of in vitro experiments, we were able to 
show that dengue virus itself nor its non-structural protein 1 were responsible for platelet 
desialylation. Instead, binding of VWF to GP1bα on platelets induced translocation of 
platelet lysosomes containing neuraminidase 1 (Neu1) to the platelet membrane, resulting 
in desialylation. In addition, we demonstrated the capacity of the neuraminidase inhibitor 
oseltamivir to reduce VWF-induced platelet desialylation, suggesting that oseltamivir 
may reduce thrombocytopenia in dengue infection. 
Whereas dengue virus does not express neuraminidases, other pathogens do. One 
example is Streptococcus pneumoniae, which expresses multiple intrinsic neuraminidases, 
including NanA. Invasive pneumococcal infections are known to be associated with 
platelet activation [5, 6] and we therefore explored the role of pneumococcal neuraminidase 
in modifying platelet surface sialic acid, its consequence for platelet function and involved 
pathways. In chapter 3, we showed that secreted NanA of S. pneumoniae desialylates 
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platelets. Whereas desialylation itself did not induce platelet activation (as measured by 
increased P-selectin expression and platelet fibrinogen binding), platelets became hyper-
reactive to ex vivo stimulation by adenosine diphosphate (ADP) and crosslinked collagen-
related peptide (CRP-XL). Platelet aggregation with leukocytes also increased. These 
processes were dependent on the ADP-pathway as inhibitors of this pathway (apyrase 
and ticagrelor) abrogated platelet hyper-reactivity. Inhibition of NanA-induced platelet 
desialylation by neuraminidase inhibitors (e.g. oseltamivir acid) also prevented the 
platelet effects of NanA. Altogether, our findings show that soluble NanA can desialylate 
platelets leading to platelet hyper-reactivity which can be prevented by neuraminidase 
inhibitors.
The role of platelets in immunity and inflammation is increasingly acknowledged. 
Platelets are also produced in the lungs [7], have the capacity to migrate into the airways 
[8] and are suggested to play an immunological role in lung infections [9]. Some respiratory 
infections, such as respiratory syncytial virus (RSV) and tuberculosis, present with 
increased platelet count.  The possible roles of platelets in host defense in these infections 
remains incompletely understood. In chapter 4 we used an in vitro model of isolated PBMC 
and washed platelets to study the role of platelets and platelet-leukocyte interaction in 
innate immune responses against RSV. We showed that platelets are able to reduce RSV 
infection of monocytes and monocyte activation by binding and internalizing of viral 
particles as well as by enhancing type I IFN production from peripheral blood mononuclear 
cells (PBMCs). This interferon-dependent antiviral effect was exhibited by reduced RSV 
infection of monocytes in the presence of platelets and confirmed by increased infection 
after blocking IFNα receptor 2 (IFNAR2) on PBMCs. Furthermore, through a direct crosstalk 
with leukocytes, platelets enhanced IFNα/γ production by PBMCs upon stimulation 
by viral TLR3 and TLR7/8 ligands, suggesting that platelets influence the inflammatory 
response to other viruses as well. In addition, platelet-mediated reductions in monocyte 
activation and IFNα production during RSV infection may be an important factor in 
preventing lung inflammation in vivo, whereas the internalization of viral particles may 
reduce viremia.
In chapter 5, we studied the contribution of platelet activation and platelet-monocyte 
interaction in inflammatory responses in pulmonary tuberculosis. In a cohort of 
Tanzanian patients with pulmonary tuberculosis, we found that platelet-monocyte 
aggregation (PMA) was increased and associated with monocyte activation with increased 
monocyte CCR5 and CD16 expression, but not with platelet activation. We next studied 
the possible consequences of increased PMA for host defence against Mycobacterium 
tuberculosis (Mtb). We found that platelets reduced production of the pro-inflammatory 
cytokines interleukin (IL)-1β, tumor necrosis factor-α (TNFα), IL-6 and IFNγ by PBMCs upon 
stimulation with Mtb, while increasing production of the anti-inflammatory cytokine IL-
10. These findings suggest that platelets may on the one hand protect against excessive 
tissue damage by counteracting the Mtb-induced pro-inflammatory leukocyte response, 
529995-L-bw-Kullaya
Processed on: 20-3-2019 PDF page: 153
7
Summary and Discussion
153
but on the other hand compromise the production of protective cytokines, such as IFNγ 
and TNFα. 
Increases in PMA not only occur in chronic infections, such as tuberculosis, but also in 
conditions that result from chronic inflammatory conditions such as cardiovascular 
diseases (CVD). In recent decades, an epidemic of non-communicable diseases (NCD), 
along a continuing burden of infectious diseases, is witnessed in many areas in SSA, 
especially in those areas facing a significant demographic transition [10–12]. The underlying 
pathophysiologic pathways of the increase in NCD are only partly understood. Changes 
in platelet numbers and reactivity are associated with the risk for CVD and mortality [13, 14]. 
We hypothesized that the replacement of a rural lifestyle by an urban lifestyle contributes 
to changes in platelet phenotype. As part of the Human Functional Genomics project, we 
enrolled a cohort of 319 healthy adult Tanzanians from Kilimanjaro district in Northern 
Tanzania and explored determinants of platelet numbers and reactivity, putting special 
emphasis on the difference between individuals living in urban or rural areas. In chapter 
6 we describe the associations of non-genetic host factors and environmental factors 
with platelet numbers and reactivity. We first show that platelet reactivity is associated 
with traditional risk factors for CVD including advanced age, high systolic blood pressure, 
alcohol use and smoking of tobacco. Other factors associated with platelet activation/
reactivity were use of a pit latrine or smoke emitting cooking fuel.  Whereas the degree of 
platelet activation and reactivity did not differ between urban and rural subpopulations, 
their associations with both host and environmental factors showed distinct patterns 
between urban and rural subpopulations. Interestingly, the positive associations 
with traditional risk factors for CVD were only seen in the urban, but not in the rural 
subpopulation. With regards to inflammation, we also found important differences in 
associations of platelet reactivity with inflammatory markers between the urban and 
rural subpopulations. Platelet reactivity correlated positively with plasma levels of alpha-
1-antitrypsin (AAT) and negatively with IL-1β and IL-18 levels in the urban but not the rural 
subpopulation. In addition, platelet reactivity was strongly correlation with IL-1Ra and IL-
18BPa levels only in the rural subpopulation. When we associated platelet parameters to 
ex vivo cytokine production capacity, platelet numbers were generally inversely related 
to cytokine production. In addition, platelet activation correlated negatively with TNFα 
production to different ligands in the rural, but not in the urban subpopulation. 
Together, the findings in this thesis add to the existing knowledge on the interaction 
between platelets, infection and inflammation in health and disease. We have identified 
platelet desialylation as a mechanism of platelet removal and determinant of platelet 
activation in infectious diseases, and described new data on the role of platelets in host 
defense against RSV and tuberculosis. Finally, we describe for the first time environmental 
and host factors that are important in regulation of platelet number and reactivity in SSA, 
which is of particular interest in view of the current demographic transition. 
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General Discussion
Regulation of platelet function in SSA
Platelets are key cells in thrombosis and hemostasis, and as such play an important role 
in the pathogenesis of cardiovascular diseases (CVD) [15].  Changes in platelet numbers 
and function are associated with increased risk for cardiovascular events and mortality 
[13, 14]. The recent Framingham Heart Study reported that platelet reactivity to adenosine 
diphosphate (ADP) is associated with incidence of myocardial infarction and stroke 
[14]. These findings may be relevant also for Sub-Saharan Africa (SSA), as this part of the 
world, apart from the heavy burden of infectious diseases, is facing an epidemic of CVD 
and other non-communicable diseases (NCD) [10–12]. Simultaneously, lifestyle is changing 
in many regions of SSA among others because of the rapid demographic transition 
resulting in mass urbanization, sedentary lifestyles, unhealthy diets, increased pollution 
and excessive use of alcohol and tobacco products [10]. These factors may also influence 
platelet phenotype and as such could contribute to the development of CVD in SSA. Data 
on platelet phenotypes generated from SSA are limited as the study of platelet reactivity is 
complicated, let alone, the effects of the demographic transition.
There is considerable heterogeneity in platelet number and reactivity between individuals. 
Different factors may influence platelets, including genetic and non-genetic factors 
such as age, weight, diet and alcohol consumption, cardiovascular health, liver and renal 
function and environmental pollutants [16, 17]. Several of these factors for example age, 
gender and genetic traits may also affect response to anti-platelet therapy [18–22]. Genome-
wide association studies (GWAS) have identified single-nucleotide polymorphisms 
(SNPs) associated with platelet number and function [16, 18, 23] and in some of the genetic 
studies, individuals from African ancestry were included [20, 24–26]. These studies showed 
a large overlap in platelet function SNPs in individuals from African or European ancestry 
[18], but also interesting differences in heritability of platelet function and response to 
anti-platelet therapy [24]. For example, inheritance of genetic variants associated with 
collagen-induced platelet aggregation within families with premature coronary artery 
disease [25] and increased response to PAR4 agonists [26] have been observed in African but 
not European descendants. Increased responsiveness to PAR4 agonists was associated 
with presence of PAR4 gene variant Thr120 in African descendants versus Ala120 variant 
present in European descendants. In addition, high on-treatment platelet reactivity to 
P2Y12 stimulation, an ADP receptor, during clopidogrel therapy was observed in carriers 
of the CYP2C19*2 allele, which is common in people from African ancestry [20]. These 
studies were carried out outside SSA, not taking into account that genes may interact 
with demographic factors [27]. It is therefore important to perform such studies in people 
living in SSA. We were the first to study platelet numbers and phenotype in people 
living in SSA, more specific in Tanzanian subjects from rural and urban settings. Our 
results indicate that platelet activation/reactivity was similar between urban and rural 
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subpopulations, however, their associations with both host and environmental factors 
showed distinct patterns between urban and rural subpopulations. Only in the urban 
population, platelet activation/reactivity was associated with traditional risk factors for 
CVD including advanced age, high systolic blood pressure, alcohol use and smoking of 
tobacco. We thereby confirm earlier data from Western populations that increasing age 
and use of tobacco or alcohol are associated with increased platelet reactivity [17, 28, 29]. The 
impact of individual determinants may complement each other, for example, effect of 
alcohol on platelet aggregation is enhanced by smoking and high intake of saturated fatty 
acids [29]. In addition, the impact of smoking may be aggravated in elderly smokers due 
to long term exposure. This is particularly important in SSA as tobacco industry is fast 
growing in low- and middle- income countries [30]. Other risk practises associated with 
low socioeconomic status include use of biomass fuel, use of pit latrine and exposure to 
domestic animals. Biomass smoke is known to activate platelets and increase platelet-
leukocyte aggregation [31]. How pit latrines or exposure to domestic animals mediate 
platelet activation is unclear. We speculate that it involves a change in the composition 
of the gut microbiota. Livestock owners are more likely to consume animal products more 
frequently, such as dairy products or meat, which will influence their gut microbiome. 
Metabolites from gut microbiome are known to influence platelet function and the risk of 
thrombosis [32]. To explore this hypothesis, we have collected data on gut microbiota from 
the SSA cohort and these data are currently under analysis.  
Important differences between urban and rural subpopulations were also found in 
associations of platelet reactivity with inflammatory markers whereby genetic and 
metabolic traits may also play a role. A detailed analysis of a combined effect of these 
determinants in a multivariate model will provide an informative prediction of the 
regulatory factors of platelet activation/reactivity in this population. Our group is therefore 
currently analyzing data on genetics, metabolome, microbiome and transcriptome in 
connection with platelet activation in this SSA cohort. These ‘omics’-based studies are 
expected to provide additional insights in urban-rural differences and determinants of 
(cardiovascular) health in populations in the middle of the demographic transition, as well 
as possible new targets to improve the health status of these populations.
Interrelations of platelets with inflammation in SSA
Apart from their key role in hemostasis, platelets are also effector cells in inflammation 
and host defence [33, 34]. A bidirectional association exists between platelets and 
inflammation: platelets can regulate inflammatory responses, but vice versa, circulating 
inflammatory proteins such as adipokines and cytokines have been reported to influence 
platelet production and platelet reactivity. For example, pro-inflammatory cytokines 
such as IL-1β and IL-6 are known to induce platelet production [35, 36]. IL-1β was also 
suggested to activate platelets [37]. Adipokines such as leptin, resistin and adiponectin are 
also known to influence platelet function [38, 39]. In our SSA cohort, we found a positive 
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association between platelet reactivity with alpha-1-antitrypsin (AAT), as also found in 
the Western European 500FG cohort [40]. AAT, an acute phase protein, is increased during 
inflammation when it exhibits strong anti-inflammatory and immunomodulatory effects 
[41–43]. Whether the association of AAT with platelet reactivity is truly causal remains 
unknown, also because earlier studies suggested that AAT inhibits platelets [44, 45]. Platelet 
activation by AAT is however possible since AAT can have divergent roles depending on its 
quantitative and qualitative characteristics as a result of post-translational modification 
[46]. For example, AAT can be cleaved, oxidized or form complexes with other molecules 
such as low density lipoproteins and free fatty acids which can activate platelets [47–49]. 
Furthermore, AAT has been found in platelets and was suggested to stabilize hemostatic 
plugs [50] reflecting its ability to induce platelet activation. 
Platelets are also important in regulating immune responses. Two well established 
mechanisms at which platelets tune immune responses of leukocytes are via direct 
platelet-leukocyte interaction or via platelet release of soluble mediators such as 
P-selectin, CCL5, CXCL4, platelet activating factor and CD40 ligand which are recognized 
by immune cells. In the 500FG cohort of healthy Caucasian subjects, platelet number 
was inversely associated with plasma IL-1β while platelet reactivity was associated with 
ex vivo IL-1β and IL-6 production capacity [40]. Such associations were not observed in SSA 
where platelet number and reactivity showed mainly negative correlations with cytokine 
production. These findings suggest that IL-1β is not a key regulator of platelet function in 
a non-inflammatory condition, and that anti-inflammatory properties of platelets may be 
more dominant in the SSA population. 
Apart from mediating cytokine responses of leukocytes, platelets have a direct role in 
host defense which relies on the antimicrobial potential of their granular peptides [51]–[53]. 
This may be very relevant for people living in SSA as for example platelets factor 4 (PF4), 
a platelet α-granule protein, can kill intraerythrocytic malaria parasites of all major 
Plasmodium species [54]. However, also globally occurring infections may be affected as in 
vitro killing of S. aureus, streptococcal species and other bacterial pathogens by platelet 
kinocidins has also been reported [52, 55, 56]. Apart from the direct killing effects of platelet 
products, immunological effects of platelets towards bacterial, viral, parasitic and fungal 
infections have been described as well [9, 53, 57–59], for instance through platelet interactions 
with monocytes, neutrophils or lymphocytes [33, 60]. Activated platelets bind rapidly to 
leukocytes mediated by platelet CD62P to leukocyte P-selectin glycoprotein ligand-1 [61]. 
Platelets have the highest affinity for monocytes as monocytes can bind platelets much 
faster than other leukocytes even at low expression of platelet CD62P [62]. As a result, 
platelet-monocyte aggregation is involved in a plethora of many patho-physiological 
processes [61].
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Platelets as inflammatory regulators in pulmonary infections
Platelets are produced in the bone marrow by megakaryocytes after which they are 
released into the circulation until their removal by the liver through the Ashwell Morell 
receptor (AMR) [63]. Emphasis has therefore been given to interaction of circulating 
platelets with other circulating cells or the vascular wall. Megakaryocytes are however 
also present in the lung vasculature, where they produce platelets that have the capacity 
to migrate into the airways [7, 8]. In this thesis, we took a special interest in studying the 
role of platelet activation and platelet-monocyte interactions in localized pulmonary 
infections. We focused particularly on respiratory syncytial virus (RSV) and Mycobacterium 
tuberculosis (Mtb) infections: both infections are known to cause thrombocytosis [64–66]. 
Findings from our studies suggest that platelets have an effect on host defense, and that 
platelets may actually be important in protecting against excessive damage of lung tissue 
by internalizing RSV (chapter 4) and modulating inflammatory responses to Mtb (chapter 
5), as also supported by the report of Luo et al. [67]. Platelets may have a dual effect during 
a TB infection. On the one hand, important cytokines in the host defence against Mtb, 
such as IFNγ and TNFα, are downregulated due to increased platelet-leukocyte crosstalk. 
On the other hand, this platelet induced shift to a more anti-inflammatory response, 
may prevent excessive tissue damage by Mtb. Thus, given the importance of IFNγ in host 
defence against Mtb, reduction of platelet-leukocyte interaction using antiplatelet drugs 
might be favourable in TB patients, but this might go hand in hand with more tissue 
damage. Careful consideration of the risk-benefit of antiplatelet therapy in TB also applies 
to the anti-thrombotic effects: TB patients have an increased risk for vascular thrombosis, 
especially those with TB meningitis. On the other hand, hemoptysis is common in 
pulmonary tuberculosis [68], and can even be a cause of death. Aspirin has been tested 
as an adjunctive therapy in several murine tuberculosis models [69–72]. Byrne et al showed 
that aspirin enhances the effects of anti-tuberculosis drugs particularly pyrazinamide but 
does not have a direct effect on the pathogenesis or clearance of Mtb [72]. Meanwhile, a 
more recent murine study showed that low-dose aspirin increases survival, reduces local 
and systemic inflammation, reduces lung pathology and enhances Th1-cell responses in 
a murine model of active tuberculosis [71]. Studies in humans are limited. A recent phase 
2 trial in tuberculous meningitis patients reported that adjunctive aspirin was safe and 
has the potential to reduce brain infarction and mortality through its anti-thrombotic 
and anti-inflammatory properties [73]. Next to aspirin, P2Y12 inhibitors such as clopidogrel, 
prasugrel or ticagrelor, are commonly used antiplatelet drugs [61, 74]. These drugs better 
interfere with platelet-leukocyte formation compared to aspirin [61]. To the best of our 
knowledge, no studies have been performed investigating the effects of these antiplatelet 
drugs in the outcome of tuberculosis. Use of clopidogrel in tuberculosis is complicated 
however, given its interaction with anti-TB drugs like rifampicin [75].  
An interesting observation was the upregulation of monocyte CCR5 in platelet-monocyte 
aggregates in the TB patients (chapter 5). CCR5 is a well-known entry co-receptor for HIV 
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on CD4+ T-cells and macrophages [76, 77]. Whereas human immunodeficiency virus (HIV) 
infection is a major risk factor for TB infection [78, 79], our data suggest that the increased 
CCR5 expression in TB patients may facilitate establishment of HIV infection as well, as 
also supported by the report of Rosas-Taraco et al [80]. 
Platelet sialic acids and thrombocytopenia
Changes in platelet numbers are common in infectious diseases. Multiple mechanisms 
underlie these changes, including direct activation by pathogens or their soluble peptides, 
decreased platelet production, platelet consumption through intravascular coagulation, 
formation of platelet-leukocytes aggregates or loss of platelet sialic acid [35, 58, 63, 81]. In this 
thesis, we focused on platelet sialic acid. Sialic acids are important mediators of platelet 
function [82] and platelet life span [63]. Removal of platelet surface sialic acid, a process 
known as desialylation, leads to platelet clearance from the circulation by the Ashwell 
Morell receptors in the liver [63, 83]. We and others have shown that platelet desialylation 
primes platelets to hyperreactivity [84, 85]. In addition, we describe a novel mechanism of 
platelet desialylation in dengue infection involving increased VWF-platelet interaction. 
Desialylation-mediated platelet clearance also occur in non-infectious conditions 
such as in transfusion of refrigerated platelets [3, 86] and in immune thrombocytopenia 
(ITP) [87]. Reduction of platelet desialylation, for instance through administration of 
the neuraminidase inhibitor oseltamivir, may therefore be a new option to prevent 
thrombocytopenia. Neuraminidase inhibitors (NIs) such as oral oseltamivir and inhalant 
zanamivir [88] are primarily in use for the treatment of influenza. Case reports and case 
series have indeed shown that oseltamivir can increase platelet numbers in conditions 
like influenza or ITP [89, 90]. Furthermore, oseltamivir is also able to prevent in vitro platelet 
desialylation and phagocytosis by macrophages [91]. By using a mouse model, Li et al 
showed that NIs can also ameliorate neuraminidase-1 mediated platelet desialylation and 
subsequent Fc-independent ITP caused by antibodies against GPIbα [87]. As GP1bα is the 
receptor for VWF on platelets, NIs may be potential therapeutic option for VWF-mediated 
thrombocytopenia observed in dengue infection. In effect, our group has already started a 
clinical study in Indonesia to explore the use of oseltamivir as adjuvant therapy to increase 
platelet numbers in dengue patients (ISRCTN35227717). 
We also showed in this thesis that desialylation influences platelet function in 
pneumococcal infections, whereby ADP-dependent mechanisms play a major role. The 
incidence of CVD is increased following pneumococcal infections and platelet activation 
was suggested to be a risk factor for myocardial infarction in pneumonia [92–94]. Our 
data suggest that P2Y12 inhibitors may be used to reduce platelet activation during 
pneumococcal infections. Interestingly, ticagrelor, an irreversible P2Y12 inhibitor was 
suggested to reduce  pulmonary adverse effects and sepsis compared with clopidogrel 
in a large trial [95]. In addition, ticagrelor has recently been shown to reduce ADP-induced 
platelet aggregation, platelet-leukocyte interaction, plasma levels of IL-6 and acute lung 
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injury in pneumococcal patients and a pneumococcal mouse model, indicating also 
additional non-platelet effects of ticagrelor [96]. 
We also speculate that NIs may also reduce platelet activation in pneumococcal infections. 
Pneumococcal infections may complicate influenza infections and some patients will 
therefore receive NIs. To the best of our knowledge, data in platelet effects of NIs in 
patients with pneumonia are not yet available. In sepsis patients, oseltamivir was  shown 
to reduce severity of illness, increase platelet response rate, shorten platelet recovery 
time, and reduce platelet transfusion [97, 98]. However, this may also not be without risk and 
again a careful risk-benefit assessment should be made, as a study in mice suggested that 
clearance of desialylated platelets and glycoproteins is a protective mechanism during 
pneumococcal sepsis preventing against lethal coagulopathy [99]. 
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Dit proefschrift bevat verschillende studies waarin de relatie tussen trombocyten 
(bloedplaatjes) en infectieziekten/ontsteking is bestudeerd. Studies zijn uitgevoerd in 
gezonde individuen en in patiënten met verschillende infectieziekten, die gekenmerkt 
worden door een verandering in het aantal en de functie van trombocyten. Bevindingen 
bij deze individuen zijn vervolgens gevalideerd door middel van experimenten in het 
laboratorium. In grote lijnen zijn bestudeerd: (1) de rol van veranderingen in siaalzuur 
op de trombocytmembraan op het aantal en de functie van trombocyten bij dengue en 
pneumokokkeninfecties, (2) hoe trombocyten ontstekingsreacties beïnvloeden tijdens 
longinfecties, en (3) determinanten van trombocytenfunctie in gezonde individuen in 
Sub-Sahara Afrika (SSA).
Siaalzuur en trombocyten
Infecties gaan vaak gepaard met een verlaging in het aantal trombocyten (trombopenie). 
Dengue is een virusinfectie die hemorragische koorts kan veroorzaken. Bij dengue is het 
ontstaan van trombocytopenie en trombocytendisfunctie gebruikelijk. Trombocytopenie 
kan ontstaan door versnelde verwijdering van trombocyten. Toegenomen binding van 
het stollingseiwit von Willebrand-factor (VWF) leidt tot versnelde verwijdering van 
trombocyten. Een ander mechanisme is de verwijdering van aanwezig siaalzuur van 
glycoproteïnen op de trombocytenmembraan, ook wel aangeduid als desialering. In 
hoofdstuk 2 beschrijven we de resultaten van studies in twee cohorten Indonesische 
patiënten met dengue. De resultaten laten zien dat circulerende trombocyten van 
denguepatiënten inderdaad meer VWF hebben gebonden en dat de mate van binding van 
VWF aan trombocyten omgekeerd evenredig is met het trombocytenaantal. Trombocyten 
bleken gedesialeerd, wat leidt tot verwijdering van trombocyten uit de circulatie. In 
aanvullende laboratoriumexperimenten tonen we aan dat desialering van trombocyten 
niet wordt veroorzaakt door denguevirus of het door denguevirus gemaakte non-
structural protein 1 (NS1). Wel leidt de binding van VWF aan trombocyten tot translocatie 
van sialidase-bevattende lysosomen naar de trombocytenmembraan, wat resulteert in 
desialering van de trombocytmembraan. Dit proces kan geremd worden door toediening 
van de neuraminidaseremmer oseltamivir, een bekend geneesmiddel tegen influenza, 
wat suggereert dat oseltamivir mogelijk de ernst van trombocytopenie bij dengue kan 
verminderen.
Denguevirus brengt geen neuraminidase (sialidase) tot expressie, maar andere 
pathogenen doen dit wel. Het bekendste voorbeeld is influenzavirus, maar ook de bacterie 
Streptococcus pneumoniae (pneumokok) brengt meerdere intrinsieke neuraminidasen tot 
expressie, waaronder NanA. Omdat invasieve pneumokokkeninfecties leiden tot activatie 
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van trombocyten, hebben we het effect onderzocht van NanA op siaalzuur-bevattende 
glycoproteïnen op de trombocytmembraan en de gevolgen van verandering hierin op 
trombocytfunctie. Hoofdstuk 3 beschrijft dat NanA leidt tot desialering van trombocyten. 
Desialering zelf leidde niet tot activatie van trombocyten, maar trombocyten werden 
wel verhoogd gevoelig voor activatie door de trombocytstimulators adenosinedifosfaat 
(ADP) en collageen-gerelateerd peptide (CRP-XL). Trombocytaggregatie met leukocyten 
nam eveneens toe. Deze processen waren afhankelijk van de ADP-gemedieerde 
trombocytactivatieroute omdat remmers van deze route (apyrase en ticagrelor) de 
hyperreactiviteit van de trombocyten tenietdeden. Ook neuraminidaseremmers (zoals 
oseltamivir) die desialering van trombocyten door NanA verhinderen, voorkwamen 
hyperreactiviteit van trombocyten. Samengevat laten deze bevindingen zien dat NanA 
leidt tot desialering en vervolgens hyperreactiviteit van trombocyten. Dit proces kan 
geremd worden door neuraminidaseremmers.
Trombocyten als regulators van ontsteking bij longinfecties
Er is steeds meer erkenning voor de rol die trombocyten spelen bij afweer en ontsteking. 
Trombocyten worden niet alleen in het beenmerg, maar ook in de longen geproduceerd. 
Ze hebben het vermogen om in de luchtwegen te migreren en er wordt gesuggereerd dat 
trombocyten een immunologische rol spelen bij longinfecties. Sommige infecties van 
de luchtwegen, zoals infecties met het respiratoir syncytieel virus (RSV) of tuberculose, 
leiden vaak tot een verhoging in het trombocytenaantal. Of en hoe trombocyten een 
rol spelen in de afweer tegen deze infecties is vooralsnog grotendeels onbekend. In 
hoofdstuk 4 gebruiken we een in vitro model van geïsoleerde perifere mononucleaire 
bloedcellen (PBMC ‘s) en trombocyten om de rol van trombocyten, en de interactie tussen 
trombocyten en leukocyten, in de afweerrespons tegen RSV te bestuderen. We tonen aan 
dat trombocyten in staat zijn de mate van infectie van monocyten met RSV, alsmede de 
activatie van monocyten te verminderen, door het binden en opnemen van virusdeeltjes, 
en het stimuleren van de productie van type I interferon door PBMC’s. Trombocyten 
stimuleren ook de productie van interferon-alfa/gamma door PBMC’s na stimulatie 
door virale liganden van de Toll-like receptoren TLR3- en TLR7 /8, wat suggereert dat 
trombocyten ook de afweerrespons op andere virussen kunnen beïnvloeden. De remming 
van monocytactivatie en productie van interferon-alfa door trombocyten kan een rol 
spelen in het voorkomen van overmatige longinflammatie tijdens een RSV-infectie, terwijl 
het opnemen van RSV door trombocyten de mate van viremie beperkt.
Hoofdstuk 5 beschrijft de mogelijke invloed van activatie van trombocyten en trombocyt-
monocyt interactie op de afweerrespons in longtuberculose. In een cohort van 
Tanzaniaanse patiënten met longtuberculose bleek de vorming van trombocyt-monocyt 
aggregaten (TMA) toegenomen, wat geassocieerd was met activatie van monocyten met 
verhoogde expressie van CCR5- en CD16. Trombocyten bleken echter niet geactiveerd te 
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zijn in de tuberculosepatiënten. Vervolgens is in het laboratorium de mogelijke gevolgen 
van de verhoogde TMA op de afweer tegen Mycobacterium tuberculosis (Mtb) bestudeerd. 
Bij blootstelling van PBMCs aan Mtb, verlagen trombocyten de productie van de pro-
inflammatoire (ontstekingsbevorderende) cytokines interleukine (IL)-1β, tumor necrosis 
factor-α (TNFα), IL-6 en IFNγ, terwijl de productie van het ontstekingsremmende cytokine 
IL-10 toeneemt. Deze bevindingen suggereren dat trombocyten tijdens tuberculose 
enerzijds beschermen tegen overmatige weefselschade door het tegengaan van 
overmatige ontsteking, maar anderzijds de productie van noodzakelijke cytokines in de 
afweerreactie tegen Mtb, zoals IFNγ en TNFα, remmen. 
Regulatie van trombocytenfunctie bij gezonde individuen 
in SSA
Trombocyten zijn essentieel bij de bloedstolling en spelen een belangrijke rol bij 
atherosclerose en hart- en vaatziekten (HVZ). Variatie in het aantal en de functie van 
trombocyten is geassocieerd met het risico op HVZ en mortaliteit. Veel landen in Sub-
Sahara Afrika (SSA) hebben te maken met een snel toenemende epidemie van HVZ en 
andere niet-overdraagbare ziekten. Migratie van rurale naar stedelijke gebieden en 
verandering in leefstijl spelen hierin waarschijnlijk een belangrijke rol. We hebben daarom 
de effecten van demografische en omgevingsfactoren en leefstijl op de functie van 
trombocyten in SSA bestudeerd, en vooral de verschillen tussen het leven in een ruraal of 
urbaan gebied. Een cohort van 319 gezonde volwassen Tanzanianen uit het Kilimanjaro-
district in Noord-Tanzania is verzameld als onderdeel van het Human Functional Genomics 
Project. Hoofdstuk 6 beschrijft de associaties tussen gastheer- en omgevingsfactoren met 
het aantal en de functie van trombocyten. De reactiviteit van trombocyten is geassocieerd 
met traditionele risicofactoren voor HVZ, waaronder leeftijd, bloeddruk, alcoholgebruik 
en het roken van tabak. Ook omgevingsfactoren die meer specifiek zijn voor SSA, zoals 
het gebruik van een latrine of het koken op een open vuur, waren geassocieerd met 
verhoogde trombocytreactiviteit. Hoewel er geen absoluut verschil was in de mate van 
trombocytactivatie en -reactiviteit tussen mensen die leefden in de stad of het platteland, 
vertoonden de associaties tussen deze trombocytkenmerken en verscheidene gastheer- en 
omgevingsfactoren een duidelijk ander patroon. Positieve associaties tussen traditionele 
risicofactoren voor HVZ en trombocytactivatie en -reactiviteit waren alleen aanwezig 
in de urbane en niet in de rurale populatie. Ook de relaties met ontstekingsmediatoren 
verschilden in de rurale en urbane populaties: trombocytenreactiviteit correleerde 
positief met plasmaconcentraties van alfa-1-antitrypsine (AAT) en negatief met IL-1β en 
IL-18 concentraties in de urbane, maar niet in de rurale populatie. Daarentegen correleerde 
alleen in de rurale populatie trombocytenreactiviteit sterk met concentraties van IL-1 
receptor antagonist en van IL-18 binding protein. Trombocytenaantallen waren in het 
algemeen omgekeerd gerelateerd aan cytokineproductie door leukocyten. 
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Samengevat vormen de bevindingen in dit proefschrift een aanvulling op de reeds 
bestaande kennis over het belang van trombocyten in infecties en ontsteking. Met 
name staat beschreven dat desialering van trombocyten een nieuw mechanisme 
is voor trombopenie in infectieziekten als dengue, en dat dit kan bijdrage aan 
trombocytenactivatie bij pneumokokkeninfecties. Belangrijk hierbij is dat remmers van 
sialidase, zoals het veelgebruikte anti-influenza medicijn oseltamivir, kunnen ingrijpen 
op deze processen. Daarnaast beschrijft dit proefschrift nieuwe gegevens over de rol 
van trombocyten in de afweer tegen RSV en tuberculose. Ten slotte beschrijven we voor 
het eerst gastheer- en omgevingsfactoren die van invloed zijn op trombocytenaantal 
en -functie in SSA. Deze gegevens zijn niet alleen van belang vanwege de huidige 
demografische transitie in SSA, maar ook voor reeds langere tijd geürbaniseerde 
populaties elders. 
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Katika andiko hili, tulijifunza mwingiliano na uhusiano uliopo  kati ya chembe sahani na 
magonjwa ambukizi na uvimbemchungu. Tulifanya tafiti kwa watu wenye afya na watu 
wenye magonjwa ambukizi ambayo yanaambatana na mabadiliko katika idadi au tabia za 
chembe sahani, na kuthibitisha/kusadifu matokeo haya kwa kutumia tafiti za kimaabara. 
Kwa ujumla, tulijifunza (1) jinsi  magonjwa ambukizi yanavyobadilisha idadi na dhima ya 
chembe sahani, hususan kuondolewa kwa asidi ya sialiki kwenye uso wa chembe sahani, 
(2) jinsi magonjwa ambukizi yanavyochangia katika kubadili dhima pamoja na kinga ya 
mwili inayotokana na chembe sahani, na (3) visababishi vya kuhitilafiana  kwa idadi na 
tabia au dhima ya chembe sahani miongoni mwa watu wenye afya waishio kusini mwa 
jangwa la Sahara (SSA). 
Mchango wa asidi ya sialiki  katika kushusha idadi ya 
chembe sahani kwenye damu
Mabadiliko katika idadi ya chembe sahani ni ya kawaida katika maambukizi ya virusi, hasa 
katika homa za virusi zinazoambatana na  kuvuja damu. Maambukizi ya virusi vya dengue 
mara nyingi huhusishwa na kufifia kwa utendaji kazi (dhima) wa chembe sahani pamoja 
na kuwa na chembe sahani batili, ambayo inaweza kuchangia kuvuja damu na plasma. 
Inajulikana kuwa kisababishi kimojawapo cha kupungua kwa chembe sahani wakati wa 
maambukizi ya dengue ni kunata kwa kiasi kikubwa cha protini ya von Willebrand factor 
(VWF) kwenye chembe sahani. Kisababishi  kingine cha kupungua kwa chembe sahani kwa 
wagonjwa wa dengue kilichoripotiwa hivi karibuni  ni kumomonyoka kwa asidi ya saliki 
kutoka utando wa chembe sahani, ijulikanayo kama mmomonyoko wa asidi ya sialiki. 
Katika sura ya 2, tulitafiti  kwa kutumia makundi mawili ya wagonjwa wa dengue huko 
nchini Indonesia kujua kama ongezeko la kunata kwa VWF kwenye chembe sahani, na 
mmomonyoko wa asidi ya sialiki kwenye chembe sahani vinajitokeza kwa wagonjwa wa 
dengue. Tulibaini kuwa chembe sahani za wagonjwa wa dengue hunata VWF nyingi zaidi, hali 
ambayo huambatana pia na kupungua kwa idadi ya chembe sahani katika mzunguko wa 
damu. Kiwango cha asidi ya saliki kwenye uso wa chembe sahani  za  wagonjwa wa dengue 
ulipungua sawia ikilinganishwa na wale wasio wagonjwa. Katika seti ya majaribio ya kwenye 
chupa (in vitro experiments), tuliweza kubainisha kuwa kirusi cha dengue peke yake au protini 
yake (non structural protein) haviwezi kusababisha mmomonyoko wa asidi ya sialiki. Badala 
yake, kunata kwa VWF kwenye kipokezi chake GP1ba  kilichopo kwenye uso wa chembe sahani 
husababisha kuhama kwa lysosome za chembe sahani zenye neuraminidase 1 (Neu1) kwenda 
kwenye utando na hatimaye kusababisha mmomonyoko wa asidi ya sialiki. Pia tulionyesha 
uwezo wa dawa ya oseltamivir (ambayo ni kipingamizi cha neuraminidase) katika kupunguza 
mmomonyoko wa asidi ya sialiki uliosababishwa na VWF, hivyo kuashiria kuwa oseltamivir 
inaweza kuzuia kupungua kwa idadi ya chembe sahani kwa wagonjwa wa dengue. 
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Wakati kirusi cha dengue hakina uwezo wa kutengeneza neuraminidase, vipo vimelea vingi 
vya magonjwa vyenye uwezo huo. Mfano mmojawapo ni  Streptocococcus pneumoniae, 
(visababishi vya ugonjwa wa nimonia) ambavyo hutengeneza neuraminidases za aina 
kadhaa ikiwemo mojawapo ijulikanayo kama NanA. Inajulikana kwamba, visababishi 
vya nimonia vamizi vinahusika katika  kuamsha chembe sahani, na kwa sababu hiyo 
tulichunguza jinsi NanA ya S. pneumoniae inavyoweza kuadhiri asidi ya sialiki kwenye 
uso wa chembe sahani, na hatma yake kwa tabia/dhima ya chembe sahani. Katika 
sura ya 3, tumeonyesha kuwa NanA kutoka kwa S. pneumoniae  humomonyoa asidi ya 
sialiki. Ingawaje kumomonyoka peke yake hakukuamsha chembe sahani, (kwa kigezo 
cha muongezeko wa kuonekana kwa P-selectin na fibrinogen katika uso wa chembe 
sahani), chembe sahani zilizopoteza asidi ya sialiki ziliamshwa kwa kiwango cha juu 
pale ziliposisimuliwa kwa kutumia adenosine diphosphate (ADP) na  peptide CRP-XL zenye 
uhusiano na collagen, katika majaribio ya chupa.  Kunata kwa chembe sahani kwenye 
seli nyeupe za damu nako kuliongezeka. Chembe sahani ziliamshwa kupitia mkondo wa 
ADP, kwani vizuizi vya mikondo hii (apyrase na ticagrelor) viliweza kupunguza mwamsho 
mkali wa chembe sahani. Kuzuia mmomonyoko wa asidi ya sialiki  unaosababishwa na 
NanA kwa kutumia vizuizi vya neuraminidase kama vile oseltamivir, vilevile ilizuia athari 
za NanA. Kwa pamoja utafiti wetu umebaini kuwa NanA ya kimelea cha S. pneumoniae 
inaweza kumomonyoa asidi ya sialiki na kusababisha mwamko mkali wa chembe sahani 
ambao unaweza kuzuiliwa kwa kutumia vizuizi vya neuraminidase.
Chembe sahani kama mdhibiti wa uvimbemchungu 
kwenye magonjwa ya mapafu 
Dhima za chembe sahani katika kinga ya mwili pamoja na uvimbemchungu inazidi 
kukubalika katika ulimwengu wa sayansi. Chembe sahani huzalishwa pia kwenye mapafu 
na zina uwezo wa kupenya katika njia za hewa. Pia, zinajulikana kuwa na uwezo wa 
kukinga maambukizi ya magonjwa ya mapafu. Magonjwa ya mfumo wa hewa kama vile 
maambikizi ya respiratory syncytial virus (virusi vya RSV) na kifua kikuu (TB) huambatana na 
ongezeko la idadi ya chembe sahani. Kazi ya chembe sahani katika kumkinga mwathirika 
wa maambukizi haya haujulikani kikamilifu. Katika sura ya 4, tulitumia mbinu za 
ndani ya chupa, zinazotumia seli nyeupe (PBMCs) na chembe sahani zilizotenganishwa 
na damu kujifunza kazi ya chembe sahani, na mwingiliano wake na seli nyeupe katika 
kinga ya mwili dhidi ya RSV. Tulionyesha kuwa chembe sahani zina uwezo wa kupunguza 
mambukizi ya RSV na mwamsho kwa seli za kiini hai kimoja (monocytes), kwa kunasa 
na kumeza chembechembe za virusi, pamoja na kuimarisha uzalishaji wa protini ya 
interferon-1 (IFN type 1) kutoka kwa seli nyeupe. Ukinzani wa virusi unaotegemea interferon 
ulidhihirika kwanza kwa kushuka kwa idadi ya maambukizi ya virusi kwenye seli za kiini 
hai kimoja zilizochanganyika na chembe sahani; Pili, kuongezeka kwa maambukizi baada 
ya kufunika kipokezi cha IFN (IFNAR2) kwenye uso wa seli nyeupe. Pia kwa kushirikiana 
na seli nyeupe za damu, chembe sahani ziliimarisha seli nyeupe kuzalisha IFNa/g pale 
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ziliposisimuliwa na viungo vya virusi aina ya TLR3 na TLR7/8. Hii inaashiria kuwa chembe 
sahani ni mdhibiti wa uvimbemchungu kwa virusi wa aina nyingine pia. Aidha, uwezo 
huu wa chembe sahani kupunguza maambukizi ya RSV na mwamsho wa seli za kiini hai 
kimoja, pamoja na kuchochea ongezeko la uzalishaji wa IFNa wakati wa maambukizi ya 
RSV inaweza kuwa kitu muhimu katika kuzuia uvimbemchungu wa mapafu na kusambaa 
kwa virusi kwenye mfumo wa damu.
Katika sura ya 5, tulitafiti juu ya mchango wa chembe sahani na mwingiliano wake na 
seli za kiini hai kimoja katika kinga ya mwili dhidi ya kifua kikuu.   Katika kikundi cha 
wagonjwa wa kifua kikuu nchini Tanzania tulibaini kuwa hakukuwa na mwamko wa 
chembe sahani kwa wagonjwa wa TB, bali kulikuwa na ongezeko kubwa ya chembe sahani 
kugandiana na seli za kiini hai kimoja. Kugandiana kwa seli hizi uliambatana na mwamko 
wa seli za kiini hai kimoja uliodhihirika kwa ongezeko la protini za CCR5 na CD16 katika uso 
wa seli za kiini hai kimoja. Baadaye tulichunguza hatma ya kuongezeka kwa kugandiana 
kwa chembe sahani na seli za kiini hai kimoja katika maambukizi ya kifua kikuu. Tulibaini 
kuwa, chembe sahani zilipunguza uzalishaji wa vichochezi vya uvimbemchungu ambavyo 
ni pamoja na protini za interleukin (IL)-1b, tumor necrosis factor-a (TNFa), IL-6 na IFNa, 
kutoka kwenye seli nyeupe zilizosisimshwa na kimelea cha TB, sambamba na kuongezeka 
kwa vikinzani vya uvimbemchungu IL-10. Matokeo haya yanaashiria kuwa, kwa upande 
mmoja, chembe sahani zinaweza kuzuia kuharibika vibaya kwa tishu za mapafu kwa 
kupunguza uzalishwaji wa protini zinazochochea uvimbemchungu, bali pia chembe 
sahani zinaweza kuathiri kinga ya mwili dhidi ya TB kwa kupunguza uzalishaji wa protein 
muhimu kwa kazi hii kama vile IFNg na TNFa.
Usimamizi wa dhima ya chembe sahani kwa watu waishio 
kusini mwa jangwa la Sahara (SSA)
Chembe sahani ni seli muhimu katika kugandisha damu na kusimamisha kuvuja 
damu, hivyo zina mchango muhimu katika kuundwa kwa magonjwa ya moyo (CVD). 
Mabadiliko ya idadi  na dhima ya chembe sahani yana uhusiano mkubwa  na kuongezeka 
kwa magonjwa ya moyo na vifo. Katika miongo ya karibuni, kuenea  kwa magonjwa 
yasiyoambukiza (NCD) licha ya kuwepo na msongo wa magonjwa ambukizi umebainika 
katika maeneo mengi ya SSA, hususan katika maeneo yenye mabadiliko ya mtindo wa 
maisha. Tulijenga hoja kuwa mabadiliko ya mtindo wa maisha kutoka maisha ya vijijini 
kwenda maisha ya mjini unachangia mabadiliko ya tabia ya chembe sahani. Katika mradi 
wa Human Functional Genomics, tulisajilli kundi la watu wazima 319 wenye afya wanaoishi 
katika mkoa wa Kilimanjaro, uliopo kaskazini mashariki mwa Tanzania. Katika kundi 
hili tulijifunza visababishi vya idadi na tabia ya chembe sahani, huku tukizingatia kwa 
umakini mkubwa tofauti iliopo kati ya watu wanaoishi mjini na wale wanaoishi vijijini.
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Katika sura ya 6, tumeonyesha uhusiano uliopo kati ya visababishi visivyo vya kigenetiki 
na vile vya kimazingira na idadi ya chembe sahani na mwitikio wake. Kwanza tulionyesha 
kwamba mwitikio wa chembe sahani una uhusiano na vitu hatarishi kwa CVD kama vile 
umri mkubwa, shinikizo la damu, unywaji pombe na uvutaji sigara. Vitu vingine vilikuwa 
ni matumizi ya choo cha kutumbukiza na matumizi ya nishati ya kupikia inayotoa moshi. 
Hatukubaini tofauti kati ya watu wanaoishi mjini na wale wanaoishi vijijini kwenye suala 
la kiwango cha mwamko na mwitikio wa chembe sahani. Badala yake, tulibaini kuwepo 
utofauti katika namna visababishi tajwa vinavyochangia mabadiliko katika kiwango 
cha mwamko wa chembe sahani kati wa watu waishio mjini na wake waishio vijijini. Cha 
kushangaza zaidi ni kuwa, uhusiano chanya na vichangia hatarishi vya CVD vilibainika tu 
kwa watu wanaoishi mjini na sio waishio vijijini. Kwenye suala la uvimbemchungu tulibaini 
tofauti muhimu kati ya mwamko wa chembe sahani na alama za uvimbemchungu kati ya 
watu waishio mjini na wale waishio vijijini. Tulibaini mlingano chanya kati ya mwamko wa 
chembe sahani  na kiwango cha plasma cha alpha-1-antitrypsin (AAT), na mlingano hasi kati 
ya mwamko wa chembe sahani  na kiwango cha IL-1b na IL-18 kwa watu wanaoishi mjini; 
lakini haikuwa hivyo kwa watu wanaoishi vijijini.  Pia kulikuweko na mlingano chanya kati 
ya mwamko wa chembe sahani na viwango vya IL-1Ra na IL-18BPa kwa wale watu wanaoishi 
vijijini tu.  Kulikuweko pia na mlingano hasi kati ya idadi ya chembe sahani na uzalishaji 
wa cytokines katika majaribio ya chupa. Zaidi ya hayo, kulikuweko na mlingano hasi kati 
ya mwamko wa chembe sahani na uzalishaji wa TNFa kwa watu wa vijijini lakini sivyo kwa 
watu wa mjini.   
Kwa kujumuisha,  matokeo ya tafiti zilizo katika andiko hili umeongeza ujuzi 
uliopo kuhusu uhusiano na mwingiliano baina ya chembe sahani, maambukizi na 
uvimbemchungu  kwa watu wenye afya na wagonjwa. Tumebaini kuwa mmonyoko wa 
asidi ya sialiki ni njia ya kuondoshwa kwa chembe sahani katika mzunguko wa damu, na 
pia ni kichangia muhimu cha mwamko wa chembe sahani   kwa magojwa ya kuambukiza. 
Zaidi ya hayo, tumeonyesha data mpya kuhusu kazi ya chembe sahani katika kuchangia 
kinga ya mwili dhidi ya RSV na kifua kikuu. Pia kwa mara ya kwanza, tumeelezea fakta 
zitokanazo na mhusika mwenyewe au mazingira yake zinazosimamia idadi na mwamko 
wa chembe sahani katika watu waishio chini mwa jangwa la Sahara. Fakta hizi tajwa 
zinavutia kuzijua zaidi tukizingatia wimbi linaloongezeka la  uhamaji wa watu kutoka 
vijijini kwenda mijini.
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